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INTRODUCTION 
Mucosal infections with enterotoxigenic E. coli (ETEC) affect neonatal and recently weaned 
animals. ETEC infections are a cause of diarrhoea and significant economical losses. In general, 
most neonatal infections can be prevented by passive colostral and lactogenic immunity. 
However, this passive protection decreases with aging and at weaning lactogenic immunity 
disappears. So, newly weaned animals become highly susceptible for enteropathogens. In order to 
protect newly weaned piglets, an active mucosal immunity is needed in the form of antigen-
specific secretory IgA (sIgA) in secretions. The only way this could be obtained immediately after 
weaning is by vaccination during the suckling period. Vaccination via the oral route is difficult 
especially in suckling piglets due to milk antibodies. Parenteral vaccination (intramuscular (IM), 
subcutaneous (SC), etc) is an other option. However, available parenteral vaccines stimulate the 
systemic (IgG antibodies) rather than the mucosal immune system. This emphasizes the need for 
the inclusion in these vaccines of immunomodulating adjuvants.  
The term immunomodulation is generally used to describe the pharmacological 
manipulation of the immune system. Normally this involves non-specific and antigen-specific 
immunostimulation with following objectives: (i) promoting a greater and more effective immune 
response and if administered with vaccines it should exert an adjuvant effect (ii) enhancing local 
protective immune (IgA) responses at mucosal surfaces in neonatal and young susceptible animals 
and (iii) selectively stimulating the immune system in order to modulate the immune response 
towards a specific direction, or stimulating non-specific immune mechanisms. The use of 
immunomodulators in vaccination must enhance a protective immune response. 
Immunomodulators (immunomodulating adjuvants), which are often used in parenteral 
vaccination, can be divided into three categories: physiological products (hormones), substances 
of microbial origin (cell wall, LPS, DNA,…) and synthetic compounds (Levamisole, β-1,3-
glucan, indomethacin, synthetic polynucleotides,…) (Mulcahy and Quinn, 1986). 
In the present thesis the immunomodulating properties of , 1α,25(OH)2D3 (calcitriol) and 
Cytidine-phospate-Guanosine oligodeoxynuclotides (CpG-ODN) after an intramuscularly (IM) 
induced immune response in piglets are studied. Both agents have well been studied in rodents 
and man but not in domestic food animals such as pigs. The steroid hormone 1α,25(OH)2D3 , the 
active form of vitamin D, appears to modulate a systemic immune response towards a protective 
mucosal (IgA) immune response (Daynes et al., 1994, 1996). This was accompanied with the 
presence of a Th2-cytokine profile. CpG-ODN, which are DNA-sequences characteristic for many 
bacteria, have potent immune enhancing properties and are classified as Th1-modulating 
adjuvants. Co-administration of CpG-ODN with a particular antigen showed enhanced antigen- 
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specific humoral and cellular immune responses with even protection upon challenge (Krieg et al., 
2001). Chapter 1 (Part I) reviews the literature on 1α,25(OH)2D3 and CpG-ODN and their 
immunomodulating characteristics. Part II describes the specific aims of the study. The 
experimental work is presented in part III (chapter 2 to 7). Part IV contains a general discussion 
and the overall conclusions (chapter 8).
Chapter 1: Immunomodulating properties of 1,25(OH)2D3 and CpG-ODN: a review 13 
 
CHAPTER 1: 
THE IMMUNOMODULATING PROPERTIES OF CALCITRIOL AND 
CPG-OLIGODEOXYNUCLEOTIDES: A REVIEW 
 
1.1. Calcitriol 
1.1.1. Calcitriol: structure and Vitamin D metabolism 
 
 1α,25-Dihydroxyvitamin D3 [1α,25(OH)2D3 or calcitriol] is the biologically active form of 
vitamin D and is required for the homeostasis of calcium and phosphorus (De Luca, 1976). It is a 
hydrophobic molecule with a molecular weight of 416,6 Da and is soluble in alcohol and acetone. 
The molecular structure of 1α,25(OH)2D3 (Fig.1.1) is similar to that of cholesterol and steroid 
hormones such as progesterone, aldosterone and testosterone except that the B-ring of the 
structure has been opened between C9 and C10. This allows the A-ring to rotate from the folded 
(steroidal or cisoid) to the extended (vitamin-like or transoid) conformation. 
 
 
FIGURE 1.1: Structure of 1,25(OH) 2D3 in both conformations. 
 
 
Only the extended conformation can interact with the nuclear vitamin D receptor (nVDR, 
Norman et al., 1993, Bouillon et al., 1995). 
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Vitamin D is a complex of steroids however the name is often used for vitamin D3, found in 
mammals. Vitamin D3 is synthesized in the skin out of a cholesterol-like precursor (7-
dehydrocholesterol) by exposure to ultraviolet light (Lips et al., 1996, Fig. 1.2) or can be 
administered in feed. Vitamin D3 is biologically inert and requires two successive hydroxylations: 
one in the liver (at C25 making 25-hydroxyvitamin D3 (25(OH)D3)) and one in the kidney (at C1 in 
the α position), to form the hormonally active 1α,25(OH)2D3 (Gascon-Barré 1997). 
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FIGURE 1.2:  Synthesis and metabolism of vitamin D  
 
The production of 1α,25(OH)2D3 in the kidney is controlled by the parathyroid hormone (PTH) 
which directly stimulates the 1α-hydroxylase activity during hypocalcemia and inhibits its activity 
during hypercalcemia (Garabedian et al., 1972). Other major regulators of the 1α,25(OH)2D3 
concentration are calcium, phosphorus (negative regulation via suppression of PTH secretion), 
calcitonin, insulin-like growth factor (positive regulation, Henry et al., 1997) and 1α,25(OH)2D3 
itself (negative feedback) (Bell et al., 1998). Acidosis also decreases the level of 1α,25(OH)2D3 by 
raising the serum calcium and by decreasing the responsiveness of the kidney to PTH. The 
negative feedback of 1α,25(OH)2D3 on its own synthesis and the positive feedback on its 
catabolism provide an important mechanism to prevent vitamin D intoxication. 1α,25-
Dihydroxyvitamin D3 activates its major catabolic enzyme 24-hydroxylase that converts 
1α,25(OH)2D3 to 24,25(OH)2D3 as well as to 1,24,25(OH)3D3. Furthermore it initiates the 
oxidation at C24 (Beckman et al., 1996), which is followed by second hydroxylation, and  
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oxidation at C23 and subsequent cleavage of the side chain at C23. The final cleavage product of 
1α,25(OH)2D3 is calcitroic acid which is biologically inert (Bouillon et al., 1998).  
Transport of vitamin D steroids is associated with vitamin D-binding proteins (DBP) which 
bind 25-hydroxyvitamin D3 with a higher affinity than the bio-active 1α,25(OH)2D3 DBP are 
synthesized in the liver and circulate in the plasma at concentrations 20 times higher than the total 
amount of vitamin D compounds. So, under normal physiological conditions nearly all-circulating 
vitamin D compounds are protein bound. This makes the metabolites less susceptible to 
metabolism and prolongs their half-life time (Cooke and Haddad et al., 1976). Actually the DBP-
unbound vitamin D compounds have greater accessibility to target cells and therefore have a 
higher biological response (Bikle et al., 1989). 
 
1.1.2. Mechanism of actions by 1α,25(OH)2D3 
1.1.2.1. Genomic actions of 1α,25(OH)2D3 
 
Most biological activities of 1α,25(OH)2D3 are mediated largely, if not exclusively, through 
the high-affinity receptor nVDR (Fig. 1.3). 
 
 
 
 
 
 
 
 
FIGURE 1.3: Structural organization of the human nuclear vitamin D receptor (nVDR). The nVDR is 
composed of 427 amino acids (aa) and consists of several domains (A/B, C, D, E/F and AF2 domain). 
 
This receptor has a molecular weight of 50 to 60 kDa depending on the species. It is a member of 
the steroid hormone-activated-transcription factor family and acts by binding as homodimer or 
heterodimer to vitamin D-responsive elements (VDREs) found in the promotor region of several 
target genes (Haussler et al., 1998). The nVDR consist of several domains: the A/B domain at the 
N-terminus (transcription-activating domain), the C-domain which contains 2 conserved zinc 
finger DNA binding motifs which interact with the VDREs. The D-domain, serves  
as a hinge region and is followed by the E-domain. The latter domain contains the 1α,25(OH)2D3 
(ligand) binding domain (consisting of 12 helices) and a ligand-dependent activation function  
NH2  
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(AF2), represented by helix 12 (Mangelsdorf and Evans 1995), which is located at the C-terminus. 
The major steps involved in control of gene transcription by the nVDR are shown in Fig. 1.4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1.4: Genomic action of 1α,25(OH)2D3. (1) The steroid hormone 1α,25(OH)2D3 enters the 
cytoplasm and nucleus of the target cells by diffusion. (2) 1α,25(OH)2D3 binds in the nucleus with the 
nVDR which results in a conformational change of the nVDR. (3) The nVDR forms a homodimer or 
heterodimer with RXR which interacts with specific DNA sequences VDRE in the promoter region of 
the target genes. (4) Subsequent, recruitment of co-activators by the activated heterodimer results in 
(5) the activation of the RNA-polymerase II complex (RNA-pol II). (6) This leads to transcription of 
the target genes followed by translation into a protein. (7) The expressed proteins exert the biological 
effects observed. 
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The binding of nVDR to its VDRE requires the presence of its ligand 1α,25(OH)2D3 and is 
favored by RXR. RXR belongs to the group of retinoic acid (Vitamin A) receptors. Although the 
active derivatives of vitamin A are not related to vitamin D3, RXR belongs to the same family of 
hormone-activated-transcription factors. This indicates that vitamin D and vitamin A are linked in 
their signalling. Indeed, the natural ligand for RXR, 9-cis retinoi acid, suppresses VDR-RXR 
binding to VDREs and subsequently 1α,25(OH)2D3-stimulated transcription. Examples of some 
1α,25(OH)2D3 actions in different target tissues are shown in Table 1.1. 
 
TABLE 1.1.: 1α,25(OH)2D3  genomic and non-genomic actions in target tissues  
 
Target tissues Action  
Parathyroid gland Inhibition of cell growth and PTH synthesis. 
 
Intestine  Enhancement of calcium and phosphate absorption. 
 
Thyroid/C-cells/Follicular cells Inhibition of calcitonin synthesis. 
 
Bone/osteoblast Enhancement of bonematrix protein synthesis, bone mineralisation, 
and synthesis of mediators with osteoclastic activity. 
 
Kidney (proximal and distal) Inhibition of 1α,25(OH)2D3 and induction of 24-hydroxylase. 
 
Immune system/monocytes 
macrophages /T cells/B cells  
Enhancement of macrophage function to control viral and bacterial 
infections. Enhancement of Th2-like cytokines (IL-4, IL-10 and IL10-
R) and Th3-like cytokines (TGF-β). Downregulation of Th1-like 
cytokines (IFN-γ, IL-12 and IL-2) and inflammatory cytokines (TNF-
α, IL-1, IL-6, IL-8). 
Skin/Muscle/Heart Antiproliferative and prodifferentiating. 
 
Cancers cells/c-myc (proto-
oncogene) 
Antiproliferative and prodifferentiating. 
Pituitary Control of T3-induced growth hormone and prolactin. 
 
Cartilage/Chondrocyte Antiproliferative and prodifferentiating. 
 
Pancreas/β-cells Enhancement of insulin synthesis and secretion. 
PTH: parathyroid thormone; Th: T-helper cells; IL: Interleukin; TNF: Tumor necrosis factor; IFN: 
Interferon; TGF: Transforming growth factor; T3: Thyroid hormone 
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1.1.2.2. Non-genomic actions of 1α,25(OH)2D3 
 
Besides its genomic action, 1α,25(OH)2D3 can also elicit rapid responses via a non-genomic 
action. There is still discussion on whether the receptor for this non-genomic action is located near 
(Barsony et al., 1997) or on the plasma membrane (mVDR). Potential membrane receptors are a 
66 kDa protein found on chicken duodenal cells (Nemere et al., 1994) and annexin-2 (36 kDa) 
found on rat osteoblast-like cells (ROS24/1, Baran et al., 2000). The major non-genomic effect of 
1α,25(OH)2D3 is calcium mobilization (Fig.1.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1.5: Non-genomic action of 1,25(OH)2D3 (transcaltachia = rapid hormonal stimulation of 
intestinal Ca++ absorption). cAMP: cyclic adenosine monophosphate, P-lipase C: phospho-lipase C, 
IP3: inositol triphosphate, DAG: diacyl glycerol, PIP2: phospho-inositol-diphosphate, PKC: protein 
kinase C. 
 
The binding of the hormone to the receptor initiates the activation of a pathway that leads to 
opening of voltage-gated Ca++-channels, increases the absorption of calcium from the small 
intestinal lumen and together with PTH, the reabsorption of calcium in the distal tubuli of the 
kidney. Protein kinase A, protein kinase C, phospholipase C/diacyl glycerol and 
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inositoltriphosphate (IP3) seem to be involved in this mechanism as second messengers. Even so 
the extra cellular signal-regulated kinase (ERK, Norman et al., 1998) as well as the c-Jun NH2-
terminal kinase-pathway (JNK, Caelles et al., 1997) are activated. However, the exact non-
genomic pathway remains unclear. It is hypothesized that some of the second messengers may 
function as a sort of ‘cross-talk’ between the non-genomic and genomic pathways so modulating 
the activity of the nVDR. Indeed, phosphorylation of the VDR by PKC has been shown to 
decrease its transcriptional activity (Matskovits and Christakos., 1995). 
 
1.1.3. Calcitriol and the immune system 
1.1.3.1. The Th1,Th2 and Th3 cytokine profiles 
 
T-helper (Th)1 and Th2 CD4+ cells were originally described in mice and later in humans 
(Mosmann et al., 1991). Th1 and Th2 cells differentiate out of the Th0 cells. Mouse Th1 cells 
produce interleukin (IL)-2, interferon-γ (IFN-γ) and tumor necrosis factor (TNF)-β which are 
involved in cellular responses, such as clonal expansion of cytotoxic T-lymphocytes (CTL), 
macrophage and natural killer (NK) cell activation and class switching to IgG isotypes (IgG2a) 
that can mediate complement lysis of sensitised cells. Th1 immune responses are important in 
controlling infections by intracellular organisms (Heinzel et al., 1989; Sher et al., 1992). 
However, Th1 responses also appear to play a central role in autoimmune diseases such as 
multiple sclerosis (Voskuhl et al., 1993). In contrast, Th2 cells produce IL-4, IL-5, IL-6, IL-9, IL-
10 and IL-13 providing more efficient help for B-cell activation and production of IgG1 and IgE 
antibodies (von Hertzen et al., 2000). Products of one subset may negatively regulate the 
development of the other as IFN-γ, produced by Th1 cells, inhibits Th2 proliferation while IL-10 
and IL-4, secreted by Th2 cells, inhibits the synthesis of Th1 cytokines probably through 
inhibition of IL-12 production by the APC (the Th1/Th2 paradigm) (Fig. 1.6) (Muraille and Leo 
1998).
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FIGURE 1.6.: Orchestration of an immune response with differentiation of naïve CD4 + and CD8+ T cells into 
armed effector cells (T-helper (Th)1, Th2 and Cytotoxic T cells (CTL)). The released cytokines influence the 
Th1/Th2 differentiation (Th1/Th2 paradigm) as well as the isotype specific immunoglobulins by activated B cells. 
Green arrow: activation/differentiation; red arrow: inhibition. The immunomodulating properties of 1α,25(OH)2D3 
and its influence on the cytokine-profile is shown. APC: antigen presenting cells, MΦ:Macrophage, DC: Dendritic 
cellls, DTH: Delayed type of hypersensitivity, pCTL: precursor cytotoxic (CD8+) T-cell, Th: T-helper (CD4+) cell.   
According to Mathieu and Adorini (2002): 1,25(OH)2D3 inhibits IL-12 and stimulates IL-10 production and thus 
inhibiting the development of Th1 cells. In addition 1,25(OH)2D3 favors the induction of CD4+CD25+ regulatory T 
cells which inhibit the development of Th1 cells. 
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The CD4+ Th-mediated response is certainly more than just Th1 and Th2, but these 
represent two extremely polarised forms. Another T-cell subset, the Th3 cells, has been identified 
more recently and produces high amounts of transforming growth factor β (TGF-β) but no IL-2, 
IFN-γ, IL-4 or IL-10 (Mosmann and Sad., 1996). TGF-β is an important cytokine in the 
development of mucosal immune responses (provides help for switch towards IgA) and oral 
tolerance in the gut (Coffman et al., 1989, Paul and Ceder 1994; MacDonald 1997). Another T-
cell subset is the T regulatory (Tr) cell. They are also essential for induction of tolerance 
(Roncarolo et al., 2001). Tr cells suppress immune responses via cell-to-cell interactions and/or 
the production of interleukin (IL)-10 and TGF-β. Many types of Tr cells have been described in a 
number of systems. Type-1 T regulatory (Tr1) cells are defined by their ability to produce high 
levels of IL-10 and TGF-β but their relationship with other T-cell subsets such as Th3 cells 
remains unclear. 
There are several factors affecting the Th1/Th2/Th3 differentiation, e.g. cytokines produced 
by ‘surrounding’ cells such as dendritic cells (DC), macrophages and B cells. Interleukin-12 
produced by macrophages and/or DC promotes Th1 differentiation while IL-4 promotes the 
differentiation towards Th2 cells. The effect of IFN-γ may be variable (Sad et al., 1994; Seder et 
al., 1993). Furthermore, co-stimulatory molecules on antigen presenting cells (APC, Thompson et 
al., 1995), and the nature as well as the concentration of an antigen (Pfeiffer et al., 1991) can 
influence the Th1/Th2 differentiation pathway. During the last decade extensive studies have been 
performed on the immunomodulating effects of several molecules such as CpG-ODN and 
1α,25(OH)2D3, for their capacity to switch the immune response towards Th1 or Th2. The 
intention is to selectively use these molecules as vaccine adjuvants or in the treatment of non-
infectious diseases (Schijns et al., 2000). 
It is hypothesized that similar Th1/Th2/Th3-profiles as in mice exist in other mammals such 
as the pigs. However, the relationship between the cytokine profile and the secretion of different  
immunoglobulin isotypes as shown in mice has not been proven in pigs. The currently known 
porcine cytokines with their main functions are summarized in table 1.2. 
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TABLE 1.2.: Porcine cytokines and their function. 
 
Cytokine (Genebank number) Source Function 
INF-α (M28623) MΦ and monocytes but any 
cell type can 
Inhibition of viral replication, 
antiproliferative activity and increase of 
MHC I. 
IFN-β (M 86762) Fibroblasts but any cell type 
can 
Inhibition of viral replication, 
antiproliferative activity and increase of 
MHC I. 
IFN-γ (X53085, S63967) T cells, NK cells and MΦ  MΦ activation; viral protection and 
increased MHC II and I expression. 
TNF-α (M29079) MΦ  Induces inflammation and co-stimulates 
lymphocyte proliferation. 
TNF-β (X54859) T cells  Activates tumor apoptosis, neutrophils, MΦ 
and B cells.  
IL-1α(X52731)  
IL-1β (M 86730) 
Many cells  Co-stimulators of Th2 cells and stimulation 
of acute-phase response. 
IL-2 (X5842, X56750) Th1 cells  Activation of T, B and NK cells. 
IL-4 (X68330) Th2 cells  Activates B-cell growth and their 
differentiation ; inhibition of IL-1, IL-6 and 
TNF-α. 
IL-6 (M86722,M802258) MΦ, T- and B cells, bone 
marrow stroma cells, 
fibroblasts and keratinocytes.  
Promote IL-2 production and T-cell 
differentiation. 
IL-8 (M99367) MΦ, fibroblasts, lymphocytes, 
granulocytes, endothelial cells, 
hepatocyes, keratinocytes  
Chemoattractant for neutrophils (activation), 
basophils and T cells.  
IL-10 (L20001) MΦ and Th2 cells  Inhibits activation of Th1 and NK cells and 
suppresses MΦ. 
IL-12 (U08317) MΦ Stimulate Th1 cells with secretion of IFN-γ 
and IL-2. Activation of NK cells and T cells.
IL-15 (U58142) Activated lymphocytes Enhances the T-cell proliferation. 
IL-18 (U68701) MΦ  Growth and differentiation factor for Th1 
cells. Induction of IFN- γ. 
GM-CSF (D21074) T cells, MΦ, endothelial cells 
and fibroblasts  
Stimulates proliferation of granulocytes, 
MΦ, erythrocytes progenitors and activates 
neutrophils, MΦ and eosinophils. 
TGFβ-1, TGFβ-2, TGFβ-3 
(M23703, M70142,X14150) 
Many cell types  Inhibitors of cell proliferation. Increase of 
cell density, fibrosis and angiogenesis. 
Switch towards IgA ? 
GM-CSF= granulocyte colony stimulating factor; TNF = tumor necrosis factor; IFN = interferon; IL= 
interleukin; TGF = transforming growth factor. MΦ = macrophages; NK cells = Natural killer cells. 
Adapted from Blecha 2001. In Biology of the Domestic Pig. 2001. Ed. Wilson G. Pond and H.J. 
Mersmann. p 689-711. 
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1.1.3.2. The nVDR in cells of the immune system 
 
The concept that 1α,25(OH)2D3 has immunomodulatory functions arises from the finding 
that certain cells of the immune system possess the nVDR. It was shown that activated peripheral 
lymphocytes, CD4+ Th cells as well as CD8+ CTL and thymocytes contain the nVDR (Manolagas 
et al., 1985; Provvedini et al., 1987). Recent studies however indicate that the nVDR is present in 
lymphocytes irrespective of their activation status (Veldman et al. 2000). They used a capture 
ELISA with two different monoclonal antibodies (MAb’s) against the nVDR and demonstrated 
that basal levels of nVDR in CD8+ cells (86,2 ± 10,4 fmol/mg) were significantly higher than 
those in CD4+ lymphocytes (40 ± 7,1 fmol/mg) and suggested that CD8+ cells may be the major 
target for 1α,25(OH)2D3  The amount of measurable nVDR is upregulated after in vitro 
stimulation with concanavalin A (ConA) co-administered with 1α,25(OH)2D3 probably due to an 
improved longevity and stability of the receptor as suggested by Veldman et al. (2000). 
Among the APC, monocytes and macrophages have significant levels of nVDR (Polly et al., 
1996) and higher levels were detected after stimulation with LPS and 1α,25(OH)2D3 (Veldman et 
al., 2000). Also dendritic cells (DC) possess a nVDR. DC are highly specialised APC, playing a 
central role in activation of naïve T cells and in initiation of cellular immune responses 
(Banchereau et al., 1998).  
Initial reports suggested that nVDR are expressed in B cells upon activation (Provvedini 1983, 
1986). Yet, no nVDR were detected by the capture ELISA in normal resting as well as activated 
and/or 1α,25(OH)2D3 treated B cells (Veldman et al., 2000). Although one research group has 
shown that nVDR is present in B cells if these B cells are activated in a specific way. This group 
detected nVDR mRNA expression in human tonsillar B cells after activation with anti-κ/λ MAb 
and/or anti-CD40 MAb supplemented with IL-4. This was also found in Epstein-Barr virus 
(EBV)-immortalized B cells (Morgan et al., 1994, 1999, 2000). However, there is discussion 
about their results and it is currently believed that B cells do not have a nVDR.  
 
1.1.3.2.1. Role of 1α,25(OH)2D3 and the nVDR in the immune function.  
 
In order to define the effect of 1α,25(OH)2D3 and the role of the nVDR in the immune system 
nVDR-deficient mice (VDR-knockout (VDR-KO) mice) were generated (Yoshizawa et al., 1997). 
These VDR-KO mice grow up normally until weaning, but after weaning they developed rickets-
like symptoms. They had severe hypocalcemia, high serum levels of 1α,25(OH)2D3, alopecia and 
impaired bone formation. The distribution of their lymphocyte subset  
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in different immune organs appeared normal in comparison with wild-type mice but their 
macrophage chemotaxis was reduced. (Mathieu et al., 2001). Proliferation of splenocytes 
following stimulation with anti-CD3 MAb, a Ca++-dependent activation, was significantly reduced 
in comparison with the wild-type mice. This was not the case after stimulation with phorbol-12-
myristate-13-acetate (PMA), which is a Ca++-independent mitogen. This suggests a Ca++-
dependent defect in VDR-KO mice. Indeed, normocalcemic VDR-KO mice show a normal anti-
CD3-stimulated splenocyte proliferation and a normal macrophage chemotaxis. 
VDR-KO mice are almost completely protected against low-dose streptozotocin-induced 
diabetes (LDSDM), a model for cell-mediated experimental autoimmune diabetes, in comparison 
with wild type mice. This indicates a defect in the cellular immunity of the VDR-KO mice. The 
protection against LDSDM disappeares by restoring serum calcium level in the VDR-KO mice. 
However, treatment with 1α,25(OH)2D3 of the wild-type and the VDR-KO mice resulted in 
complete protection against LDSDM of the wild-type mice with no change in the VDR-KO mice. 
The observed protection in the wild-type mice confirms the role of 1α,25(OH)2D3 as 
pharmacological immunomodulator, probably by the nVDR. Besides the nVDR, it can be 
concluded that calcium also may play an essential role in the immune system (Mathieu et al., 
2001). 
 
1.1.3.3. Effect of 1α,25(OH)2D3 on APC. 
 
The effects of 1α,25(OH)2D3 on cells of the monocyte-macrophage lineage depends on their stage 
of activation. Abe and co-workers (1981) were the first to discover that 1α,25(OH)2D3 causes the 
differentiation of resting HL-60 (a human promyelocytic leukemia cell line) and M1-cells (a 
murine promyelocyte line) towards phenotypically mature monocytes after several days of culture 
(prodifferentiation effect) but inhibits, in a dose dependent fashion, the proliferation of these cells 
(antiproliferative effect). The differentiation of these cell lines involves morphological maturation 
as well as physiological changes: increased non-specific esterase staining, enhanced cytotoxicity 
and phagocytosis, production of reactive oxygen intermediates in response to PMA stimulation 
and increased expression of CD14, CD18, CD11a CD11b and CD11c. CD18 and CD11 are cell 
surface antigens, which form the dimeric β2-integrin cell-adhesion molecules (Rigby et al., 1984, 
1985). The production of cytokines is also affected displaying increased IL-1, TNF-α mRNA 
expression and IL-6 cytokine production (Miyaura et al., 1989). Later it was found that 
1α,25(OH)2D3 also accelerates the maturation of resting human blood monocytes towards 
macrophages with an increased ability to control the intracellular proliferation of Mycobacterium  
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tuberculosis (Rook et al., 1986). Treatment of resting purified human monocytes with 
1α,25(OH)2D3 during 48 hours in the absence of other cytokines results in reduced expression of 
human MHC class II antigens (Rigby et al., 1990; 1992). However, this effect has not been 
observed in all studies (Poulter et al., 1987, Xu et al., 1993). Using a culture of 
monomorphonuclear cells (MC, mix of monocytes, macrophages, T- and B cells) the overall 
effect of 1α,25(OH)2D3 is a reduced antigen-dependent T-cell proliferation (Rigby et al., 1984). 
In contrast with resting monocytes, LPS-activated monocytes show in vitro a dose dependent 
inhibition of their IL-1α, TNF-α and IL-6 secretion by a 24 hours incubation with 1α,25(OH)2D3 
(Muller et al., 1990, Panchini et al., 1998). Another monocyte-derived cytokine, IL-8 is also 
reduced by 1α,25(OH)2D3 (Larsen et al., 1991). Comparison of the inhibitory effects  
of 1α,25(OH)2D3 obtained in cultures of MC and purified monocytes suggested a direct action of 
1α,25(OH)2D3 on the monocytes rather than an indirect one via interference with lymphocyte 
functions (Muller et al., 1992).  
Monocytes and macrophages possess 1α-hydroxylase which intracellularly converts 
25(OH)D3 to 1α,25(OH)2D3. As a consequence, 1α,25(OH)2D3 locally produced by macrophages 
can influence cellular events (lymphocyte reactions) in an autocrine (the secreting cells) and a 
paracrine way (surrounding cells) (Bouillon et al., 1995). Indeed, activation of monocytes leads to 
the production of inflammatory cytokines as well as to a high local concentration of 
1α,25(OH)2D3, which then may limit further cytokine release by these cells.  
In contrast with its effect on monocytes, 1α,25(OH)2D3 inhibits the differentiation, 
maturation and survival of DC (Penna et al., 2000, Griffin et al. 2001). In fact the steroid hormone 
directs DC towards an immature state with decreased levels of IL-12 (Adorini et al., 2001). 
Immature DC have the capacity to take up antigen and migrate towards secondary lymphoid 
tissues to initiate an immune response. A preference for migration of DC towards mucosal 
surfaces (Peyer’s patches of the gut) with subsequent activation of mucosal immune responses has 
been observed in mice by Enioutina et al. (1999, 2000). 
 
1.1.3.4. Effect of 1α,25(OH)2D3 on T cells 
 
1α,25-Dihydroxyvitamin D3 inhibits in vitro the mitogen- or antigen-induced T-cell 
proliferation in cultures of MC (Tsoukas et al., 1984; Rigby et al., 1984). Cell cycle analysis 
revealed that 1α,25(OH)2D3 blocks the transition from the G1a phase to the late G1b phase but 
1α,25(OH)2D3 has no effect on the expression of the IL-2 receptor (IL-2R, Rigby et al., 1990). As  
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described above the reduced T-cell proliferation is indirectly mediated by APC. However, it was 
also shown that 1α,25(OH)2D3 directly inhibits the proliferation of CD4+ and CD45 RO+ T-cell 
lines, activated by anti-CD3 MAb (Muller et al., 1993). Flow-cytometric analysis of mitogen-
activated MC showed no effect of 1α,25(OH)2D3 on the percentage of CD4+ and CD8+ 
lymphocytes indicating that the proliferation of both subsets is equally affected. Within subsets, 
1α,25(OH)2D3  inhibits the proliferation of a pure culture of activated (memory) T cells 
(CD45RO+) while this of naïve (CD45RA+) was unaffected during 6 days of culture (Muller and 
Bendtzen., 1992). It was not shown if this was also the case when the subsets were cultured 
together. 1α,25(OH)2D3 failed to affect the CD45RA+/CD45RO+ ratio of cultured MC.  
1α,25-Dihydroxyvitamin D3 also affects the Th cytokine profiles. The steroid hormone 
reduces directly the transcription, and subsequently the secretion of several cytokines including 
IFN-γ (Cipitelli et al., 1998), IL-2 (Alroy et al., 1995; Takeuchi et al., 1998), IL-8 (Harant et al., 
1997), IL-12 (D’ Ambrosio et al., 1998, Adorini et al., 2001) and granulocyte-macrophage colony 
stimulating factor (GM-CSF, Towers and Freedman., 1998). IL-12 is the most important cytokine 
for promoting differentiation of Th0 cells towards Th1 cells. Furthermore, 1α,25(OH)2D3 
enhances the production of Th2-cytokines such as IL-4 and IL-10 (Daynes et al., 1994, 1996; 
Cantorna et al., 1998) which in turn indirectly inhibit Th1-responses by acting on monocytes and 
APC. This indirect inhibition of Th1 probably occurs via decreased levels of IL-12 (D’ Andrea et 
al., 1993). 1α,25-Dihydroxyvitamin D3 is also known to stimulate TGF- β (Weinreich et al., 
1999). In mice and man TGF-β, a Th3-cytokine (Fukaura et al., 1996), is involved in mucosal 
immunity, isotype-switching towards IgA as well as IgG2b and in tolerance regulation (Letterio et 
al., 1998). So the steroid hormone can be classified as a Th2 (Th3?)-modulating-adjuvant (see 
also Fig. 1.6). A recent review (Mathieu and Adorini 2002) describes in secondary lymphoid 
tissues the inhibition of IL-12 and stimulation of IL-10 production by 1α,25(OH)2D3 with 
downregulation of costimulatory molecule expression (CD40, CD80 and CD86) by DCs, thus 
inhibiting the development of Th1 cells. The steroid hormone favored the induction of 
CD4+CD25+ regulatory T cells and of Th2 cells, which are able to further inhibit Th1 cells. The 
immune deviation towards a Th2-pattern was also described in nonobese diabetic (NOD) mice but 
this was limited to diabetic inducing antigens (pancreatic auto antigens, Overbergh et al., 2000).  
 
1.1.3.5. Effect of 1α,25(OH)2D3 on B cells and immunoglobulin secretion 
 
The role of 1α,25(OH)2D3 on B-cell function has yet to be fully elucidated. First of all 
reports concerning expression of nVDR yielded conflicting evidence as described above.  
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Furthermore conflicting data came on the effect of 1α,25(OH)2D3 on B cells. Some groups showed 
a direct inhibition of proliferation and Ig production of EBV-transformed and purified B cells 
(Provvedini et al., 1986, Iho et al., 1986). Others were unable to detect a direct 1α,25(OH)2D3-
mediated inhibition of B-cell function (Chen et al., 1987). Later there was evidence to believe that 
inhibition of Ig production is not caused by a direct effect of 1α,25(OH)2D3 on B cells, but rather 
mediated through impairment of T-cell and monocyte functions (Muller et al., 1992). Indeed, the 
inhibitory effect of 1α,25(OH)2D3 on the Ig production was seen after activation with poke weed 
mitogen (PWM, T cell dependent mitogen), but not after activation with EBV (T cell independent 
mitogen). In addition, 1α,25(OH)2D3 was not effective in T-lymphocyte- or monocyte-depleted 
cultures and thirdly the effect of 1α,25(OH)2D3 on PWM-activated MC was reversed by 
recombinant monokines (IL-1, IL-6) as well as lymphokines (IL-2). So 1α,25(OH)2D3 seems to 
inhibit Ig production in response to T-cell-dependent antigens but not to T-cell-independent 
antigens. This is accordance with a previous observation (Komoriya et al., 1985).  
As mentioned earlier, the action of 1α,25(OH)2D3 on T cells in mice results in a Th2 
response with increased IgG1 and decreased IgG2a concentrations (Lemire et al., 1995). 
However, in man no effect was observed on the humoral immune response after IM injection of 
influenza with 1 µg of the steroid hormone. This suggest that factors such as dose, antigen, 
species, activation stage in vivo, etc. can influence the outcome of 1α,25(OH)2D3 on B-cell 
responses. 
 
 1.1.4. Toxicity of 1α,25(OH)2D3 
 
Vitamin D intoxication is often accompanied with hypercalcemia. Multiple factors may 
influence susceptibility to vitamin D toxicity: concentration of vitamin D metabolites itself, the 
nVDR expression by target tissues, the activity of 1α-hydroxylase, the metabolism and the 
capacity to bind with DBP. Furthermore vitamin D toxicity can be due to an increase of 
1α,25(OH)2D3 and/or vitamin D metabolites but also by several diseases such as sarcoidosis 
(Sharma et al., 1996), tuberculosis ( Need et al., 1980), leprosy (Hoffmann et al., 1986), 
histoplasmosis (Walker et al., 1977) but also lymphoproliferative neoplasm such as Hodgkin’s 
lymphoma (Davies et al., 1985).  
Physiological routes and sources of vitamin D3 normally do not cause vitamin D 
intoxication as pharmacological and high doses (40,000-200,000 International Units (IU with 40 
IU = 1 µg 1α,25(OH)2D3) daily for weeks to months) are required as shown in humans (Jubiz et 
al., 1977). In contrast with the vitamin D ‘precursors’, the biological active 1α,25(OH)2D3 can  
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induce intoxication very quickly. Despite this, the use of 1α,25(OH)2D3 in treatment of 
osteoporosis is preferred over high pharmacological dosages of vitamin D ‘precursors’ because 
the latter and its main metabolite 25-hydroxyvitamin D3 with a half-life of 15 days (Haddad et al., 
1976) are stored in muscle and fat and can be retained in large amount. This can lead on the long 
term to severe hypercalcemia and hypercalcuria. This is not the case for 1α,25(OH)2D3 with a 
half-life time of 15 hours (Kawakami et al., 1979; Klein et al., 1977). The most favorable results 
from 1α,25(OH)2D3 treatment have been achieved using dosages in the order of 0.5 to 0.75 µg per 
day (oral intake). Dosages above 1 µg per day result in increased serum calcium and increased 
bone resorption due to activation of osteoclasts by the 1α,25(OH)2D3. At the recommended 
dosages of 0.5 to 0.75 µg 1α,25(OH)2D3 per day and with calcium intake restricted to 1000 mg 
per day, 1α,25(OH)2D3 appears to be safe (Tilyard et al., 1992).  
 
1.1.5. Applications of 1 α,25(OH)2D3 
 
Besides the ‘classical’ effects of 1α,25(OH)2D3 on mineral homeostasis and its use for 
osteoporosis, the steroid hormone also has other (therapeutic) applications. 
An important aspect of the immunosupressive actions of 1α,25(OH)2D3 is the therapeutic 
application of the steroid hormone in the control of autoimmune diseases such as experimental 
autoimmune encephalitis (EAE, model for multiple sclerosis), systemic lupus erythematosus 
(SLE), and type I (juvenile) diabetes. There is strong evidence that these autoimmune diseases are 
Th1-mediated (Baron et al., 1993; Bach et al., 1994). Studies using the non-obese diabetic mice 
showed that 1α,25(OH)2D3 can prevent the clinical development of type I diabetes (Mathieu et al., 
1994). Multiple injections of 1α,25(OH)2D3 resulted in a reduction of the incidence and severity of 
EAE (Renno et al., 1995) and was due to the production of Th2/Th3-cytokines (TGF-β1 and IL-4) 
that suppress TNF-α and IFN-γ secretion (Cantorna et al. 1998). Similar results were obtained 
with rheumatoid arthritis induced by Borrelia burgdorferi (Lyme disease). 
The immunosuppressive actions of 1α,25(OH)2D3 may also be useful in the regulation of 
transplant rejection. Acute rejection is prevented by immunosuppressants like cyclosporin A or 
FK 506, but these are toxic (nephrotoxic, hypertension, etc). The use of 1α,25(OH)2D3 as an 
alternative for these immunosuppressants was demonstrated in a heart allograft mouse model. 
Continuous administration of low doses of 1α,25(OH)2D3 significantly prolonged graft survival 
but caused hypercalcemia (Lemire et al., 1992). Currently, 1α,25(OH)2D3 and new 1α,25(OH)2D3-
analogs in combination with cyclosporin A are tested for their capacity to enhance survival of  
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xenografts. These analogs have the advantage that they do not cause hypercalcemia. In addition, 
combination of 1α,25(OH)2D3 and cyclosporin or of 1α,25(OH)2D3 and FK 506 allows a 10-to 5-
fold reduction in dosage of cylcosporin and FK506, respectively (Mathieu et al., 1994). 
Due to its capacity to control growth and differentiation, 1α,25(OH)2D3 has been therapeutically 
exploited to treat leukaemia, different cancers (Miller et al., 1998; Kawaura et al., 
1990) and psoriasis (Morimoto et al., 1986). Moreover, it has been described that 1α,25(OH)2D3 
enhanced the nerve growth factor in the central nervous system and may be a therapeutic agent in 
neuro-degenerative disease like Alzheimer’s disease (Wion et al., 1991). 
 
1.2. CpG-oligodeoxynucleotides (CpG-ODN) 
 
1.2.1 General aspects about CpG-ODN 
 
1.2.1.1. Definition 
 
Cytidine-phosphate-Guanosine (CpG) are unmethylated dinucleotides present at a frequency 
of 1 on 16 nucleotides in bacterial DNA, whereas they are underrepresented (1/50 to 1/60) and 
methylated in the vertebrate (mammalian) genomes (Cardon et al., 1994, Pisetsky 1996). Because 
of these differences, a nonself pattern recognition mechanism has evolved in the vertebrate 
immune system using ‘pattern recognition receptors’ (PRRs) enabling them to encounter invading 
pathogens and unmethylated CpG-dinucleotides (Krieg et al., 1995,2000, 2001). The biological 
activity of these CpG-dinucleotides can be mimicked by using in vitro and in vivo chemically 
synthesized CpG-oligodeoxynucleotides (CpG-ODN). 
CpG-ODN are chemically synthesized single stranded DNA sequences and are able to 
stimulate macrophages, NK cells, DC and B cells. They were originally synthesized in mice in a 
specific motif in which the CpG-dinucleotide is flanked preferentially by two purines, adenine (A) 
or guanine (G) at the 5’-end, and two pyrimidines, cytosine (C) or thymine (T) at the 3’-end, 
making for example AGCpGTT. The experimental use and success of some DNA-vaccination 
trials is partly due to the presence of CpG-motifs in many vectors (Babiuk et al., 2000). Based on 
its backbone and the context in which the CpG-ODN are arranged, they can be divided into 2 
classes of which the characteristics are shown in Table 1.3. 
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TABLE 1.3.: Distinct immune effects of different CpG-ODN 
 
Class¶ Backbonea Poly G stretchb Palindromec B-cell-
activationd 
NK-
activatione 
DC-
activationf 
CpG-A O, SOS + + +/- ++++ ++++ 
CpG-B S - - ++++ + ++++ 
abackbone of the DNA includes phosphodiester (O), nuclease-resistent phosphorothioate (S) or both (SOS, 
at which 5’ and 3’ ends are S nucleotides) ; bfour or more consecutive Gs might enhance its cell uptake ; 
cflanking complementary sequences such as AACGTT; dproliferation, expression of CD80 and CD86, Ig 
secretion and IL-6;e increased lysis and IFN-γ secretion; fexpression of MHC II and of CD80 and CD86. 
Adapted from Krieg et al (2001). 
¶According to Verthelyi et al. (2001,2002). Class A is also called “D-ODN”, triggers the maturation of 
APC and induces the secretion of IFN-α and IFN-γ by NK cells. Class B is also called “K-ODN” and 
triggers the maturation of DC, and stimulates B cells to produce IgM and IL-6. 
 
Normally, the bases are linked by phosphodiester (O-backbone) bridges although several 
modifications in the backbone of the CpG-ODN are possible (Fig. 1.7). An example is the 
formation of phosphorothioate oligonucleotides (S-backbone), in which one of the non-bridging 
oxygens in the phophodiester backbone is replaced by a sulfur atom (Fig. 1.7). This makes the 
CpG-ODN more resistant to nucleases, resulting in vivo in a decreased degradation and an 
increased cell-uptake (Liang et al., 2000; Sester et al., 2000). Base modifications have been shown 
to affect the level of immune stimulation of the CpG-ODN (Boggs et al.,1997) such as 
modification at the 5’ position on the cytosine ring. 
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FIGURE 1.7: Chemical structure of CpGA-sequence. Chemical modifications of CpG-ODN at the 
phosphodiester bond, sugars as well as at bases are indicated.  
 
The immunostimulating effects of CpG-ODN also depend on the sequence of the 
nucleotides flanking the CpG-dinucleotide as well as the target species. Optimal CpG-ODN 
motifs have been reported for several animal species (Table 1.4.). Comparing these motifs, it was 
obvious that recognition of a GTCGTT motif is highly conserved. A GACGTT motif however, 
was optimal for inbred strains of mice and rabbits (Rankin et al., 2001). 
Not all CpG-ODN have immunostimulatory properties and may have even neutralizing 
effects when co-administered with stimulating CpG-ODN. This is the case with CpG-dinucleotide 
sequences in the genome of adenoviruses in which the CpG-dinucleotide is preceded by a C 
and/or followed by a G (Krieg et al., 1998a). 
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TABLE 1.4.: Optimal CpG-ODN motifs for humans and several animal species. 
 
Species Backbone ODN-sequence 5’-3’ Reference 
Sheep S TCGTCGTTTGTCGTTTTGTCGTT Rankin et al., 2001 
Goat S TCGTCGTTTGTCGTTTTGTCGTT Rankin et al., 2001 
Horse S TCGTCGTTTGTCGTTTTGTCGTT Rankin et al., 2001 
Pig S, SOS TCGTCGTTTGTCGTTTTGTCGTT 
ggTGCATCGATGCAGggggg 
Rankin et al., 2001 
Kamstrup et al., 2001 
Dog S TCGCGTGCGTTTTGTCGTTTTGACGTT Wernette et al., 2002 
Cat S TCGTCGTTTGTCGTTTTGTCGTT Wernette et al., 2002 
Cow S TCGTCGTTTGTCGTTTTGTCGTT Brown et al., 1998, 2000; 
Pontarollo et al., 2002.,  
Chicken S TCGTCGTTTGTCGTTTTGTCGTT Rankin et al., 2001 
Rat S TCGTCGTTGTCGTTTTGTCGTT Rankin et al., 2001 
Rabbit S TCCATGACGTTCCTGCAGTTCCTGACGTT Rankin et al., 2001 
Mouse S TCCATGACGTTCCTGACGTT Klinman et al., 1999 
Sparwasser et al., 1998 
Fish S pcDNA3* with ampR gene with 2 repeats  
of AACGTT 
Kanellos et al., 1999. 
Human/primates  S TCGTCGTTTTGTCGTTTT Hartmann et al., 2000. 
Backbone details are abbreviated: SOS (mixture of phosphorothioate and phosphodiester bonds within the same 
ODN); S (phosphorothioate ODN), O (phosphodiester ODN). Potential stimulatory motifs are underlined. 
*:pcDNA3 is an eukaryotic plasmid which contains an ampicillin-resistance-gene and is often used in DNA-
vaccination trials. g = phosphorothioate Guanosine-stretch. 
 
1.2.1.2. Molecular mechanisms of CpG-ODN 
 
Hemmi et al. (2000) demonstrated that the Toll Like Receptor (TLR)-9 is required for the 
immune activation by CpG-ODN. The TLR-family, first discovered in Drosophila, is a 
phylogenitically-conserved family of receptors that plays a central role in the initiation of cellular 
innate immune responses and is essential for microbial recognition (Medzhitov et al., 1997). So 
far 10 members (TLR 1-10) have been identified in mammalia and the current idea is that these 
members have distinct ligands (Metzhitov et al., 1997, 2001; Vasselon et al., 2002). Toll of 
Drosophila and its mammalian homologues are type I transmembrane proteins, with an extra-
cellular domain consisting of leucine-rich repeats (LRRs) and one or two cysteine-rich regions  
followed by a transmembrane region. The intracellular domain contains a Toll/IL-1 receptor (TIR) 
domain which is also found in the IL-1 and IL-18 receptor. However, in the latter two, the extra 
cellular LRR domains are replaced by three immunoglobulin domains in their extra-cellular 
domain (Fig. 1.8). 
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FIGURE 1.8: The Toll-like receptor 9 (with leucine rich regions in their extra-cellular domain) and 
the interleukin-1 receptor (IL-1R)-family members (three immunoglobulin domains extra-cellular) 
share several signalling components, including MyD88, Toll-interacting protein (TOLLIP), the protein 
kinase IRAK (ILR-associated kinase) and TRAF 6 (TNF-receptor associated factor 6). MyD88 can 
bind to activated Toll and IL-1R through interactions with the Toll/IL-1 receptor (TIR) domains of the 
receptor. Subsequently, MyD88 associates with IRAK and this leads to activation and association with 
TRAF 6. TRAF 6 can activate nuclear factor-κB (NF- κB) through TAK (TGF-β activated kinase), 
and JNK (c-jun N-terminal kinase) and p38 MAP kinases through MKK6 (mitogen-activated protein 
kinase kinase 6) which induce transcription (via different transcription factors). TOLLIP lacks a TIR 
domain, but contains a C2 domain, which is known to interact with membrane lipids. TOLLIP can 
also associate with IRAK and the TIR domains of the TLR-9 and binds IRAK to the receptor complex. 
LRR: Leucine rich regio.  
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The TIR domain of Toll proteins is a conserved protein-protein-interaction module, which 
is also found in a number of transmembrane and cytoplasmic proteins in animals and plants. TIR 
domain-containing proteins have a role in host defence. Signalling pathways activated by TLRs 
can be divided into ‘shared’ and ‘specific’ pathways. A shared pathway is induced by all TLRs as 
well as by the IL1-R. The specific pathways are activated in some TLRs and may account for 
differences in signalling between some TLRs and IL-1R. The signalling pathway of TLR-9 
includes four essential components: the two adaptor proteins, MyD88 (Aravind et al., 2001) and 
TOLLIP (Toll-interacting protein, Burns et al., 2000); a protein kinase, IRAK (IL-1 receptor-
associate kinase) and an other adaptor molecule TRAF 6 (TNF-receptor-associated factor 6). 
TRAF 6 induces activation of TAK 1 (=TGF-β activated kinase) and MKK6 (MAP kinase kinase 
6), which, in turn activate NF-κB and JNK (c-jun-N-terminal kinase) + p38 MAP kinase, 
respectively (Hacker et al., 1998, Yi and Krieg 1998). Activation of the signal transduction 
pathways by TLR-9 leads to the induction of various genes that function in the host defence and 
results among others in the production of ROS (reactive oxygen species), inflammatory cytokines, 
chemokines, MHC II and co-stimalatory molecules. JNK phosphorylates the activator protein 1 
(AP-1)-family transcription factor Jun while p38 activates the activation transcription factor 
(ATF)-2 and leads to expression of IL-12 and TNF-α in macrophages. Also the expression of 
oncogenes such as c-myc is induced by CpG-ODN (Yi et al., 1998). The induction of c-myc may 
be related to anti-apoptotic effects of CpG-ODN as observed in macrophages and B cells (Yi et 
al., 1998). 
The nature and location of TLR-9 remains controversial. In general, TLRs are found on the 
cell membrane surface and this was recently confirmed for TLR-9 by flow cytometry (Chuang et 
al., 2002). However, previous experimental studies by Yamamoto and co-workers (1994) showed 
that lipofection of murine splenocytes with liposomes containing CpG-ODN enhances IFN-γ and 
NK-activity. Since lipofection allows CpG-ODN to enter the cell without binding on a cell 
membrane receptor, it appears that interaction with a cell surface receptor is not essential for 
CpG-ODN to exert their biological effects. Results of Manzel and Macfarlane (1999) seem to 
confirm this. They demonstrated that cellular uptake of CpG-ODN was needed for B-cell 
activation and suggested that CpG-ODN interact intracellularly with a receptor or a signal 
transduction pathway. An other argument for this intracellular interaction is that the uptake into 
the cells seems to be sequence (CpG)-independent (Krieg et al., 1995, Yamamoto et al., 1994) 
whereas the biological effect is not. This indicates that distinction between activating and non-
activating CpG-ODN takes place after the uptake. Interestingly, signalling by CpG-ODN requires 
internalisation into late endosomal or lysosomal compartments. This was shown by addition of  
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drugs that prevent acidification of endosomes such as chloroquine or monensin (Hacker et al., 
1998 ; Yi et al., 1999). The lysosomes or late endosomes are possible candidates for harboring 
this intracellular receptor. Indeed, MyD88 co-localises with CpG-ODN in endosomal structures 
and not at the cell membrane  as shown by flow-cytometry and confocal microscopy (Schnare et 
al., 2000; Horng et al., 2001). Also the presence of a transmembrane domain in the TLR-9 
suggests that the TLR-9 can interact into the membranes of the endosomes. So at this moment, the 
mechanism proposed is binding of CpG-ODN to the TLR-9 followed by endocytosis and the 
release into the cytoplasm. Subsequently, CpG-ODN bind to a ‘intracellular’ receptor and activate 
the signalling pathways. 
1.2.2. CpG-ODN and the Immune system 
 
1.2.2.1. Effect of CpG-ODN on macrophages and DC. 
 
One of the properties of macrophages and to a greater extend of DC is processing and presenting 
an antigen to T cells via MHC class II. This is accompanied with the co-expression of co-
stimulatory molecules and subsequent secretion of cytokines (Bancherau and Steinman, 1998). 
Upon stimulation with CpG-ODN, both APC are directly stimulated and subsequently produce 
IL-12. This in turn activates NK cells into the production of IFN-γ which suppresses Th2 cells and  
stimulates macrophages to produce more IL-12. All this results in a Th1 microenvironment. 
Besides IL-12 and IFN-γ, there is also increased secretion of IL-18, which also modulates towards 
Th1 (Klinman et al., 1995, 1997; Yi et al., 1996, Lipford et al., 1997). 
CpG-ODN may also affect T-cell responses by altering antigen processing and presentation 
functions of macrophages and DC. Theoretically, an increase in antigen presentation can explain 
the adjuvant effects of CpG-ODN. However, it was shown in vitro that CpG-ODN cause a 
decrease in the synthesis of MHC II molecules by peritoneal macrophages resulting in down 
regulation of antigen presentation (Chu et al., 1999). How this relates to the in vivo effects of 
CpG-ODN is not clear since the in vivo situation is a summary of direct and indirect effects on 
macrophages. The latter are due to stimulation of other cell types such as NK cells which can 
produce IFN-γ enhancing antigen processing and presentation.  
Macrophage responses to CpG-ODN differ significantly from that of DC. Treatment of DC 
with CpG-ODN induces maturation, increased expression of both MHC II and co-stimulatory 
molecules and a transient increase in antigen processing followed by a decline in antigen 
processing (Jakob et al., 1998, Sparwasser et al., 1998). The presentation of a previously 
processed antigen is not affected. (Hartman et al.,1999). 
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1.2.2.2. Effect of CpG-ODN on T cells. 
 
CpG-ODN have been shown to act as Th1-modulating adjuvants as shown in mice and man 
(Forsthuber et al., 1996; Chu et al., 1997). 
It is still controversial whether CpG-ODN have a direct effect on T cells. Lipford and co-workers 
(1997) showed that CpG-ODN do not directly activate a culture of pure T cells. Sun et al. (1998) 
showed that CpG-ODN could increase proliferation as well as expression of surface-markers 
(CD69, B7-2, Ly6C and MHC I) of purified CD4+ (Th) and CD8+ (CTL) T cells and that this was 
dependent on the presence of APC but independent of a TCR/MHC (class I and II) interaction. 
Later on, they demonstrated that the surface-marker upregulation was mediated by CpG-ODN 
induced type-I interferon (IFN-I, Sun and Sprent 1999) secretion by APC. The type-I IFN-
secretion could not explain the increased proliferation since type I IFN normally inhibit T-cell 
proliferation. Bendigs et al. (1999) showed that CpG-ODN act as a co-stimulatory signal (signal 
2) for T cells activated by cross-linking their T-cell receptors (signal 1 = addition of anti-CD3 
MAb). This mechanism could promote antigen-specific T-cell proliferation. 
 
1.2.2.3. Effect of CpG-ODN on B cells and immunoglobulin (Ig) secretion. 
 
CpG-ODN are very potent B-cell mitogens (equally stimulatory for both resting as activated 
B-cell subsets (Krieg et al., 1998)) that drive more than 95% of the B cells into the cell cycle 
(Krieg et al., 1995). The mechanism of this polyclonal B-cell activation remains unclear. 
B-cell stimulation with CpG-ODN also results in the secretion of IL-6 and IL-10 and IgM. 
Addition of IFN-γ (Th1) results in a higher secretion of IL-6 (Yi et al., 1996). CpG-ODN also 
seem to rescue B cells (Mower et al., 1994, Yi and Krieg, 1998) from apoptosis. This requires the 
activation of the NFκB pathway and the expression of c-myc and bcl-xl (Fischer et al., 1994). 
For human B cells it was shown that these CpG-ODN that induced maximal proliferation, 
also enhanced the production of IgM, IgA and IgG, in the absence of exogenous cytokines or T 
cells (Liang et al., 1996). Co-administration of IL-2 (Th1), but not IL-4 and IL-10 (Th2), 
enhanced B-cell proliferation and Ig secretion. In vivo, addition of CpG-ODN leads to isotype 
switch to IgG2a. In mice, this isotype is correlated with a Th1 response and with the presence of 
NK cells and APC (Mosmann et al., 1991; Davis et al., 1998). More than 80% of CpG-activated B 
cells show enhanced expression of activation markers including CD69, CD86, IL-2R (CD25) and 
IFN-γR (Martin-Orozco et al., 1999). Besides the polyclonal activation of B cells, CpG-ODN also  
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stimulate the antigen-specific B-cell responses. This stimulation occurs indirectly via APC after 
cross linking the BCR (Krieg et al., 1995). 
 
1.2.2.4. Effect of CpG-ODN on NK cells 
 
NK cells protect against viruses and other pathogens by releasing the contents of their 
granules and killing the infected cells. NK cells seem to be very important in the innate immune 
response providing a first defence in the immune system. Tokunaga and colleagues (1984) 
showed that bacterial DNA (CpG-ODN) strongly activates NK cells with enhanced IFN-γ 
secretion and lytic activity. These effects are not observed using highly purified NK cells 
indicating that other cells are needed and that the effect on NK cells is indirect. The adding of 
MAb against IL-12, TNF-α and type I IFN  blocked NK cell-activity and indicated that these cells 
were APC (Cowdery et al., 1996). Furthermore, addition of CpG-ODN together with IL-12 had a 
synergistic effect on the activity of NK cells in comparison with NK cells incubated with only an 
equal amount of IL-12. The same seemed to be true for IL-18 (Weiner et al., 2000). The effect of 
both cytokines (IL-12 + IL-18) enhances the production of IFN-γ by NK cells. In conclusion, 
CpG-ODN activate NK cells in a Th1-environment (IL-12 and IL18) provided by activated APC. 
These activated NK cells in turn produce IFN-γ and have an increased lytic activity. The secretion 
of IFN-γ further maintains and/or enhances this Th1-environment. 
 
1.2.3. Toxicity of CpG-ODN 
 
Weeratna et al. (2000) showed that CpG-ODN , when used as a vaccine adjuvant, are safe 
and even less toxic than other conventional adjuvants. There has been fear that CpG-ODN could 
trigger systemic autoimmune diseases, as most autoimmune diseases are mediated by Th1-
responses. Indeed, Bachmaier et al. (1999) reported that CpG-ODN can induce autoimmune 
myocarditis. Moreover, CpG-ODN activate auto-reactive Th1-effector cells specific for myelin 
basic protein and trigger the development of experimental autoimmune encephalitis (EAE) 
(Tsunoda et al., 1999). In contrast Boccacio et al. (1999) could reduce the symptoms of EAE with  
CpG-ODN due the high secretion of IFN-γ. However, this could be due to a different sequence of 
ODN, dose, etc. 
A single dose of 500 µg CpG-ODN does not cause toxic shock in mice. However, repeating 
this dose within a week can cause death by either enhanced TNF-α, IFN-γ and IL-12 secretion or  
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by massive proliferation of B cells (Krieg et al., 2000). Toxicity has also been seen in 
combination with LPS: CpG-ODN seems to prime for a schwartzmann reaction when a sublethal 
dose of LPS is given a few hours after the CpG-ODN. This schwartzmann reaction is a LPS-
mediated-shock due to dramatic increase of TNF-α and IFN-γ (Cowdery et al., 1996; 
Sparwasser et al., 1997). 
 
1.2.4. In vivo applications of CpG-ODN 
CpG-ODN can be administered either by injection (intravenous, intraperitoneal, 
intramuscular or intradermal injection) or via non-invasive methods (gene gun, topical 
administration on the skin, administration via mucosae). The use of CpG-ODN in vivo results in 
an overall increase of antigen-specific Ig secretion but with a prominent increase of the IgG2a Ig 
isotype and a Th1-cytokine pattern (Fig. 1.9). 
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FIGURE 1.9: Schematic presentation of the mechanism postulated for the induction of an antigen-specific Th1 
and antibody response by CpG-ODN vaccination. Initially CpG-ODN trigger the release of IFN-γ by NK cells as 
well as inducers of IFN-γ such as IL-12, IL-18 and TNF-α, which are secreted by APC (DC and macrophages 
(MΦ)). Furthermore CpG-ODN act as direct mitogens for naïve B cells which proliferate and secrete IL-6, IL-10 
and IgM antibodies. At the same time CpG-ODN activate and induce maturation of DC resulting in the 
expression of co-stimulatory molecules (CD80, CD86, MHC II, CD40). The mature DC migrate to the 
secondary lymphoid organs where APC-T-cell interaction as well as T-cell -B-cell interactions occur. The initial 
secreted Th1-cytokines (IFN-γ) prime naïve T-helper cells to differentiate towards Th1 cells. Th1 cells secrete 
Th1-cytokines. These cytokines induce activated B cells to produce antigen-specific IgG2a antibodies. DC 
=dendritic cells; APC=antigen presenting cells; IFN=interferon. 
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The modulation towards a Th1-response together with the increased Ig secretion make CpG-
ODN very potent adjuvants for vaccines and were shown to be safe after intramuscular injection 
(Weeratna et al, 2000). Modulation towards a Th1-response can be desirable because (i) in mice 
Th1-responses are associated with the production of IgG2a which have better neutralizing 
capabilities than IgG1 antibodies and (ii) Th1 cytokines (IFN-γ, IL-2, IL-12) enhance the cell 
mediated immunity (CMI) in general and more specific the maturation of CTL-responses. The 
adjuvant effects of CpG-ODN have been demonstrated in immunisation with several pathogens 
and antigens such as live attenuated measles virus (Kovarik et al., 1999), Brucella melitensis (Al-
Mairiri et al., 2001), hen-egg lysozyme (Chu et al., 1997), ovalbumin (Shirota et al, 2000), β-
galactosidase (Roman et al., 1997). Adjuvants effects were also seen for responses against T-cell 
independent polysaccharide antigens (Kovarik et al., 2001). 
CpG-ODN can also be used as a mucosal adjuvant. Nasal administration of β-galactosidase 
(β-gal) together with CpG-ODN resulted in an enhanced β-gal-specific IgA response in serum as 
well as mucosal secretions (feces, vagina, broncho-alveolar fluid, Horner et al., 1998, 2000). The 
antibody response was comparable with the response seen after intranasal administration of β-gal 
together with cholera toxin (CT), a very potent mucosal adjuvant (Lycke et al., 1992).  
The neonatal immune system is still immature. Immune responses are Th2 based, the cell-
mediated responses are poor but also the B-cell responses are weak and preferentially generate 
IgM and IgG1 antibodies with low affinity. CpG-ODN might be helpful for the maturation of this 
neonatal immune system and in controlling infections in young animals. Indeed, CpG-ODN have 
been shown to be protective in young mice against challenge with Listeria monocytogenes, 
Anthrax, Malaria, Leishmania or Schistosoma after injection with antigens of these pathogens 
supplemented with CpG-ODN. (Krieg et al., 1998, Elkins et al., 1999, Zimmerman et al., 1999, 
Walker et al., 1999, Stacey et al., 1999).  
One of the most important therapeutic applications of CpG-ODN could lay in treatment of 
allergies such as asthma. Allergies are becoming very important problems in Western countries. 
They are characterized by a Th2-type of immune response involving IL-4, IL-5 and IL-13 
(Robinson et al., 1996; Wills-Karp et al., 1998). IL-4 induces the formation of IgE (Del Prete et 
al., 1994), IL-5 stimulates the proliferation and activation of eosinophils (Clutterbuck et al., 1988) 
and basophils and IL-13 causes airway hyperresponsiveness and inflammation (Grunig et al., 
1998). Studies in animal models (murine models of asthma) revealed that CpG-ODN prevent 
eosinophylic airway inflammation and bronchial hyperreactivity to non-specific stimuli (Kline et 
al., 1998). Moreover, less IL-4 but increased IFN-γ and IL-12 were found in lung lavage fluid. 
The antigen-specific IgE antibody response was also suppressed by CpG-ODN (Roman et al.,  
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1997). So, CpG-ODN seems to reverse an established Th2-mediated allergic disease towards a 
Th1 response (Kovarik et al.,1999). However, the Th2-response could only be redirected in older 
but not in neonatal animals. The new Th1-response remained for a long period even in the 
presence of antigens, which normally evoke a Th2-response (Goodman et al., 1998). 
The ability of CpG-ODN to co-stimulate T cells (signal 2) might be important in situations 
where no APC are present or where the antigen presentation is not sufficient to evoke a response, 
as it is the case in some tumor cells. CpG-ODN could bypass this insufficient presentation by 
acting as co-stimulators for T cells. Moreover, CpG-ODN enhance the production of cytokines 
such as TNF-α, IL-12 and IFN-γ which all have anti-tumor activity (Ballas et al., 1996; Cowdery 
et al., 1999; Lipford et al., 1997). Limited data suggest that CpG-ODN themselves can have anti-
tumor effects. Smith and Wickstrom (1998) showed that CpG-ODN inhibit the growth of 
lymphomas. In addition CpG-ODN are able to enhance the efficacy of antibody therapy using 
MAb against tumor antigens by increasing the cell killing of the antibody-coated tumor cells 
(ADCC) by NK cells, macrophages and/or monocytes (Maloney et al., 1997, Pegram et al., 1998). 
Most challenging in the development of cancer vaccines is the induction of a tumor-specific 
immune response. This requires a cellular rather than a humoral response. Mice immunised with 
the tumor antigen, an antigen of lymphoma, to which CpG-ODN were added as an adjuvant, were 
protected against tumor challenge (Weiner et al., 1997). These mice showed enhanced IgG2a 
antibodies and CTL responses. Normally, exogenously delivered antigens are loaded on MHC II 
molecules and evoke a humoral response, while intracellular proteins are processed and presented 
by class I which lead to CTL-responses. Some extra-cellular antigens, however, are taken up by 
APC and processed in a manner that leads to presentation in class-I molecules, which is termed 
“cross-priming” (Rock et al., 1996). The results above support the concept that an effective 
cellular response (CTL responses) can be induced by immunisation with an intact tumor antigen 
plus CpG-ODN. CpG-ODN activate immune cells and induce cross-priming (Davis et al., 2000). 
Among the cells activated by CpG-ODN important in cancer therapy are the DC. The 
combination of CpG-ODN and DC could be useful in cancer-immunotherapy.  
 
1.3. Use of Calcitriol and CpG-ODN in veterinary medicine and vaccines 
 
The majority of publications regarding immunoregulatory properties of 1α,25(OH)2D3 and 
CpG-ODN are based on models in rodents (mice) and man. Little is known about its role in the 
immune system of domestic animals such as pigs, cattle, dogs, cats, horses, chickens, etc. 
However, it was already found in the early eighties that T cells in the calf thymus and lymph node  
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exhibit nVDR (Reinhardt et al., 1982). In cattle, an inhibitory effect of 1α,25(OH)2D3 on ConA-
induced proliferation of lymphocytes was observed in bovine MC. In higher doses however the 
steroid hormone enhanced the ConA-induced proliferation (Reinhardt and Hustmyer, 1987). 
Furthermore, 1α,25(OH)2D3 inhibits Th1-like responses as the secretion of IFN-γ by bovine MC 
was abolished (Ametaj et al., 1996). This is accompanied with enhanced immunoglobulin 
secretion as observed by Nonnecke et al. (1992). Indeed, IM vaccination with the J5-vaccin 
(containing cell wall core antigens of Escherichia coli causing coliform mastitis) supplemented 
with high doses of 1α,25(OH)2D3 (2 x 200 µg) enhanced the J5-specific IgA, IgG1 and IgG-titer in 
milk but decreased the IgG2-milk antibody titer (Reinhardt et al., 1999). In sheep, 1α,25(OH)2D3  
altered the ratio between IgG1 and IgG2 but no typical mucosal immune response in a peripheral 
lymph node, as characterised by IgA antibodies, was induced (Scheerlinck et al., 2001). Little is 
known about the immunomodulating effects of 1α,25(OH)2D3 in swine. However, the presence of 
the nVDR in porcine leukocytes and macrophages is expected (Bondarenko et al., 1994; Reichel 
et al., 1991). Moreover, it was shown that porcine alveolar macrophages are able to produce 
1α,25(OH)2D3 (Reichel et al., 1991). 
As described earlier CpG-ODN may have adjuvants effect in many veterinary species 
(Rankin et al., 2001). Recently it was demonstrated that even mice-specific CpG-ODN 
enhance the humoral responses in chickens after IM immunisation (Vleugels et al., 2002). In 
cattle it was shown that CpG-ODN (GTCGTT-motif) or CpG DNA from Babesia bovis, 
Trypanosoma cruzi and Trypanosoma brucei sequences stimulates bovine leukocytes with 
enhanced IL-12, IL-6, NO and TNF-α production. This was accompanied with increased 
proliferation of B cells (Brown et al., 1998, 2001; Shoda et al., 2001; Zhang et al., 2001; 
Pontarollo et al., 2001). Recently, Kamstrup et al., (2001) showed in vitro that porcine blood 
MC are stimulated by CpG-ODN. In addition, the plasmid pcDNA 3, containing an 
AACGTT-motif, induced production of IFN-α and IL-6 in cultures of porcine leukocytes 
(Magnusson et al., 2001). Methylation of all cytosines in these CpG-motifs abolished the IFN-
α inducing capacity. The pcDNA3 is a commonly used expression vector for eukaryotic cells.
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AIMS OF THE STUDY 
 
Intestinal infections caused by enterotoxigenic Escherichia coli (ETEC) can lead to neonatal 
and post-weaning diarrhea in swine and to severe economic losses. Many parenteral vaccines are 
available for inducing a lactogenic protection against neonatal diarrhea. These vaccines can not be 
used against post-weaning diarrhea since parenteral vaccines in general do not induce an active 
intestinal mucosal immunity which is needed to protect the weaned piglets.  
The goal of the present work is to study in pigs if a systemic (intramuscular) immunisation 
can induce or prime a mucosal (IgA) response using immunomodulators and if so to gain insights 
into the mechanism of the immunomodulation. In this work two different immunomodulators 
(adjuvants) are used: 1α,25(OH)2D3 and Cytidine-phosphate-Guanosine oligodeoxynucleotides 
(CpG-ODN). Immunisation is performed using different antigens: (ovalbumin (OVA), human 
serum albumin (HSA) and purified F4-fimbriae from F4+-ETEC. 
 
In particular for 1α,25(OH)2D3 the following issues are examined: 
• Can 1α,25(OH)2D3 enhance the antigen-specific IgA immune response ? 
• If so, is the enhanced IgA response correlated with a Th2-like cytokine profile? 
• Is it possible by adding 1α,25(OH)2D3 to prime for an intestinal mucosal immune 
response?  
 
In particular for CpG-ODN the following issues are investigated: 
• Can CpG-ODN be used as immunomodulating/immunoenhancing adjuvants for IM 
immunisation?  
• If so, which CpG-ODN sequences are most immunostimulatory for pigs and which 
immune cells become activated by CpG-ODN ? 
 
In particular for the F4+-ETEC infection in piglets we wondered if:  
 
• Different doses of F4-fimbriae can evoke different isotype-specific antibody 
responses after intramuscular immunisation ? 
• Intramuscular immunisation of piglets with an optimal dose of F4-fimbriae 
supplemented with 1α,25(OH)2D3 or CpG-ODN could protect against an F4+-ETEC 
challenge ? 
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2.1. Abstract 
 
In this study, the immunomodulating effect of two steroid hormones namely 1α,25-
dihydroxyvitamin D3 [1α,25(OH)2D3] and dehydroepiandrosterone [DHEA] was examined on 
the antigen-specific antibody responses by intramuscular immunisation of pigs with human serum 
albumin alone (HSA) or supplemented with 2µg of 1α,25(OH)2D3, 40 µg of DHEA or the 
combination of both steroids. 1α,25(OH)2D3  significantly enhanced the antigen-specific IgA and 
IgM serum response. Higher HSA-specific IgA titers were also found in the mucosal secretions 
(saliva, feces and nasal) of the steroid treated animals, especially in the 1α,25(OH)2D3  group. 
Furthermore, 1α,25(OH)2D3  and DHEA increased the number of antigen-specific IgA and IgG 
antibody-secreting cells in the local draining lymph nodes, but only few numbers were detected in 
lymph nodes draining the mucosa. DHEA decreased the IgM serum response and  had the 
tendency to enhance the IgG2 and IgG serum responses. Strong and comparable IgG, IgG1 and 
IgG2 serum responses were seen in all groups. Combining both steroids did not result in a higher 
IgA serum response. On the contrary DHEA seems to neutralize the effect of 1α,25(OH)2D3  on 
the IgA response. In conclusion, 1α,25(OH)2D3  significantly enhanced the antigen-specific IgA 
and IgM response in serum and the number of antigen-specific IgA and IgG ASC in the local 
draining lymph nodes following intramuscular immunisation. 
 
 
2.2. Introduction 
 
Mucosal surfaces are continuously exposed to environmental organisms and antigens and 
have therefore developed a variety of protective mechanisms (ΜcGhee et al., 1992). Mucosal 
protection is mainly due to the active secretion of IgA antibodies. These antibodies are induced 
following contact of the mucosae with potential harmful microorganisms resulting in 
neutralisation and subsequent elimination of these pathogens. Although mucosal immune 
responses are generally induced at mucosal sites, Daynes and co-workers (Daynes et al., 1996 ; 
Enioutina et al., 1999) demonstrated in mice that a mucosal immune response can also be induced 
systemically using immunomodulators, such as the steroid hormone 1α,25(OH)2D3,  the active 
metabolite of vitamin D. 1α,25(OH)2D3  influences the production of different lymphokines in the 
local draining lymph node. Indeed, in vitro stimulation with anti-CD3ε of cells from the local 
draining lymph node of a mouse treated with 1α,25(OH)2D3 resulted in an enhanced production of 
IL-4, IL-5 and IL-10 and a reduced production of IL-2 and interferon-gamma (IFN-γ). So the 
steroid compound appears to modulate a switch of the cytokine-profile from a Th1 towards a Th2- 
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profile as occurs in the mucosal-associated lymphoid tissue (MALT). This was accompanied with 
an increase in antigen-specific IgA in serum and mucosal secretions and with the homing of IgA 
and IgG antibody secreting cells to the lamina propria of the intestine and the lungs. 
1α,25(OH)2D3 exerts its effect via binding to a nuclear receptor which presence is well 
documented in activated T-cell subpopulations  (T-helper (Th) and T cytotoxic cells (CTL)) as 
well as in  activated B-lymphocytes (Baran et al., 1994; Minghetti et al., 1988; Povvedine et al., 
1986, 1989). 1α,25(OH)2D3 modulates via this receptor not only the production of cytokines but 
also induces a dose-dependent suppression of Th cell proliferation. Furthermore, inhibition of B 
cell proliferation and a dose-dependent suppression of the IgG1 immunoglobulin production have 
been described (Lemire et al., 1984). 
Dehydroepiandrosterone (DHEA) also seems to have immunomodulatory effects. DHEA is 
produced by the adrenal glands and is one of the major androgen steroid hormones in men and 
women between the second and fifth decade of life (Regelson et al., 1994) A specific receptor for 
this hormone is found in T cells (Meikle et al., 1992). It directly enhances Th1 activity as 
demonstrated in vitro on isolated lymphocytes from peripheral lymph nodes, spleen and Peyer’s 
Patches (PP) with an increased interleukin-2 (IL-2) production (Suzuki et al., 1991).  
In the present study, the immunomodulatory activity of both steroids was evaluated on the 
antibody responses in pigs following intramuscular immunisation with human serum albumin 
(HSA). 
 
2.3. Materials and Methods 
2.3.1. Experimental animals 
 
Thirteen conventional pigs (Belgian Landrace x Piétrain) were weaned at the age of 4 weeks 
and were subsequently housed in isolation units where they obtained food and water ad libitum. 
All animals were negative for serum antibodies against human serum albumin (HSA) as 
determined by ELISA. 
 
2.3.2. Experimental procedure 
 
At the age of 7 weeks, the pigs were divided into four groups which were all 
intramuscularly immunized in the musculus  gluteobiceps with 1 mg of HSA (SIGMA, Sigma-
Aldrich, Bornem,  
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Belgium) in 0,5 ml PBS suspended 1/1 [vol/vol] in incomplete Freund’s adjuvans (IFA).  The first 
group was immunized with the antigen supplemented with 2 µg 1.25(OH)2D3 (n=3, 1.25(OH)2D3  
group), the second group with 40 µg of DHEA  (n=3, DHEA group) and the third group with a 
combination of both steroids (2 µg of 1α,25(OH)2D3 and 40 µg of DHEA) (n=3, combination 
group). The fourth group served as a control and only received 1 mg HSA (n=4, control group). 
The steroids were dissolved in 95% (vol/vol) ethanol at a concentration of 1.10-4 M and stored at -
20°C until used. Forty-three days after the first immunisation all animals were identically 
reimmunized. 
The immune response after the intramuscular immunisation was evaluated by determining 
the HSA-specific antibody titers in serum (IgM, IgA, IgG1, IgG2 and IgG), in rectal content, nasal 
and oral secretions (IgA) weekly or twice a week until 4 weeks post secondary immunisation. 
Furthermore in some animals ELIspot assays were performed for localizing and quantifying the 
numbers of HSA-specific IgM, IgA and IgG antibody secreting cells in different lymphoid tissues 
16 days post primary immunisation (PPI) and 10 and 43 days post secondary immunisation (PSI). 
2.3.3. Samples 
 
2.3.3.1. Serum  
 
Blood was sampled from the jugular vein at different time points PPI and PSI. Time points 
are presented in Fig. 2.1 and Table 2.1. Serum was collected and inactivated at 56°C during 30 
min and subsequently treated with kaolin (SIGMA) as described to decrease the background 
reading in ELISA (Van den Broeck et al., 1999). Final dilutions of 1/10 (vol/vol) were prepared in 
ELISA dilution buffer (PBS + 0.05% (vol/vol) Tween 20 + 5% (wt/vol) glycine) whereafter the 
diluted samples were stored at –20°C until used in ELISA. 
 
2.3.3.1. Mucosal secretions 
 
Rectal contents, nasal and oral secretions were sampled weekly until 4 weeks PSI using 
cotton swabs. The mass of the collected secretions was determined by weighing the swabs before 
and after the sampling.  Subsequently the secretions were rapidly diluted 1/10 in PBS (pH 7.4, 
150 mM) supplemented with 0.05% [vol/vol] Tween 20 and 20% [vol/vol] fetal bovine serum  
(FBS, Gibco, BRL, Life Technologies, Merelbeke, Belgium) and stored at -80°C until used in 
ELISA. 
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2.3.3.2. Lymph node monomorphonuclear cells 
 
Sixteen days PPI, 10 and 43 days PSI, 2 (Fig. 2.2.A), 4 (Fig.2.2.B) and 2 pigs (Fig. 2.2.C) 
respectively were euthanatized by intravenous injection of an overdose pentobarbital (24mg/kg; 
Nembutal, Sanofi Sant Animale, Brussels, Belgium) followed by exsanguination. Subsequently 
the bronchial (BLN), mesenteric (MLN), gluteal (GLN) and iliacal lymph nodes (ILN) were 
aseptically collected. After removing surrounding fat, the MC were isolated by gently teasing the 
tissues apart. The MC were collected in RPMI 1640 (Gibco, BRL) on ice, and the erythrocytes 
were lysed  with ammoniumchloride (0.8% [wt/vol]). After centrifugation (380 x g at 4°C for 10 
min), the pelleted cells were washed and resuspended in leukocyte medium (RPMI-1640 
supplemented with penicillin (100 IU/ml) and streptomycin (100 µg/ml), kanamycin (100µg/ml), 
glutamine (200 mM), sodiumpyruvate (100mM), non-essential aminoacids (100mM) and 10% 
FBS ([vol/vol] Gibco BRL, Life Technologies, Merelbeke, Belgium)) at the concentration of 
1.107 cells/ml. 
 
2.3.4. Titration of HSA-serum antibodies 
 
 HSA-specific serum IgG1, IgG2 and IgG titers were determined in an indirect ELISA. 
Briefly, the wells of a 96-well microtitre plate (NUNC, Polysorb Immuno Plates, Gibco BRL) 
were coated with HSA at a concentration of 50µg/ml of coating buffer (carbonate-bicarbonate 
buffer, 50mM, pH=9.4). After 2 hours of incubation at 37°C, the remaining binding sites were 
blocked with PBS supplemented with 0.2 % Tween80 (PBS-Tw) during 2 hours at room 
temperature. Subsequent the plates were incubated for 1 hour at 37°C with twofold dilutions of 
sera (starting from 1/10) in ELISA dilution buffer (PBS, pH 7.2 + 0.05% [vol/vol] Tween 20 + 
5% glycine), swine-specific IgG1, IgG2 or IgG monoclonal antibody (MAb, (Van Zaane et al., 
1987), biotinylated rabbit anti-mouse IgG1 (Zymed laboratories, Sanbio B.V., Uden, Nederland) 
in ELISA dilution buffer supplemented with 2% [vol/vol] pig serum and horseradish peroxidase-
linked (HRP) streptavidin. Between each step, the plates were washed with PBS + 0.2% [vol/vol] 
Tween 20. Finally, ABTS, containing H2O2, was added and after 30 min incubation the optical 
density was measured at 405 nm (OD405).  
The HSA-specific IgA (serum and mucosal secretions) and IgM (serum) antibodies were 
determined by an antibody capture ELISA. Microtitre plates were coated with 5µg/ml of swine-
specific IgA or IgM MAb’s [13] in PBS (pH 7.4) for 2 hours at 37°C. Subsequent steps were: 
blocking overnight at 4°C with PBS supplemented with 0.2% Tween 80, adding twofold  
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dilutions of the treated sera or the mucosal secretions in ELISA diluting buffer during 1 hour at 
37°C, adding 10 µg/ml HSA in PBS (pH 7.4) supplemented with 0.3 M NaCl and 0.2%Tween80 
(1 hour at 37°C). Finally an optimal dilution of sheep anti-HSA polyclonal antibodies (Serotec, 
Oxford, England) was added. Bound conjugate was visualised as described for the HSA-specific 
IgG ELISA. Between each step the plates were washed with PBS supplemented with 0.3M NaCl 
and 0.2% Tween80. The antibody titer was determined  as the inverse of the highest dilution that 
still had an OD405 higher than the cut-off value. The cut off value was determined by calculating  
the average plus 3 times the standard deviation of the optical densities of the 1/10 diluted samples 
measured at day 0. 
2.3.5. ELIspot assay for HSA-specific IgA, IgG and IgM antibody secreting cells (ASC)  
 
The ELIspot test was performed as described previously by Van den Broeck and co-workers 
(Van den Broeck et al., 1999). Briefly coating and blocking of the plates were similar to the HSA-
specific IgG ELISA. Subsequently each MC cell suspensions (107 cells/ ml leukocyte medium) 
was added to 10 different wells (100 µl/well), after which the plates were incubated for 3 hours at 
37°C in a humidified 5% CO2 atmosphere. The cells were removed by three subsequent washes 
with washing buffer. Thereafter, the plates were incubated with the swine-specific IgA, IgM and 
IgG MAb’s for 1 hour at 37°C. After three washes the biotinylated rabbit anti-mouse IgG1 was 
added. Unbound conjugates were washed away and horseradish peroxidase-linked streptavidine 
was added. Following 3 washes the spots were developed in a substrate solution consisting of 3-
amino-9-ethylcarbozole (AEC) [(4 volumes of AEC working solution {0.67 ml AEC stock 
solution (0.4%,[wt/vol] in dimethylformamide) in 10 ml Na-acetate (0.1 M, pH 5.2) + 10µl 30% 
H2O2 and 1 volume of 3% [wt/vol] low-melting point agarose gel (BIOzym, Landgraaf, The 
Netherland). Spots were counted after overnight incubation in the dark at room temperature. For 
each MC suspension, spots in 10 wells (106 MC/well) were counted, so that finally the amount of 
isotype-specific ASC per 107 MC was obtained. 
2.3.6. Statistical analysis 
 
Differences in log2 antibody  serum titers (IgM, IgA, IgG1, IgG2 and IgG) and mucosal 
secretions (IgA) between the groups were tested for statistical significance using General Linear 
Model (Proc. Mixed, SAS V8, Repeated measures Analysis of variance). A first order 
autoregressive variance covariance matrix was considered to take into account the correlations of 
the measurements on the same pig in time.  The significance level was set to 5%. 
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2.4. Results 
 
2.4.1. The HSA-specific IgM, IgA, IgG1, IgG2 and IgG serum responses 
 
The HSA-specific antibody titers are presented in Fig. 2.1. The first immunisation induced a 
temporary increase in HSA-specific IgM 14 days PPI in all four groups. This increase was similar 
in all groups with geometric mean titers (GMT) of 640 (29.3) except for the DHEA group where 
the IgM response was clearly but not significantly lower (26.3). After the first immunisation a  
HSA-specific IgA response was only seen in the group supplemented with 1.25(OH)2D3  IgA 
appeared 4 weeks PPI with antibody titers going from 160 (27.3) at day 28 PPI to 640 (29.3) at day 
43 PPI. Following the re-immunisation, a secondary immune response was observed in all groups 
with 10- to 20-fold increases of the IgM (GMT 28.7 to 211.3) and IgA (GMT from 210.3 to 212) 
antibody titers 5 days PPI. These IgM and IgA serum responses were significantly higher in the 
1α,25(OH)2D3 in comparison  with the control group (p = 0.03). The HSA-specific IgG antibody 
titers increased in all groups on day 14 PPI and reached a plateau 21 days PPI with GMT going 
from 12,900 for the control group to 25,800 in the DHEA group. Both IgG subtypes (IgG1 and 
IgG2) showed slightly different responses but  the response for each subtype was similar for the 
different groups: IgG1 immediately reached a plateau 3 weeks after the immunisation whereas 
IgG2 gradually increased between 2 and 4 weeks PPI. The booster immunisation induced a  3 to 
5-fold increase of HSA-specific IgG, IgG1 and IgG2 in all groups without significant  differences 
between the groups. 
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FIGURE 2.1: Kinetics of the HSA-specific IgM,IgA ,IgG, IgG1 and IgG2 serum response following 
intramuscular immunisation of pigs with HSA (◊), HSA  + 1α,25(OH)2D3 (■), HSA plus DHEA (▲), 
HSA  + combination of both steroids (Ο). The booster immunisation was given 43 (arrow) days post 
primary immunisation. The antibody titers are plotted as mean log 2 titers +/- the SEM. Significant 
differences (p<0.05) between the 1α,25(OH)2D3 and the control group were found for IgM and IgA 
responses in as indicated with ∗. 
 
2.4.2. HSA-specific IgA response in mucosal secretions (Table 2.1.) 
 
Following the primary immunisation HSA-specific IgA titers were detected 7 and 14 days 
PPI in the saliva of some animals of all groups except in the DHEA group. One animal of the 
1α,25 (OH)2D3 group and one animal of  the combination group showed  titers of 10 on day 7 PPI 
while in the combination group two animals had titers of 10 and 20. One week later all animals of 
this latter group showed titers of 40. In the DHEA group IgA was found in the saliva of 2 on 3 
animals 21 days PPI and in all 3 animals at 35 days PPI (titer of 20). In the nasal secretions and  
rectal contents however, a low HSA-specific IgA titer of 10 was detected for almost all pigs and 
no obvious differences could be observed between the groups. 
Following the second immunisation, IgA titers appeared already 6 days PSI in the rectal  
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content of all animals of the 1α,25(OH)2D3 group and of the combination group. IgA could still be 
detected one week later in the 1α,25(OH)2D3 group. At that moment, IgA appeared in the rectal 
content of one animal of the control group and the DHEA group. The highest IgA titers were 
found in the saliva of the 1α,25(OH)2D3 group 14 and 21 days PSI ranging from 40 to 80 which 
was significantly higher (p = 0.023) than for the control animals. At that moment only slightly 
lower HSA-specific IgA titers were found in the rectal contents of the DHEA group. 
 
TABLE 2.1.:HSA-specific IgA antibody titers in saliva, nasal secretions and rectal content following 
two immunisations (day 0 and 43*) of pigs with HSA, HSA + 1α,25(OH)2D3, HSA+ DHEA or HSA + 
combination of both steroid hormones. 
 
 Sample                   Immunization                                            IgA titers 
  7 14 21 28 35 42** 49 56 63 70 
  
DPPI* 
 
Pigs           
SALIVA HSA 1 -*** 10         
  2 - 20 - 10 - - - - 20 - 
  3 - 20 - - - 10 - - - - 
  4 10 - - - - - 10    
 HSA+ 1,25(OH)2D3 1 - 10 - - - - - 40 40 - 
   2 10 20 - - - - - 80 - - 
  3 - - - - - - -    
 HSA+ DHEA 1 - - 10 - 20 40 10 30 10 - 
  2 - - 20 - 20 - -    
  3 - - - - 20 - - 20 - - 
 HSA+ Combination 1 - 40         
  2 20 40 20 - - - - - - 10 
  3 10 40 - - - - -    
NASAL SECRETIONS HSA 1 - -         
  2 - - - - - 10 10 10 20 40 
  3 - - - - 10 - - - - - 
  4 - - - - - 10 -    
 HSA+ 1,25(OH)2D3 1 - - - - 10 - - - 10 10 
   2 - - - - - 10 - 20 - - 
  3 - - 10 - - - -    
 HSA+ DHEA 1 - - - - - - - 10 20 20 
  2 - - - - - - -    
  3 10 - - - - - - 10 - - 
 HSA+ Combination 1 - -         
  2 - 10 - - - - - - - - 
  3 - - - 10 - - -    
RECTAL CONTENT HSA 1 - -         
  2 - - - 10 - - - - - - 
  3 - - - - - - - 10 - - 
  4 - - 10 - - - -    
 HSA+ 1,25(OH)2D3 1 - - - - - - 10 10 - - 
   2 - - - - - - 20 20 - - 
  3 - - - - - - 10    
 HSA+ DHEA 1 - - - - - - - 10 - - 
  2 - - - 10 - - -    
  3 - - 10 10 - - - - - - 
 HSA+ Combination 1 - -         
  2 10 - - - - - 10 - - 10 
  3 - 10 - - - - 10    
*DPPI: days post primary immunisation; ** boosterimmunisation 43  DPPI 
-*** : HSA-specific IgA titre < 10 ;  : euthanatized 
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2.4.3. HSA specific IgA, IgG and IgM ASC in lymphoid tissues 
 
Differences in the number of HSA-specific isotype-specific ASC between groups were 
determined at different time points for the lymph nodes directly draining the injected muscle 
(GLN), as well as the secondary draining iliacal lymph node (ILN),  the bronchial lymph node 
(BLN) and the intestinal mucosa draining nodes (MLN). The effect of the primary immunisation 
was determined at 16 days PPI for one animal of the combination group and one of the control 
group. The effect of the second immunisation was evaluated for one animal of each group at 10 
days PSI and for one control animal and a 1α,25(OH)2D3 treated animal at 43 days PSI. Because 
results present only one animal of each group at each time point no statistical analysis could be 
performed. 
 
2.4.3.1. Primary immunisation 
 
HSA-specific ASC were not observed in the lymphoid tissues of the control animal 
euthanatised 16 days PPI whereas at that time more than 2000 IgG ASC and 182 IgM ASC were 
counted in the local draining lymph node and 13 IgG and 10 IgM ASC in the iliacal lymph node 
of the pig from the combination group (Figure 2.2.A). HSA-specific ASC were not enumerated in 
the BLN and MLN. 
 
2.4.3.2. Booster immunisation 
 
Ten days PSI the GLN of the animal of the DHEA group could not be found (Figure 2.2.B). 
Furthermore HSA-specific ASC were still not detected in tissues of the control animal whereas 
high number of IgG ASC were detected in the found primary (GLN) and/or  secondary draining 
lymph nodes (ILN) of all three steroid treated animals: 360 IgG ASC in the GLN for the 
1α,25(OH)2D3 treated animal and 1000 for the animal of the combination group. In the ILN of the 
DHEA injected animal even more than 1400 IgG ASC were enumerated.  In the MLN of steroid 
treated animals however only a few IgG ASC were seen: 2, 5 and 13 for the 1α,25(OH)2D3, 
DHEA and combination animal respectively. Only three IgG ASC could be found in the BLN of 
the combination animal 10 days PSI. At that time neither IgM nor IgA ASC were found in any of 
the sampled lymphoid tissues. 
Forty-three days PSI the local draining lymph node of the control animal could not be found 
(Figure 2.2.C). However low numbers of IgG and IgM ASC were observed in the other lymphoid 
tissues of the control animal with the highest numbers in the secondary draining lymph node (150  
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IgG ASC in ILN) and few positive cells in the BLN ( 27 IgG and 4 IgM ASC) and the MLN (8 
IgG, 3 IgM and 2 IgA ASC). The 1α,25(OH)2D3  treated animal showed much higher numbers of 
HSA-specific IgG ASC in the different lymphoid tissues. More than 2000 IgG ASC were found in 
the GLN and ILN while 106 and 34 IgG ASC were counted in the BLN and MLN, respectively. 
Furthermore, significant numbers of IgA ASC were counted in the local draining lymph nodes 
(GLN (430) and ILN (17)), but only few in the BLN (2) and MLN (2). The number of IgM ASC 
cells in the different lymphoid tissues were low: no IgM ASC in the local draining lymph nodes of 
both animals, while in the 1α,25(OH)2D3 treated animal 5 and 6 HSA-specific IgM ASC were 
enumerated the MLN and BLN respectively. These numbers were similar to those seen for the 
control animal (4 in the BLN and 3 in the MLN). At 43 days PSI there was an important 
enlargement of the GLN of the 1α,25(OH)2D3  injected animal. The size was about 2 to 3 cm in 
length while the normal size of the GLN is 0.5 to 1.5 cm. 
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FIGURE 2.2: Number of HSA-specific IgM (black bars), IgG (white bars) and IgA (striped bars) 
antibody-secreting cells (ASC) per 107 monomorphonuclear cells (MC) in the local draining lymph 
node (GLN), iliacal lymph node (ILN), bronchial lymph node (BLN) and mesenteric lymph node 
(MLN) of a pig immunized with HSA and a pig  immunized with HSA + a combination of 
1α,25(OH)2D3 and  DHEA at 16 days post primary immunisation (PSI) (Figure 2.2.A), a pig of each 
group 10 days PSI (Figure 2.2.B) and a pig of the control and 1α,25(OH)2D3 group at  43 days PSI 
(Figure 2.2.C). 
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2.5. Discussion 
 
This study demonstrated a significantly enhanced antigen-specific IgA and IgM response in 
pigs after IM immunisation using the steroid hormone 1α,25(OH)2D3 as immunomodulator. 
Indeed supplementing HSA with 2µg of 1α,25(OH)2D3 resulted in an earlier and higher HSA-
specific IgA serum response after a first immunisation which consistently remained higher after 
the booster immunisation. The IgM serum response was most pronounced after the booster 
immunisation. This could be of importance for mucosal immunity since not only dimeric IgA but 
also IgM can be secreted at mucosae (Porter et al., 1974, Bianchi et al., 1992). Furthermore there 
was a tendency that 1α,25(OH)2D3-treated  animals showed more HSA-specific IgA antibodies in 
the saliva and nasal secretions following the first immunisation and in saliva, rectal content and 
nasal secretions following the second immunisation. This tendency resulted in significantly higher 
IgA titres in saliva at 14 and 21 DPSI. These results seem to support the findings of Daynes and 
co-workers (Daynes et al., 1996) in mice that a subcutaneous or topical administration of 
1α,25(OH)2D3 resulted in a significant increase of the antigen-specific IgA response in serum as 
well as in the mucosal secretions. A recent study in humans however (Kriesel et al., 1999) did not 
show an IgA enhancing effect after IM injection of 1µg 1α,25(OH)2D3 with antigen. This 
difference in effect is most likely not due to a dose effect, since the 2 µg in the present study 
induced a clear effect. Results in human and mice could suggest that the effect of 1α,25(OH)2D3 
on IgA is species related with most effect in mice, less in pigs followed by man. Indeed, in mice 
the use of 1α,25(OH)2D3 resulted in high numbers of antigen-specific IgA ASC in the local 
draining lymph nodes but also in the mucosa-associated lymphoid tissue (MALT) whereas in pigs 
the effect of 1α,25(OH)2D3 was most pronounced in the local draining lymph node and was only 
weak in lymph nodes draining the mucosa (MLN). This is consistent with (i) the enlargement of 
the local draining lymph node of the 1α,25(OH)2D3 treated animal 43 days PSI, (ii) the absence of 
this enlargement in the control animal and (iii) with the higher numbers of HSA-specific IgA and 
IgG ASC in the local draining  lymph nodes of steroid-treated animals. This illustrates that steroid  
hormones, like 1α,25(OH)2D3 and DHEA, exert their adjuvant effect locally. Whether or not this 
is due to an increase of MC and/or changes in membrane expression of receptors on the MC or 
endothelial cells of the local draining lymph node, has still to be elucidated. Conversely, studies in 
mice showed a decrease of 50% of MC in the local draining lymph node after application of 
1α,25(OH)2D3 (Cantorna et al., 1998). 
Even though the control animals lacked IgM and IgG ASC in their local draining lymph 
nodes they had high serum antibody levels for both isotypes. The spleen could account for these 
serum responses as 43 days PSI high numbers of HSA-specific IgM (420/107 MC) and IgG  
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(50/107MC) ASC were found in this tissue. However, this can not exclude the bone marrow, 
which has not been looked at in this study, as another site of antibody production (Bianchi et al., 
1999; Jaraskova et al., 1978).  
In two animals, one control animal and one DHEA animal, the local draining lymph node 
(GLN) was not found. This indicates that the lymph node was either too small or absent. Absence 
of lymph nodes from the ischiatic lymphocenter is not an uncommon finding in pigs (Saar et al., 
1975). The absence of the GLN in the pig of the DHEA group 10 days PSI could explain why the 
number of IgG ASC was even higher in the ILN in this animal than in the GLN of the other 
animals. Indeed the ILN receive lymph from the GLN and the muscles of the lumbosacral region  
and most likely have overtaken the role of the missing GLN.  
The use of 40 µg of DHEA resulted in a decreased serum IgM response and an  increased 
number of IgG ASC. DHEA did not seem to influence the IgA serum response as was shown in 
mice (Daynes et al., 1996). This seems to indicate that DHEA enhances the switch of IgM to IgG 
in pigs. The mechanism of this effect has not been examined in the present study. In mice, DHEA 
enhances the IL-2 production, suggesting that it exerts its effect in mice by inducing a Th1 
response (Araneo et al., 1993). Indeed, in mice and humans, Th1 and Th2 cytokines regulate the 
production of IgG1 and IgG2a antibodies. The use of steroid compounds also seems to modulate 
the subclass of antibodies. Lemire and co-workers (Lemire et al., 1995) described in mice an 
enhanced IgG1 and a decreased IgG2a response using 1α,25(OH)2D3. This was also seen in a 
recent study with midlactating cows using 200 µg 1α,25(OH)2D3 (Reinhardt et al., 1999). In the 
present study on pigs, 1α,25(OH)2D3 seems to induce a switch towards the IgA subclass with only 
little effect on the IgG subclasses. There was a tendency towards a higher IgG2 serum response in 
the DHEA treated animals although the differences again were very small. If cytokines are 
responsible for the effects in pigs is not investigated in the present study. However, it should be 
emphasised that the presence of Th1 and Th2 cells and their relationship with the secretion of 
different isotype-specific immunoglobulins has not been proven in pigs.  
Combining DHEA with 1α,25(OH)2D3 abolished the effect of 1α,25(OH)2D3 on the IgA 
response. This is not in accordance with the observations in mice where DHEA had an additive 
effect. The reason for this difference is not clear. A possible explanation is an age-related effect of 
DHEA. Indeed the pigs in the present study were still very young  (7 weeks at the moment of 
immunisation). Endogeneous DHEA synthesis in humans and mamalian species decline in an age-
related way so that most immunomodulatory effects of DHEA can be expected in older animals 
(Parker et al., 1999). Other explanations for the difference in effect in pigs can be the induction of 
a different cytokine profile, the different dossage and species differences.  
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In conclusion this study examined the effect in pigs of 1α,25(OH)2D3 and DHEA on the 
humoral immune response following IM immunisation. 1α,25(OH)2D3 is capable to significantly 
enhance  the IgA and IgM antibody serum response . Also higher numbers of IgA and IgG ASC 
were found in the local draining lymph nodes of the 1α,25(OH)2D3 treated animals. DHEA had 
the tendency to decrease the antigen-specific IgM and enhanced the antigen-specific IgG2 and 
total IgG responses in serum and local draining lymph node, respectively. 
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3.1. Summary 
 
Pigs were intramuscularly (IM) injected twice with human serum albumin (HSA) with or 
without 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) with a 5 weeks interval.  The 
supplementation of 1α,25(OH)2D3 enhanced the HSA-specific IgA serum antibody response but 
decreased the IgM, IgG, IgG1 and IgG2 response. Furthermore, higher numbers of HSA-specific 
IgA antibody secreting cells were obtained in systemic lymphoid tissues (local draining lymph 
node, spleen and bone marrow) as well as in Peyer’s patches and lamina propria of the gut 
(GALT). In addition, the in vivo mRNA expression for Th1 (IFN-γ, IL-2), Th2 (IL-4, IL-6 and IL-
10) and Th3 (TGF-β) cytokines as well as the percentage of different cell subsets (CD2+, CD4+, 
CD8+, IgM+, MHC II+, CD25+) of monomorphonuclear cells from the local draining lymph node 
were determined at different time points after the IM immunisations. Cytokine profiles didn’t 
resemble a typical Th-cytokine profile using 1α,25(OH)2D3 : higher levels of IL-10 and 
significantly lower levels of IL-2 were observed the first day after the primary immunisation but 
significantly higher levels of IL-2 and significantly lower levels of IFN-γ were observed the first 
day after the second immunisation. Furthermore, after the second immunisation TGF- β mRNA 
expression decreased more rapid in the 1α,25(OH)2D3 group. This difference became significant 7 
days after the second immunisation. One week later a significantly higher percentage of CD25+-
cells was observed in this group, indicating more activated T- and B cells using the steroid 
hormone. These results suggest that in pigs the addition of 1α,25(OH)2D3 to an intramuscularly 
injected antigen can enhance the antigen-specific IgA-response and prime GALT tissues, but 
relation with cytokines and cell phenotype in the local draining lymph node needs further 
clarification. 
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3.2.Introduction 
 
1α,25-dihydroxyvitamin D3 [(1α,25(OH)2D3], the active metabolite of vitamin D3,  is a 
liphophilic steroid hormone which exerts its actions through binding to a nuclear receptor, the 
vitamin D receptor (Bouillon et al., 1995). Traditionally 1α,25(OH)2D3 has been associated with 
calcium homeostasis but the discovery of the nVDR in most cells of the immune system such as 
monocytes, macrophages, dendritic cells (Adorini et al., 2001), T- and B-lymphocytes (Lemire et 
al., 1984; Veldman et al., 2000; Morgan et al., 1994, 1996, 1999) suggested a role of the hormone 
in the immune system. Indeed, 1α,25(OH)2D3 stimulates the differentiation and maturation of 
monocytes (Abe et al., 1981) while it inhibits the differentiation and maturation of dendritic cells 
(Penna et al., 2000; Griffin et al., 2001). The steroid hormone also diminishes T-cell proliferation 
(Rigby et al., 1984; Bhalla et al., 1984) as well as production of cytokines required for Th1 
differentiation such as interleukin (IL)-12 (D’Ambrasio et al., 1998; Adorini et al., 2001), IFN-γ 
(Cipitelli et al., 1998), IL-2 (Alroy et al., 1995; Takeuchi et al., 1998) as well as GM-CSF 
(Towers et al., 1998). On the other hand, 1α,25(OH)2D3 is able to enhance the production of Th2-
cytokines such as IL-4 and IL-10 (Daynes et al., 1994, 1996; Cantorna et al., 1998; Adorini et al., 
2001) as well as of the Th3-cytokine TGF-β (Fukaura et al., 1996; Weinreich et al., 1999) . The 
latter cytokine is involved in the induction of a mucosal immune response and/or oral tolerance. 
Moreover, in man and mice TGF-β is responsible for the switch in B cells towards the IgA isotype 
(Letterio et al., 1998). Therefore, the steroid hormone is classified as a Th2 and/or Th3-
modulating-adjuvant. In addition, 1α,25(OH)2D3 is able to mimic in the local draining lymph node 
the cytokine pattern which is normally produced by the intestinal Peyer’s patches after oral 
immunisation with replicating antigens. This cytokine pattern is essential for the development of a 
mucosal protective immune response after oral immunisation (McGhee et al., 1992). In mice, 
subcutaneous injection of antigen together with 1α,25(OH)2D3 evoked a Th2 pattern in the local 
draining lymph node, an increased homing of IgA and IgG ASC to the LP of the intestine and the  
lungs as well as an enhanced IgA response in serum and mucosal secretions (Daynes et al., 1994, 
1996). Later it was shown by the same group, that the induction of the mucosal immune response 
is also due to the migration of antigen-pulsed dendritic cells from the local draining lymph nodes 
towards the Peyer's patches, where the activation and differentiation of antigen-specific B cells is 
initiated (Enioutina et al., 1999, 2000).  
In pigs it was shown that supplementation of antigen with 1α,25(OH)2D3 increased the 
antigen-specific IgA serum antibody response as well as the number of IgA and IgG ASC in the 
local draining lymph node of an IM induced immune response (Van der Stede et al., 2001). This 
suggested that a similar immunomodulating mechanism for 1α,25(OH)2D3 as described for mice  
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could also occur in the pig. However, in pigs the effect of 1α,25(OH)2D3 on the cytokine-profile 
as well as on homing of antigen-specific antibody secreting cells (ASC) towards mucosal 
lymphoid tissues was not yet demonstrated. The aim of the present study was to obtain insights 
into the immunomodulating mechanism of 1α,25(OH)2D3 in pigs. Therefore, phenotype of and 
Th1-/Th2-/Th3-like cytokine mRNA expression by MC from the local draining lymph node were 
examined after IM injection with human serum albumin (HSA) supplemented with 1α,25(OH)2D3. 
In addition, the antigen-specific serum antibodies as well as the number of antibody secreting 
cells (ASC) in systemic and mucosal lymphoid tissues (Peyer’s patches and lamina propria) were 
analysed to determine the effect of 1α,25(OH)2D3 on homing towards the mucosae. 
 
3.3. Material and Methods 
3.3.1. Pigs 
 
In total 37 conventional pigs (Belgian Landrace x Piétrain) from 6 different litters were used 
in the experiments. These pigs were weaned at the age of 4 weeks, transported to the faculty and 
housed in isolation units where they obtained water and food ad libitum. All pigs were 
seronegative for antibodies against human serum albumin (HSA) as determined by ELISA at the 
start of the experiment. 
 
3.3.2. Experimental design 
a) Effect of a single injection on immune parameters in the local draining lymph node 
(the popliteal lymph node): at the age of 7 weeks, pigs were intramuscularly (IM) immunized 
with 1 mg HSA (Sigma-Aldrich, Bornem, Belgium). Fifteen animals received one IM 
injection in the right musculus gastrocnemius with 1mg of HSA and 2 µg of 1α,25(OH)2D3 
(Sigma-Aldrich, Bornem, Belgium) (D3-group) and one in the left m. gastrocnemius with 
HSA only (control group). So each of these animals received one injection at each site to 
compare different immune parameters at the left (without 1α,25(OH)2D3) and at the right site 
(with 1α,25(OH)2D3) on the same pig.  
b) After the first IM immunization cells of the local draining lymph node will also home 
to other lymphoid tissues. Therefore the effect of a booster immunization on immune 
parameters was analysed in another 24 animals. These animals received two identical IM 
injections with a 5 weeks interval: 12 animals received the antigen together with 
1α,25(OH)2D3 (left and right musculus gastrocnemius, D3-group) while the other 12 animals 
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received HSA only (control group). In these animals not only effects in the local draining 
lymph node but also on the serum antibody response and the HSA-specific ASC numbers in 
systemic and mucosal lymphoid tissues were analysed.  
The HSA-antigen was dissolved in 0.5 ml PBS and suspended in an equal volume of incomplete 
Freund’s adjuvant (IFA, DIFCO Laboratories). IFA was used as an additional adjuvant allowing a 
gradual and slow release of the antigen and 1α,25(OH)2D3. The 1α,25(OH)2D3 was dissolved in 
absolute ethanol at a concentration of 8 µg/ml and stored at –20°C. Only at the moment of 
immunisation, the HSA antigen in IFA and the dissolved 1α,25(OH)2D3 were mixed. The control 
group received the same amount of HSA-antigen and an equal volume of ethanol (250 µl) as the 
D3-group.  
The immune response after the IM immunisations was evaluated by (i) determining weekly 
the HSA-specific antibody titers (IgM, IgA, IgG1, IgG2 and IgG) in serum from the moment of 
the first immunisation until 14 days post secondary immunisation (dpsi), (ii) quantifying and 
localising the number of HSA-specific IgM, IgA, IgG1, IgG2 and IgG antibody secreting cells 
(ASC) in different lymphoid tissues via ELIspot assays: 10 and 30 days post primary 
immunisation (dppi) and at 1, 2, 7, and 15 dpsi, (iii) defining the phenotype of MC of the local 
draining lymph node using flow cytometric analyses 1,2, 10 and 30 dppi and at 1, 2, 7 and 15 dpsi 
and (iv) determining the cytokine mRNA expression for  interleukin (IL)-2, IL-4, IL-6, IL-10, 
interferon(IFN)-γ and transforming growth factor (TGF)-β in the local draining lymph node via 
real time RT-PCR at 1,2 and 10 dppi and at 1,2 and 7 dpsi. Euthanasia was performed by 
intravenous injection of an overdose pentobarbital (24 mg/kg; Nembutal, Sanofi Sant Animale, 
Brussels, Belgium) followed by exsanguination. The number of animals used for each parameter 
in both groups is shown in table 3.2 and in the legends of figures 3.1. to 3.4. 
3.3.3. Samples  
3.3.3.1. Serum 
Blood samples were taken from the jugular vein at the time points shown in Fig. 3.1. Serum 
was collected and subsequently inactivated at 56°C during 30 minutes. Thereafter, the serum was 
treated with kaolin (Sigma-Aldrich) to decrease the background reading in ELISA as also 
described by Van den Broeck et al. (1999a). Finally the serum was diluted 1/10 (vol/vol) in 
ELISA buffer (Phosphate buffered saline (PBS, 150mM, pH 7.4) + 0.05% (vol/vol) Tween® 20). 
The diluted samples were stored at –20°C until tested in ELISA.  
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3.3.3.2. Monomorphonuclear cells (MC) 
 
3.3.3.2.1. Spleen and lymph nodes 
The spleen and popliteal lymph node (LN) cells were aseptically removed by gently teasing 
the tissues apart followed by lysis of erythrocytes with ammonium chloride (0.8% (wt/vol)). After 
centrifugation (380 x g at 4°C for 10 min.), the cells were washed and resuspended at 1 x 107 
MC/ml in leukocyte medium (RPMI-1640 supplemented with penicillin (100 IU/ml) and 
streptomycin (100 µg/ml), kanamycin (100 µg/ml), glutamine (200 mM), sodiumpyruvate (100 
mM), non-essential amino acids (100 mM) and 10% (vol/vol) fetal bovine serum (FBS, Gibco 
BRL, Life Technologies, Merelbeke, Belgium)). 
 
3.3.3.2.2.Bone marrow MC 
The sternum was compressed with a forceps and cells from the bone marrow (BM) were 
collected in centrifugation tubes. Following centrifugation, the cells were washed 3 times in PBS 
(150 mM, pH 7.4). The erythrocytes were lysed as described above and the cells were 
resuspended in leukocyte medium at 1 x 107 MC/ml. 
 
3.3.3.2.3. Lamina propria and Peyer’s patches MC 
Lamina propria (LP)  and Peyer’s patches (PP) were only sampled 7 and 15 dpsi. The MC 
of the LP of the jejunum were isolated as described by Van der Heijden and others (1987) with 
slight modifications. Fifteen to 20 cm long segments of the mid jejunum were flushed with PBS 
(150mM, pH 7.4) to remove the intestinal content. Subsequently, these segments were opened 
longitudinally and cut into pieces of 4 cm2. These pieces were rinsed twice with PBS and twice 
with Ca2+ and Mg2+-free balanced salt solution (CMF-buffer, pH 7.2). This was followed by 
incubation for 15 min at 37°C in the CMF-buffer containing 0.37 mg/ml EDTA (Sigma) and 0.37 
mg/ml dithiothreitol (DTT, Sigma) to remove the epithelial cells and intraepithelial lymphocytes. 
The remaining tissue fragments were rinsed with RPMI 1640 containing 5% FBS and 20 mM 
HEPES (Gibco) and thereafter incubated with collagenase and DNAse (RPMI -1640 + 0.1 mg/ml 
DNAse (Roche Diagnostics) + 300 U/ml collagenase (Sigma) + 100 IU/ml penicillin + 100 µg/ml 
streptomycin) during 30 min at 37 °C and rotating at 250 rounds per minute. A first fraction of 
cells was collected following filtration through stainless steel sieves (80, 150 and 200 mesh 
screens, Sigma). A second fraction of MC was collected by mechanical scraping and squeezing 
the remaining tissue pieces on the sieves. Subsequently, the obtained cell suspension was filtered 
through a gauze filter. Both cell fractions were combined and washed in RPMI-1640 containing 
5% (vol/vol) FBS, 20 mM HEPES and 0.1 mg/ml DNAse. The MC were isolated by Percoll 
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(Amersham Pharmacia, Uppsala, Sweden) gradient centrifugation. Subsequently, the MC were 
washed and resuspended in leukocyte medium. 
For the isolation of MC from jejunal PP (JPP) and ileal PP (IPP), small intestinal pieces 
were washed and incubated in CMF-EDTA medium as described for the lamina propria MC 
isolation. Subsequently, MC were collected by scraping the PP’s with glass slides followed by 
washing, filtration through a gauze filter and resuspending of the MC in leukocyte medium. 
 
3.3.4. ELISA for HSA-specific serum antibody responses 
 
HSA-specific serum IgM, IgA, IgG1, IgG2 and IgG titers were determined in an indirect 
ELISA as previously described (Van der Stede et al., 2001). The antibody titer was determined as 
the inverse of the highest dilution that still had an OD405 higher than the cut-off value. The cut off 
value was determined by calculating the average plus 3 times the standard deviation of the optical 
densities of the 1/10 diluted samples measured at day 0. The cut off values were 0.10, 0.14, 0.11, 
0.15 and 0.35 for IgM, IgA, IgG1, IgG2 and IgG respectively. 
3.3.5. ELIspot assay for HSA-specific antibody secreting cells 
 
The ELIspot test was performed as described previously (Van der Stede et al., 2001). 
For each MC suspension, spots in 10 wells (1 x 106 MC/well) were counted, so that finally the 
amount of isotype-specific ASC per 1 x 107 MC was obtained. 
3.3.6. Flow cytometric analysis  
 
MC cell suspensions of the LN were analysed for expression of cell surface antigens by 
flow cytometry. MC (1.106/ml) were suspended in ice-cold 100 µl RPMI-1640 supplemented with 
2% immunoglobulin free horse serum and 0.02 % sodium azide (staining medium). Subsequently, 
100 µl of staining medium containing a swine leukocyte surface-specific MAb was added for 45 
min on ice: MSA-4 = anti-CD2 (IgG2a), 74-12-4 = anti-CD-4 (IgG2b, Pescovitz et al., 1984), 76-
2-11 = anti-CD8 (IgG2b, Zuckerman et al., 1998B), anti-IgM = anti IgM+B cells (IgG1, Van 
Zaane et al., 1987), MSA3 = anti MHC II (SLA-DR, IgG2a, Hammersberg et al., 1986), 231.3B2 
= anti-CD25 (IL-2R, IgG1, Bailey et al., 1992). Subsequently, the cells were washed twice with 
staining medium and resuspended in staining medium containing FITC-conjugated (Sheep anti-
mouse IgG (whole molecule) Fab-fragment (Sigma-Aldrich). Cells were incubated for 45 min on 
ice, washed twice with staining medium and once with PBS. Flow cytometric analysis was 
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conducted using a FACScalibur flow cytometer (Becton-Dickinson, San Jose, California) 
equipped with a 15mW air-cooled argon ion laser. At least 10,000 cells were analysed per sample. 
Data are presented as mean percent positive cells ± SEM and as mean fluorescence intensity 
(MFI) per cell. 
3.3.7. RNA extraction and RT-PCR. 
RNA was extracted from MC of freshly isolated LN of each pig using the acid 
guanidinium-isothiocyanate phenol-chloroform-based method (RNAgents®, Promega, Leiden, 
The Netherlands) as described by Verfaillie et al. (2001). Reverse transcription was performed in 
a 20 µl reaction mixture containing (i) 3 µg of total RNA (ii) 1 µl of random hexanucleotide 
primer (50 µM, Perkin Elmer, Oosterhout, The Netherlands) (iii) 4 µl of MgCl2 (25 mM) (iv) 2 µl 
10 x PCR II buffer (500 mM KCl, 100 mM Tris-HCl, pH 8.3) (v) 1 mM deoxynucleotide 
triphosphate mix (dNTP-mix) of the four dNTPs (Roche, Mannheim, Germany) (vi) 200 units of 
Superscript II Rnase H- reverse transcriptase (GIBCO, BRL, Life Technologies, Merelbeke, 
Belgium) and (vii) 20 U of RNAsin® Ribonuclease inhibitor (Promega) in diethylpyrocarbonate-
treated (DEPC) water. Briefly, the template RNA and the random hexanucleotide primer were 
preincubated during 10 min at 70°C. After chilling on ice, all other components were added. 
Subsequently, the reaction mix was incubated at room temperature for 10 min and then at 42 °C 
for 45 min followed by heating for 5 min at 95 °C to inactivate the reverse transcriptase.  
The oligonucleotide primers used for the detection of the porcine interleukins (IL)-2, IL-4, 
IL-6, IL-10, IFN-γ, TGF-β and of cyclophilin cDNA were designed from the published nucleic 
acid sequences available from the GenBank/EMBL databases (Table 3.1.). 
 
TABLE 3.1.: Sequences of primers with the fragment length of PCR-products for different porcine 
cytokines. 
 
Target 
mRNA Oligonucleotide  sequences  5’-3’ 
Length PCR-
fragment Reference 
Cyclophylin 
Sb 
ASc 
F14571a 
TAA CCC CAC CGT CTT CTT 
TGC CAT CCA ACC ACT CAG 
 
 
368 
 
 
(Dozois et al., 1997) 
Interleukin 2 
S 
AS 
X56750  
GAT TTA CAG TTG CTT TTG AAG 
GTT GAG TAG ATG CTT TGA CA 
 
 
338 
(Goodall et al., 1991) 
Interleukin 4 
S 
AS 
F68330 
TAC CAG CAA CTT CGT CCA 
ATC GTC TTT AGC CTT TCC AA 
 
 
311 
(Bailey et al., 1993) 
Interleukin 6 
S 
AS 
M86722 
ATG  AGA ATC ACC ACC GGT CTT G 
TGC CCC AGC TAC ATT ATC CGA 
 
 
310 
(Richards et al., 1991) 
Interleukin 10 
S 
AS 
L20001 
CCA TGC CCA GCT CAG CAC TG 
CCC ATC ACT CTC TGC CTT CGG 
 
 
295 
(Blancho et al., 1995) 
Chapter3:Increased IgA serum response and IgA ASC in PP after IM with 1,25(OH)2D3      73  
 
Target 
mRNA Oligonucleotide  sequences  5’-3’ 
Length PCR-
fragment Reference 
Interferon-γ 
S 
AS 
X53085 
A TGT ACC TAA TGG TGG ACC TC 
C TCT CTG GCC TTG GAA CAT AG 
 
 
360 
(Dijkmans et al., 1990) 
TGF-β 
S 
AS 
Y00111 
GAC CCG CAG AGA GGC TAT AG 
GAG CCA GGA CCT TGC TGT AC 
 
 
399 
(Derynck et al., 1987) 
a: genebank accesion number, b: sense primer, c:antisense primer 
 
Cyclophilin was used as constitutively expressed 'housekeeping control gene’ to determine 
the uniformity of the reverse transcription reactions and as a reference for quantification of 
cytokine mRNA (Dozois et al., 1997). Cytokine-cDNA was amplified and quantified by real time 
PCR using the Light Cycler (Roche, Mannheim, Germany) and the lightcycler-faststart DNA 
Master SYBR Green I kit (Roche, Mannheim, Germany, nr 2239264). The reaction mixture 
consists of a master mix containing Taq DNA polymerase, dNTP mixture and SYBR Green I, 3-5 
mM MgCl2, 20 pmol of sense and anti-sense primer and 2 µl of template cDNA in a total volume 
of 20 µl. Subsequent steps were initial denaturation for 10 min at 95 °C, followed by 40 cycles of 
denaturation for 15 sec at 94 °C, annealing for 5 to 14 sec at 50-60°C depending on the particular 
cytokine and an extension for 7 to 15 sec at 72 °C depending on the length of the product 
(~1sec/25 bp). These products were subjected to a melting curve analysis and subsequently 
agarose gel electrophoresis for confirmation of the specificity of the PCR-products. Quantification 
occurred using external standards of cytokine cDNA. Calculation was performed with the 
LightCycler analysis software. The relative amount of cytokine-expression was plotted as a ratio 
((=copy number of target cytokine/copy number of house keeping gene) x 105). 
 
3.3.8. Statistical Analysis 
 
Statistical analysis was done using SPSS 7.5 for windows. Differences in log2 serum 
antibodies (IgM, IgA, IgG1, IgG2 and IgG) between the 1α,25(OH)2D3 (D3-group) and the control 
group were tested for statistical significance using the General Linear Model (Repeated Measures 
Analysis of Variance). For ELIspot assays differences in the number of HSA-specific ASC 
between the D3 group and the control group as well as differences in the expression of surface 
antigens (flow cytometer) were tested for statistical significance using a two-sample t test. For 
RT-PCR experiments, the concentrations of the cytokines were corrected for variations between 
different samples by using cyclophylin as a housekeeping gene and are presented as a ratio (= 
copy numbers of target cytokine gene/1 x 105 copy numbers of house keeping gene). Within each 
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group the ratios of the individual pigs were grouped and the differences in the mean ratios 
between the D3-group and the control group were tested for statistical significance with a two-
sample t test. . Statistical significance was assessed at a P value of < 0.05. 
 
3.4. Results 
 
3.4.1. The HSA-specific IgM, IgA, IgG1, IgG2 and IgG serum responses 
 
The HSA-specific IgM titer peaked 7 days post primary immunisation (dppi) in both groups. 
At that time the titer was significantly higher (P<0.05) in the control group (Fig.3.1.). The IgM 
titers declined to base line values at 35 dppi when the second IM immunisation was given. This 
second immunisation induced temporarily a slight increase of the IgM titer in the control group 4 
dpsi but not in the D3-group. In the D3-group, IgM became significantly higher 14 days post 
second immunisation (dpsi).  
Serum HSA-specific IgA titers were continuously higher in pigs of the D3-group than in pigs of 
the control group between 35 and 49 dppi. This difference was significant (P<0.05) at moment of 
second immunisation (35 dppi) and 14 days later. In contrast, the HSA-specific IgG1, IgG2 and 
IgG titers in the D3-group were reduced in comparison with the control group and this reduction 
was significant for IgG2 (P<0.05) between 21 and 35 dppi. 
 
 
 
FIGURE 3.1 (next page): : Kinetics of the HSA-specific IgM, IgA, IgG1, IgG2 and IgG serum 
response following 2 intramuscular (IM) immunisations. Pigs (the number of pigs sampled/group is 12 
between 0 and 35 days primary immunisation (dppi), 6 on 37 and 42 dppi and 3 on 45 and 49 dppi) 
had been injected in the m. gastrocnemii with 1mg HSA in IFA supplemented with either 2 µg of 
1α,25(OH)2D3 (∎) or without steroid hormone supplementation (). The antibody titers are plotted as 
mean log 2 titers ± the SEM. Significant differences (p<0.05) between both groups are indicated with 
an asterisk. 
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3.4.2. HSA specific IgM, IgA, IgG1, IgG2, IgG and IgM ASC in lymphoid tissues 
 
At different time points post primary (10 and 30 dppi) and secondary immunisation (1, 2, 7 
and 15 dpsi) pigs were euthanized for quantifying and localising of the HSA-specific IgM, IgA, 
IgG1, IgG2 and IgG ASC in the LN, the spleen and the BM (systemic lymphoid tissues). The IPP, 
JPP and LP (gut-associated lymphoid tissues (GALT)) were only sampled at 7 and 15 dpsi. 
Ten dppi, only HSA-specific IgM ASC could be detected in the LN. The number of IgM 
ASC was slightly higher in the D3-group (mean of 23 IgM ASC per 1 x 107 MC) than in the 
control animals (10 IgM ASC per 1 x 107 MC) (data not shown). The highest numbers of HSA-
specific IgM were found in the spleen and this one day after the second immunisation. However 
there were no significant differences in IgM ASC between the groups (Fig. 3.2.a).  
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FIGURE 3.2: Mean number of HSA-specific IgM (Fig. 3.2a), IgA (Fig. 3.2b) and IgG (Fig. 3.2c) 
ASC per 1 x 107 MC in different systemic lymphoid tissues [local draining lymph node (LNN), spleen 
and bone marrow (BM)] at different time points post primary (PPI) and second immunisation (PSI). 
Animals were IM injected with either 1 mg HSA in IFA supplemented with either 2 µg of 
1α,25(OH)2D3 (+) or without steroid hormone (-). The numbers of HSA-specific ASC are the mean of 
3 pigs/group ± SEM. 
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The numbers of HSA-specific IgA ASC were always higher for the D3-group in the LN 
while this was not the case in the spleen and BM indicating the local effect of the steroid hormone 
on IgA (Fig. 3.2.b). The numbers of IgA ASC peaked after the second immunisation with more 
than 50 IgA ASC in the D3-group 2 dpsi. However, this was not significantly higher than in the 
control group (less than 20 IgA ASC 2 dpsi).  
HSA-specific IgG ASC were higher in the 3 systemic lymphoid tissues than in the GALT 
(Fig. 3.3) and peaked 7 dpsi with no significant differences between the groups (Fig. 3.2.c). 
Similar results were obtained for the IgG1 and IgG2 ASC (data not shown). 
GALT was only collected 7 and 15 dpsi. Seven dpsi higher numbers of HSA-specific IgM, 
IgA and IgG ASC were found in the IPP of the D3-group (P = 0.268 for IgM, P = 0.242 for IgA 
and P = 0.238 for IgG) (Fig. 3.3A). Interestingly, in both groups the number of IgG ASC was 
higher than the number of IgA ASC. Similar tendencies were seen in the JPP (data not shown). At 
that moment, low numbers of IgM, IgA and IgG ASC were found in the LP of both groups (Fig. 
3.3B). One week later, HSA-specific ASC were low in both PP and in the LP in both groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.3: Mean number of HSA-specific IgM (open bars), IgA (filled bars) and IgG (shaded bars) 
ASC per 1 x 107 MC in ileal Peyer’s patches (Fig. 3.3A) and lamina propria (Fig. 3.3B) 7 days psi and 
15 days psi. Animals were IM injected with 1 mg HSA in IFA supplemented with either 2 µg of 
1α,25(OH)2D3 (+) or without steroid hormone (-).The numbers of HSA-specific ASC are the mean of 
3 pigs/group ± SEM. 
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3.4.3. Phenotype of MC from local draining lymph node 
 
No significant differences were detected between both groups either in the percentages of 
CD2+, CD4+, CD8+, IgM+and MHC II+ -cells at any moment tested (Table 3.2.). However, 7 and 
14 dpsi the mean percentage CD8+ cells was clearly lower in the D3-group. Furthermore, 15 dpsi 
the percentage CD25+ cells was significantly higher in the D3-group and the degree of MHC II-
expression was significantly lower (P= 0.019) in this D3-group (MFI 651 ± 38) in comparison 
with the control group (MFI 917 ± 59). The MHC II expresion after the second immunisation in 
both groups (MFI of 653 ± 60) was also significantly higher than after the first immunisation 
(MFI 175 ± 30). 
 
TABLE 3.2.: Percentages of positive cells (± SEM) in the local draining lymph node at different times 
post primary and secondary immunisation 
 
  Mean percentage of leukocyte subpopulation 
 1,25(OH)2D3 CD2 CD4 CD8 IgM  MHC II CD25 
1 DPPIb - 49 ± 12,7 34 ± 5,8 32 ± 4,5 33 ± 8,0 NDd ND 
(n=2) + 49 ± 8,14 33 ± 2,7 35 ± 3,4 42 ± 4,5 ND ND 
2 DPPI - 69 ± 2,4 45 ± 4,1 30 ± 5,1 26 ± 5,1 35 ±14,6 43 ± 3,0 
(n=5) + 68 ± 3,7 42 ± 2,2 28 ± 5,6 30 ± 5,0 31 ± 11,4 41 ± 1,9 
10 DPPI - 61 ± 7,8 33 ± 4,4 27 ± 1,6 38 ± 7,1 52 ± 9,9 49± 4,8 
(n=5) + 65 ±4,5 37 ± 2,8 27 ± 1,7 34 ± 5,8 48 ± 9,6 42 ± 3,6 
30 DPPI - 77 ± 1,6 35 ± 1,42 30 ± 2,5 25 ± 3 62 ±3,2 47 ± 5,2 
(n=3) + 79 ± 1,9 40 ± 3,1 29 ± 2,5 24 ± 2,2 56 ± 6,8 50 ± 4,5 
1 DPSIC - 68a ± 2 29 ± 3,24 29 ± 3,2 36 ± 7,6 39 ±4,5 52 ± 1,8 
(n=3) + 69 ±2,1 36 ± 6,5 30 ± 1,8 32 ± 1,3 39 ± 3,6 43 ± 4,1 
2 DPSI - 68 ± 3,7 31 ± 2,0 34 ± 1,2 33 ± 4,7 47 ± 7,1 57 ± 2,3 
(n=3) + 62 ± 5,5 31 ± 3,1 33 ± 1,6 34 ± 2,7 51 ± 5,0 56 ± 6,6 
7 DPSI - 71± 2,0 40 ± 5,6 44 ± 3,6 30 ± 2,5 46 ±3,4 54 ± 2,3 
(n=3) + 65 ± 3,2 38 ± 2,4 33 ± 2,9 27 ± 0,2 39 ± 6,4 44 ± 6,5 
15 DPSI - 67 ± 2,5 28 ± 1,5 37 ± 3,2 23 ± 3,7 47 ± 1,6 56 ± 2,0 
(n=3) + 65 ± 4,2 32 ± 1,7 31 ± 0,6 20 ± 3,1 56 ± 2,8 66† ± 1,7 
aAfter the first immunisation the percentages were determined on the same animals by comparing left (without 
1α,25(OH)2D3) and right (with 1α,25(OH)2D3) popliteal lymph node while different animals were used after the second 
immunisation. MC suspensions form popliteal lymph nodes were stained with MAbs directed against porcine CD2, 
CD4, CD8, IgM, CD25 and MHC II.  b DPPI: days post primary immunisation c DPSI: days post secondary 
immunisation dND: not determined †: P< 0.05  
3.4.5. In vivo cytokine mRNA-expression by MC from local draining lymph node 
 
The in vivo cytokine mRNA-expression was measured 1, 2 and 10 dppi and 1, 2 and 7 dpsi. 
The cytokine mRNA responses peaked 1 to 2 days after the first (innate response) as well as after 
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the second (memory response) IM injections. The cytokine mRNA-expression per cytokine 
revealed the following descending rank irrespective of the use of 1α,25(OH)2D3: TGF-β (1,67 x 1 
x 105 ± 1,8 x 1 x 105) > IL-10 (1,38 x 104 ± 2,65 x104) > IFN-γ (7,9 x 103 ± 1,3 x 104) > IL-2 
(2,91 x102 ± 5,24 x102) > IL-4 (1,3 x 102 ± 3,17 x 102) > IL-6 (1 x 102 ± 1,2 x 102).  
The relative amount of cytokine mRNA-expression in both groups is shown in Fig. 3.4.  
One day after the first immunisation IL-10 mRNA was higher and IL-2 was significantly 
lower (P<0.05) in the D3-group than in the control group. The IFN-γ, TGF-β and IL-6 mRNA 
expression did not differ statistically between the groups whereas IL-4 mRNA was not detected. 
One day later IL-2 and IL-10 mRNA were almost absent in both groups whereas levels of IFN-γ 
and TGF-β mRNA expression had not changed. On the other hand IL-6 mRNA expression was 
higher in the control group and traces of IL-4 mRNA were detected in the D3-group. However, ten 
dppi IL-4 and TGF-β mRNA expression could only be detected in the control group (P = 0.26 and 
0.15 respectively) in comparison with the D3-group while the expression of the other cytokines 
was similar in both groups. 
One day after the booster immunisation, the expression of IL-2 and IL-10 mRNA were 
significantly higher (P = 0.043) and lower (P = 0.14) respectively, in the D3-group than in the 
control group, which was opposite to the first immunisation. The other cytokines showed a higher 
mRNA expression than after the first immunisation but expression was lower in the D3-group than 
in the control group. Moreover 1α,25(OH)2D3 seems to inhibit significantly the IFN-γ mRNA 
expression with at least 50 % 1 and 2 dpsi (P = 0.023 and 0.013 respectively) whereas the TGF-β 
mRNA expression became significantly lower (P = 0.04) in the D3 group 7 dpsi. Interleukin-2, IL-
6 and IL-10 mRNA were low to absent 2 and 7 dpsi. Interleukin-4 could only be detected in the 
D3-group (P = 0.37) 7 dpsi.  
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FIGURE 3.4: Porcine cytokine mRNA expression 1 (n=5), 2 (n=5) and 10 (n=3) days post primary 
immunisation (dppi), 1 (n=2) , 2 (n=3) and 7 (n=3) days post second immunisation (dpsi) of MC from 
the local draining lymph node (lnn popliteus) of pigs IM injected with either 1 mg HSA supplemented 
with (black bars) or without 2 µg of 1α,25(OH)2D3 (white bars). In vivo cytokine mRNA-expression 
was measured and quantified using real time PCR and corrected for individual variation by making a 
ratio to a housekeeping gene. The mean ratios/cytokine for the pigs with the same immunisation at the 
same time point (copy number of particular cytokin/105 copy numbers of housekeeping gene) were 
calculated. The cytokine mRNA expression was determined on the same animals after the first IM 
immunisation by comparing left (without 1α,25(OH)2D3, control) and right (1α,25(OH)2D3-
supplemented) popliteal lymph node while different animals were used after the second immunisation. 
Significant differences (p<0.05) between both groups are indicated with an asterisk. 
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3.5. Discussion 
 
In the present study, it was examined whether addition of 1α,25(OH)2D3 could result in the 
appearance of antigen-specific ASC in the GALT after IM administration of an antigen and 
whether the steroid hormone polarises the cytokine response towards a Th2-cytokine profile. As 
in a previous study (Van der Stede et al., 2001), co-administration of 1α,25(OH)2D3 significantly 
enhanced the serum HSA-specific IgA response and increased the numbers of HSA-specific IgA 
ASC in the local draining lymph node of pigs after IM injection. However, in the present study it 
decreased the antigen-specific serum IgM, IgG1, IgG and IgG2 (P<0.05) serum response. This 
was most pronounced after the first IM injection. This decreased IgM antibody response was not 
observed in a previous study (Van der Stede et al., 2001). The reason is not clear but the IM 
injection occurred at a different place (musculus gastrocnemius as compared to musculus 
gluteobiceps) and it has been observed in previous experiments with pigs comparing 
immunisations in the back versus neck (Vanderpooten et al., 1997) that the injection site can 
influence the isotype profile of the antibody response. So, in contrast to the serum IgA response, 
the steroid hormone does not consistently enhance the serum IgM response in pigs. A decreased 
as well as an increased serum IgM response using 1α,25(OH)2D3 was also observed in man 
(Lemire et al., 1984). In cattle, milk IgM and IgA titers increased and IgG2 decreased (Reinhardt 
et al., 1999) and in mice serum IgG2a decreased, whereas IgG1 increased using high doses of 
1α,25(OH)2D3 (Lemire et al., 1995). The situation in the mice led to the interpretation that 
1α,25(OH)2D3 stimulates the Th2 or humoral branch of the immune system as a Th2-cytokine 
profile preferentially stimulates the formation of IgG1, IgM and IgA (Mosmann et al., 1996). 
However, it should be emphasized that the correlation between Th1 and Th2 cytokine profiles and 
the secretion of isotypes is well established in mice and man but not in domestic animals such as 
pigs and cattle (Blecha, 2001). 
In order to know whether IM immunisation with 1α,25(OH)2D3 directed the response 
towards the GALT, the number of HSA-specific ASC in the PP as well as in the LP were 
determined. Intramuscular immunisation induced IgA and IgG ASC first in the PP and later, 
although in very low numbers, in the LP. This seems to indicate that there is no direct homing of 
the LN cells to the effector sites in the GALT but a preferential homing to the inductive sites. 
Others found that memory B cells can reside in the GALT inductive sites after a systemic 
immunisation (Pierce et al., 1975; Fuhrman et al., 1981; Yuan et al., 2001). Upon mucosal antigen 
challenge these memory B cells differentiate and migrate towards the lamina propria where they 
produce antigen-specific IgA (Coffin et al., 1998). In the present study however no mucosal 
antigen challenge was performed. So, it is not surprising that only low numbers of ASC were  
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found in the LP. Another reason for these low numbers might be a too short interval of 7 days 
between both samplings of GALT. Indeed, the time required for activation, differentiation and 
homing of antigen-specific ASC from PP towards LP is at least 6 days (Coffin et al., 1997). 
Nevertheless, the low number of ASC may already result in a protective effect. Indeed, IM 
injection with F4-fimbriae co-administered with 1α,25(OH)2D3 induced a partial protection upon 
oral challenge with F4+ enterotoxigenic E. coli (Chapter 7) which was accompanied with a 
secondary serum IgA response, indicating priming of the intestinal mucosal immune system. 
Further studies are necessary in pigs to elucidate if this mucosal priming occurs via migration of 
dendritic cells towards the GALT as observed in mice (Enioutina et al., 1999,2000). 
As 1α,25(OH)2D3 primarily enhances the antigen-specific ASC in the local draining lymph 
node and clearly enlarges the local draining lymph node (Van der Stede et al., 2001), the 
distribution of various lymphocyte subsets in the local draining lymph node was analysed at 
different time points after the IM injection. In the present study however, enlargement of the local 
draining lymph node due to 1α,25(OH)2D3 was not consistently observed. Moreover no 
statistically significant changes were observed in neither the percentage of CD2+ (T cells), CD4+ 
(Th cells), CD8+ (CTL-cells) and IgM+ (B cells) cells nor in the degree of expression of these 
molecules on the cells. In human studies however a decreased CD4+/CD8+ ratio, due to a 
significant increase in CD8+-cells, was observed after treatment with 0.5 µg or 2 µg of 
1α,25(OH)2D3 for 60 and 14 days respectively (Fujita et al., 1984; Matsui et al., 1985; Zofkova et 
al., 1997). Although not statistically significant, the CD4+/CD8+ T-cell ratio appeared to be 
increased 7 and 15 dpsi in the present study. Most obvious differences were observed after the 
second IM injection. This booster immunisation with 1α,25(OH)2D3 resulted in a significant 
higher % of CD25+-cells with however a lower expression of MHC II molecules. The latter is 
consistent with human studies in which a decreased expression of MHC class II molecules on 
human monocytes was observed due to 1α,25(OH)2D3. This decrease was observed was dose and 
time dependent (6 days) (Rigby et al., 1992; Xu et al., 1993; Splitter et al., 1997). The higher 
percentage of CD25+-cells suggest at least an activation of more cells or a better persistance of 
activated cells by the steroid hormone as the porcine IL-2R (CD25) is expressed on activated T- 
(Lunney et al., 1994) and B cells in lymph nodes (Denham et al., 1994). For human B cells it was 
shown that the degree of cellular activation, rather than the differentiation, is a criterion for the 
biological receptivity to 1α,25(OH)2D3 (Morgan et al., 2000). 
The in vivo mRNA expression of Th1-like (IFN-γ, IL-2), Th2-like (IL-4 and IL-10) and 
Th3-like (TGF-β) cytokines showed a high variability among the pigs. Following, the first 
immunisation with 1α,25(OH)2D3, increased IL-10 and IL-4 mRNA and decreased levels of IL-2 
mRNA (Th1-like) were observed indicating a Th2 modulation by 1α,25(OH)2D3. A Th2-like 
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response could also explain the increased serum IgA and the higher number of IgA ASC in the 
local draining lymph node. Th2-polarisation by 1α,25(OH)2D3 was also observed after in vitro 
stimulation of mice lymph node cell suspensions (Daynes et al., 1996; Boonstra et al., 2001) while 
others observed inhibition of IL-4 by naïve murine T cells (Staeva-Viera et al., 2002). However, 
in the present study TGF-β, which is involved in the isotype switching towards IgA (Lebman et 
al., 1990) was not increased. 
More striking differences were observed after the secondary immunisation with 
1α,25(OH)2D3. Significant lower levels of IFN-γ mRNA were observed as compared with the 
control group indicating a Th2-cytokine modulating response using 1α,25(OH)2D3. However, also 
lower levels of Th2- (IL-4 and IL-10) and Th3-like (TGF-β) cytokines mRNA together with 
statistically significant higher levels of IL-2 were observed in the 1α,25(OH)2D3-treated animals. 
This indicates a rather Th1-cytokine modulating response. In conclusion, the results of the present 
study do not allow us to conclude that 1α,25(OH)2D3 induces a Th2-like response in pigs except 
possibly after the primary inoculation. The inverse correlation between IL-10 and IL-2 mRNA 
expression appears consistent in our experiments and suggest that IL-10 is able to down-regulate 
Th1-mediated immune responses as described for man (Wanidworanun et al., 1993; Randow et 
al., 1995) as well as for pigs (Blancho et al., 1995). However, in man and cattle, IL-10 is 
expressed by all Th and not selectively by Th2 cells as in mice (Brown et al., 1994). 
In conclusion, supplementation of 1α,25(OH)2D3 to parenteral immunisation enhanced the 
IgA serum antibody response as well as the number of antigen-specific ASC in different systemic 
lymphoid tissues. Moreover, 1α,25(OH)2D3 administatrion resulted in an enhanced priming of the 
GALT, especially in the Peyer’s patches. This was not correlated with major changes in T/B-cell 
subsets and a clear Th2-like (IL-4, IL-6, IL-10) cytokine profile in the local draining lymph node.
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4.1. Abstract 
 
In this study, the effect of two oligodeoxynucleotide (ODN) sequences 5’GCT-AGA-CGT-
TAG-CGT-3’ (CpG-ODN) and 5’-GCT-AGA-GCT-TAG-GCT-3’ (GpC-ODN) on the antigen-
specific antibody and cellular immune response after intramuscular immunisations with 
ovalbumin (OVA) was analysed in pigs. Pigs immunized with OVA supplemented with these 
ODN’s showed a significantly enhanced primary antibody response in comparison with the 
control group which received OVA without ODN. This enhanced primary antibody response 
appeared ODN-sequence-independent as similar effects were seen in both ODN-groups. The 
OVA-specific antibody titers obtained after a single injection of antigen combined with either of 
both ODN’s were as high as the titers in the control group after two injections. Furthermore, the 
ODN-supplemented animals showed significantly higher OVA-specific IgA antibodies in their 
saliva and nasal secretions at some time points after the first immunisation. Proliferation assays 
showed that CpG- as well as GpC-ODN significantly enhanced the antigen-specific as well as the 
mitogen-induced proliferation in different lymphoid tissues. Furthermore, 48 hours after the third 
immunisation both the CpG-group showed a significantly decreased IL-6 mRNA expression in 
cells of the local draining lymph node but no significant difference in TGF-β (Th3-like) and  IL-
10 (Th2-like). The ODN injected animals showed the tendency to have higher IFN-γ (Th1-like) 
mRNA-expression in comparison with the control group. To our knowledge, these are the first  in 
vivo studies in pigs, which demonstrate the appropriateness of  CpG-ODN as immunostimulating 
adjuvants in vaccines for farm animals.  
 
4.2. Introduction 
 
Microbial (plasmid) DNA has potent immunostimulatory properties that result from short 
sequence motifs called CpG-motifs or immunostimulatory sequences. These motifs consist of an 
unmethylated  CpG dinucleotide flanked by two 5’ purines and two 3’ pyrimidines and can be 
synthesized chemically (Krieg et al., 1998). As a consequence these CpG-motifs can be used as 
adjuvant and/or immunomodulator. The immunomodulatory properties in mice include the 
induction of different cytokines by APC and T-helper (Th) cells such as interferon-α, IFN-β, IFN-
γ, interleukin (IL)-6, IL-12, IL-18, so directing the Th cells towards Th1 and the activation of NK 
cells (Ballas et al, 1996; Stacey et al., 1996). CpG-oligodeoxynucleotide sequences (ODN) are 
also capable to directly activate B-lymphocytes triggering the secretion of immunoglobulins (Ig) 
with more IgG2a and less IgG1 (Krieg et al., 1995; Liang et al., 1996). It has been shown that 
vaccination with CpG-ODN can lead to protective immune responses against several viral, 
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bacterial and parasitic infections including hepatitis B, influenza (Davis et al., 1998), tuberculosis 
(Huygen et al., 1996), malaria (Hoffmann et al., 1995) and leishmania (Zimmermann et al., 1998). 
Moreover, CpG-ODN’s induce anti-tumor responses (Weiner et al., 1997) and decrease the IgE 
responses in allergic individuals (Slater et al., 1997; Bohle et al., 1999). Recently, Hemmi et al. 
(2000) showed in mice that the Toll-like receptor 9 (TLR –9), present on a variety of immune 
cells, including macrophages and dendritic cells, is responsible for  the uptake of CpG-ODN and 
subsequenlty the immunostimulatory effects of these motifs. 
The majority of publications regarding CpG-vaccination and the use of CpG-motifs is based 
on rodent models. In literature, almost no information is available for the effects of synthetic 
CpG-ODN in livestock or domestic animals such as cattle, pigs, horses and poultry. One study by 
Brown and co-workers (1998) showed that CpG-ODN derived from Babesia bovis were 
mitogenic for bovine B cells and enhanced the antigen-specific IgG1 and IgG2 secretion. 
Recently, Kamstrup et al. (2001) and Magnusson et al. (2001)  showed that porcine PBMC can be 
stimulated in vitro by CpG-ODN. 
The observation that CpG-ODN can enhance innate as well as adaptive immune responses 
makes CpG-ODN a promising candidate adjuvant for veterinary vaccines.  In the present study, 
the immunostimulating effects of CpG-ODN on cellular and humoral immune responses are 
evaluated in pigs, after intramuscular immunisation with the test protein OVA.  
 
4.3. Material and methods  
4.3.1. Pigs and immunizations 
 
Pigs (Belgian Landrace x Piétrain) were selected that were negative for antibodies against 
OVA as tested by ELISA. The pigs were conventionally housed and received food and water ad 
libitum. Subsequently, pigs were i.m. immunized  in the musculus splenius at the age of 5 weeks 
with 1 mg OVA (Sigma Aldrich, Nr. A-5503 Bornem, Belgium) in IFA (Difco Laboratories) 
supplemented with either 500 µg CpG-ODN (n=7, CpG-group) or 500 µg GpC-ODN (n=7, GpC-
group) or without supplement (n=6, control group). CpG-ODN (ODN containing a CG-motif 
marked with bold letters 5’GCT-AGA-CGT-TAG-CGT-3’) and GpC-ODN (inverted CG =  5’-
GCT-AGA-GCT-TAG-GCT-3’) were chosen from experiments in mice according to Klinman et 
al. (1999) and were manufactured by Biosource Europe. As it is known that phosphodiester-ODN 
are rapidly degraded in vivo (Krieg et al., 1995) a high dose of 500 µg was used. Thirty-five days 
and seventy-five days later the pigs received identical booster immunisations. All pigs were 
euthanatized by intravenous injection of an overdose pentobarbital (24mg/kg; Nembutal, Sanofi 
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Sante Animale, Brussels, Belgium) followed by exsanguination 48 hours after the third 
immunisation (77 days post primary immunisation, PPI). 
For determining the serum-antibody response, blood was taken from the jugular vein once a 
week PPI or twice a week post secondary immunisation (PSI). Ten days PSI blood was sampled  
on Alsever’s solution for isolation of PBMC. These PBMC were used for proliferation assays. 
Three or four pigs of each group were sampled for nasal and oral secretions weekly until 5 weeks 
PSI using cotton swabs (Novolab, Belgium). The volume of the collected secretions was 
determined by weighing the swabs before and after the sampling. Subsequently, the saliva and 
nasal secretions were rapidly diluted 1/2 [vol/vol] and 1/8 [vol/vol], respectively, in PBS (pH 7.4, 
150 mM) supplemented with 0.05% [vol/vol] Tween 20 and 20% [vol/vol] fetal bovine serum 
(FBS, Gibco, BRL, Life Technologies, Merelbeke, Belgium) and stored at –80 °C until analysis in 
ELISA. At euthanasia, the local draining lymph node and spleen were aseptically collected and 
the MC were isolated for use in proliferation assays and total RNA was extracted for quantifying 
the mRNA expression of  IL-6, IL-10, TGF-β and IFN-γ. 
4.3.2. ELISA 
 
OVA-specific (IgM, IgA, IgG1, IgG2 and IgG) antibodies in serum and OVA-specific IgA 
antibodies in secretions were measured by an indirect ELISA, as previously described for human 
serum albumin (Van der Stede et al., 2001). Briefly, microtiter plates (Polysorb, Nunc, Life 
Technologies, Merelbeke) were coated with OVA (50 µg/ml in 50 mM carbonate-bicarbonate 
buffer, pH 9.6) during 2 hrs at 37 °C.  Subsequently, the plates were blocked overnight at 4 °C 
with 0.2% (vol/vol) Tween 80 in PBS and thereafter incubated with series of two-fold dilutions 
of serum starting at 1/10 (vol/vol) in PBS + 0,05% Tween 20. Then, the plates were incubated 
with anti-swine IgM, IgA (27.8.1), IgG1 (23.49.2), IgG2 (34.1.1a) and IgG (23.3.1.b)-specific 
MAb’s (Van Zaane et al., 1987) diluted in ELISA buffer (PBS + 0.2% Tween20 + 3% BSA) , 
with biotinylated rabbit anti-mouse Ig (DAKO, Prosan, Merelbeke, Belgium) supplemented with 
2% [vol/vol] pig serum and with horseradish peroxidase-conjugated (HRP) streptavidin (Roche, 
Germany). Between each step, the plates were washed with PBS + 0.2% [vol/vol] Tween 20. 
Finally, ABTS, containing H2O2, was added and after 30 min incubation the optical density was 
measured at 405 nm (OD405).  
The antibody titer was determined as the inverse of the highest dilution that still had an 
OD405 higher than the cut-off value. The cut-off values was determined by calculating the average 
OD405 plus 3 times the standard deviation of the serum, oral and nasal secretions before i.m. 
immunisation, diluted 1/10, ½ and 1/8 respectively.  
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4.3.3. Preparation of cell suspensions 
 
PBMC were isolated from  blood on Alsever’s solution by density gradient centrifugation 
using Lymphoprep (Nycomed, Pharma AS, Life Technologies, Merelbeke).  
MC from spleen and lymph nodes were prepared as described by Van den Broeck et al (1999). 
Briefly, after removing surrounding fat, the MC were isolated by gently teasing the tissues apart. 
The MC were collected in RPMI 1640 (Gibco, BRL) on ice, and the erythrocytes were lysed with 
ammoniumchloride (0.8% [wt/vol]). After centrifugation (380 x g at 4°C for 10 min), the pelleted 
cells were washed and resuspended in leukocyte medium (RPMI-1640 supplemented with 
penicillin (100 IU/ml) and streptomycin (100 µg/ml), kanamycin (100 µg/ml), glutamin (200 
mM), sodiumpyruvate (100mM), non-essential aminoacids (100mM), 10% FBS ([vol/vol] Gibco 
BRL, Life Technologies, Merelbeke, Belgium) and β-mercaptoethanol (5.10-5 M, Life 
Technologies) at the concentration of 5 x 106 cells/ml. 
4.3.4. Lymphocyte proliferation test 
 
MC from each immunized pig were brought into  4 to 5 wells of a 96-well flat-bottom 
microtitre plate (Nunc) at 5 x 105 cells/well in 100 µl leukocyte medium whereafter OVA (final 
concentration 100 µg/ml medium), concanavalin A (Con A, final concentration 10 µg/ml) or 
medium were added giving a final volume of 200 µl.  The plates were incubated at 37.5 °C in a 
humid atmosphere with 5% CO2. After 72 hours the cells were pulse-labelled with [3H]-thymidine 
(1 µCi/well, Amersham ICN, Bucks, UK) and 18 hours later the cells were harvested onto glass 
fibre filters. The radioactivity incorporated into the DNA was measured using a  β-scintillation 
counter (Perkin Elmer, Brussels, Belgium). 
4.3.5. RNA-extraction, cDNA synthesis and PCR-amplification of porcine cDNA. 
 
Total RNA was extracted from the cell suspensions of the local draining lymph node 48 
hours after the third immunisation using the acid guanidinium-isothiocyanate phenol-chloroform- 
based method (RNAgents® Total RNA Isolation System, Promega, Leiden, the Netherlands). 
Three microgram total RNA was pre-incubated with 1 µl (50 µM) random hexanucleotide primer 
(Perkin Elmer, Brussels, Belgium) during 10 min at 70 °C. After chilling on ice 5mM of MgCl2, 1 
x PCR buffer (10 mM Tris-HCl (pH 8.3), 50 mM KCl), 1 mM dNTP-mix (Roche, Mannheim, 
Germany) 20 units of RNAsin® Ribonuclease inhibitor (Promega) and 200 units of Superscript II 
Rnase H- reverse transcriptase (GIBCO, BRL) were added. The reaction mix was incubated at 
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room temperature for 10 min and then at 42 °C for 45 min followed by heating for 5 min at 95 °C 
to inactivate the reverse transcriptase. The oligonucleotide primers used for detection of  the 
porcine interleukins (IL)-6, IL-10, IFN-γ, TGF-β and cyclophilin cDNA were designed from the 
published nucleic acid sequences available from GenBank/EMBL databases and described by 
Verfaillie et al (2001). Cyclophilin was used as constitutively expressed 'housekeeping' gene 
control to determine the uniformity of the reverse transcription reactions.  
Cytokine-cDNA was amplified and quantified via real time PCR using the Light Cycler 
and the lighcycler-faststart DNA Master SYBR Green I kit  (Roche, Mannheim, Germany, 
catalogue nr. 2239264). The reaction mixture consists  of a master mix containing Taq DNA 
polymerase, dNTP mixture and SYBR Green I, 3-5 mM MgCl2, 0.3 µM of each primer and  2µl 
of template cDNA in total volume of 20 µl. Subsequent steps were  initial denaturation for 10 min 
at 95 °C, followed by 40 cycles of denaturation for 15 sec at 94 °C, annealing for 5-7 sec at 60°C 
sec and an extension for 7-15 sec at 72 °C  depending on the length of  the product (~1sec/25 bp). 
Confirmation of the specificity of the PCR-products was performed by subjecting these products 
to a melting curve analysis and subsequent agarose gel electrophoresis. Quantification occurred 
using external standards of cytokine cDNA. Calculation was performed with the LightCycler 
analysis software. The relative amount of cytokine-expression was plotted as a ratio ((= copy 
numbers of target cytokine/ copy numbers of house keeping gene) x 105 ). Target cytokines were 
IFN-γ (Th1-like), IL-10 (Th2-like), TGF-β (Th3-like), and IL-6 (pro-inflammatory cytokine).  
4.3.6. Statistical anaylysis 
Differences in log2 antibody serum titers ( IgM, IgA, IgG1, IgG2 and IgG) between the 
groups were tested for statistical significance using General Linear Model (Repeated Measures 
Analysis of Variance). Differences between groups in cytokine-mRNA expression and in T-cell 
proliferation were analysed for statistical significance with an unpaired t test and a Mann-Whitney 
U test, respectively. P < 0.05 was considered as statistically significant.  
 
4.4. Results 
4.4.1. Effect of ODN on the OVA-specific serum antibody response 
Animals injected with OVA and one of both oligonucleotide sequences, CpG-ODN or GpC-
ODN, showed significantly higher serum antibody titres than the animals injected with OVA 
alone (Fig. 4.1). 
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FIGURE 4.1: Kinetics of the OVA-specific IgM, IgA , IgG, IgG1 and IgG2 serum response following 
intramuscular immunisation of pigs with OVA (), OVA+ CpG (■), OVA + GpC () The booster 
immunisation was given 35 (arrow) days post primary immunisation. The antibody titers are plotted as 
mean log 2 titers ± SEM. Significant differences (p<0.05) are indicated with ∗. 
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There were however no significant differences between the two ODN-groups. The effects of 
the oligonucleotide-supplement on the antibody response was most obvious after the primary 
immunisation. This resulted in significantly higher OVA-specific IgA  (27.46 –2 9.18) , IgG2 (210.46–
212.89) and IgG (212.2–215.5) serum antibody titers 14 and 21 days PPI  in comparison with the  
control group (IgA:25.49–27.2, IgG2:28.7–29.8, IgG:211–213.2 ). No significant differences could be 
found for the OVA-specific IgG1 and IgM  responses, although the mean IgM response was 
higher for both ODN-groups. The second immunisation induced a secondary antibody response 
with serum titers increasing 4-to 8-fold in all groups. This resulted in significantly higher OVA-
specific IgG2 serum antibody titers for the CpG and GpC groups, 7 days PSI. The titers reached 
after a single immunisation with CpG or GpC-ODN were as high as titers reached after two 
injections with OVA alone. This was most obvious for the OVA-specific IgM, IgA  and IgG 
response. 
 
4.4.2. Effect of ODN on the OVA-specific antibody response in mucosal secretions 
 
To determine if there was an effect of CpG and GpC-ODN on the IgA response in  the 
mucosal secretions, the OVA-specific IgA in saliva and nasal secretions was measured weekly 
until 5 weeks PSI in the sampled pigs (Table 4.1.). 
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TABLE 4.1.: OVA-specific IgA antibody titer of each pig in  saliva and  nasal secretions following 
immunisation at day 0 and day 35 days PPI with OVA , OVA + CpG and OVA + GpC. 
DPPIa:  days post primary immunization 
 
35b:  Booster immunisation 35 DPPI; NTc:  not  tested  -d : lower than detection limit (<2 for saliva 
and <8 for nasal secretions) 
 
The results demonstrate that CpG and GpC-ODN enhanced the primary OVA-specific IgA 
response in both secretions: in the control group only one animal had a titer of 2 in its saliva 21 
days PPI whereas the pigs of the ODN-groups had significantly higher IgA titers at that moment 
(p = 0.021). Moreover, in the CpG-group all pigs had low OVA-specific IgA titers in their saliva 
one week later whereas in the GpC-group, 3 out of 4 animals were negative. In nasal secretions no 
IgA (titer < 8) could be detected in the control group after the first immunisation whereas in both 
ODN-groups, 3 out of 4 animals had at least on one occasion titers of 8 or 16.  
After the second immunisation all animals showed 2- to 8-fold increases of the OVA-
specific IgA response in the saliva and nasal secretions. No major differences could be observed 
between the groups, although slightly higher titers were observed in the GpC-group. 
 
 Sample                         Immunization       Pigs                                DPPIa 
   7 14 21 28 35b   42 49 56 63 70 
SALIVA OVA 1 -d - - - - 64 8 4 4 2 
  2 - - - - - 2 4 - - - 
  3 - - - - - 32 32 64 32 16 
 OVA + CpG 1 - - 2 2 - 16 8 4 2 8 
   2 - - 4 4 - 8 32 16 8 2 
  3 - 2 2 2 - 16 16 16 8 2 
  4  - 2 2 - 4 2 8 2 - 
 OVA + GpC 1 - 2 16 4 - 32 16 16 8 - 
  2 - - 2 - - 8 - - - - 
  3 - - 2 - - 8 8 2 4 - 
  4 - - 2 - - 8 8 4 4 2 
             
NASAL SECRETIONS OVA 1 - - - - - - 16 32 16 - 
  2 - - - - - - 8 16 16 32 
  3 - - - - - 8 NTc 64 32 16 
 OVA + CpG 1 - - 8 - - - - 8 8 16 
  2 - - 8 - - 8 - 16 - 8 
   3 - 16 16 8 16 16 16 32 16 16 
  4 - - - - 8 - 8 NT 8 - 
 OVA + GpC 1 - 16 16 - - 16 128 64 16 8 
  2 - 8 - - - 8 16 16 - NT 
  3 - - 16 8 8 8 32 8 32 8 
  4 - - - - - 8 16 16 8 8 
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4.4.3. Effect of oligonucleotides on lymphocyte proliferation 
 
OVA-specific (Fig. 4.2A) as well as ConA-induced (Figure 4.2B) proliferation of PBMC 10 
days PSI of local draining lymph node cells and spleen cells collected 48 hours after the third 
immunisation were always significantly higher for the CpG-group (p<0.01 or p<0.05) ) than in the 
control group. The OVA-specific and ConA-induced proliferation in the GpC-group was always 
higher than in the control group but not always at statistically significant levels. Spontaneous 
proliferation (cpm of control medium cultures) of PBMC, spleen cells and local draining node 
cells were below 530, 2730 and 1720 cpm, respectively. No significant differences (P>0.05) were 
observed between the groups for this spontaneous proliferation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4.2: A) OVA-specific (100 µg/ml final concentration)  B) ConA-induced proliferation (10 
µg/ml final concentration) of PBMC (n=6 for OVA group (open bars), n=7 for ODN-groups) 10 days 
PSI, spleen cells (n=3 for OVA-group, n=4 for CpG (black bars) -and GpC-group (hatched bars)) and 
cells from local draining lymph node (n=1 for OVA-group and n=4 for CpG and GpC-group) 48 hours 
post tertiary immunisation (=77 days PPI). Results are presented as mean cpm ± SEM Significant 
differences with the control group are indicated with * (P<0,05) or ** (P<0,01). 
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4.4.4. Effect of ODN on cytokine mRNA expression 
 
The relative amount of cytokine mRNA-expression 48 hours after the third immunisation 
for IL-6, IFN-γ, TGF-β and IL-10 showed a high variation among the animals. No significant 
differences were observed between the groups for IL-10, TGF-β and IFN-γ mRNA expression. 
However, the IL-6 mRNA-expression was significantly higher for the control group as compared 
to the CpG-group (p=0.035) but not to the GpC-group (Fig. 4.3). 
 
 
 
 
FIGURE 4.3: In vivo mRNA-expression of IL-6, IFN-γ, TGF-β and IL-10, 48 hours after the third 
immunisation with OVA (open bars), GpC-group (hatched bars), CpG-group (black bars). The relative 
amount of cytokine-expression was plotted as a ratio (= copy numbers of target cytokine/ 105 copy 
numbers of house keeping gene) ± SEM. Significant differences between the test and control group 
(P<0.05) are indicated with * 
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4.5. Discussion 
 
The ability of CpG-ODN to activate the immune system and its use as potent immune 
adjuvants has clearly been shown in mice and man  in vivo as well as in vitro (Krieg et al., 
1995,1996,1998,2000,2001; McCluskie et al., 1998). Only few studies examined in vitro the 
effect of CpG-ODN on cells of farm animals. Brown et al. (1998) and Shoda et al. (2001) showed 
in vitro that ODN-sequences derived from the parasite Babesia bovis, Trypanosoma Cruzi and T. 
brucei were mitogenic for bovine B cells and enhanced the antigen-specific IgG1 as well as the 
IgG2 secretion. Recently, Kamstrup et al. (2001)  showed that porcine PBMC can respond to 
palindromic hexamer motifs containing an unmethylated CpG-ODN. Moreover, they found that 
ATCGAT was the optimal sequence to stimulate the  proliferation and/or the expression of 
cytokine (IL-6, IL-12, TNF-α) mRNA. Since both studies were performed in vitro they do not 
necessarily reflect the in vivo situation. The present study was undertaken to examine in pigs the 
effects of CpG-ODN on antibody responses and lymphocyte proliferations against intramuscularly 
injected OVA. The CpG-sequence used in the present study was selected as it appeared the most 
active in mice whereas a non-active GpC-dinucleotide was used as a control (Klinman et al., 
1999). The effect of both sequences on the immune responses was compared with the immune 
response of pigs injected with OVA without ODN.  
Surprisingly, we observed that the in mice active sequence CpG-sequence as well as the in 
mice non-active GpC-sequence significantly enhanced the primary serum IgA and IgG (IgG2) 
antibody responses in pigs. Moreover, the serum antibody titers obtained in both ODN- groups 
after a single injection were as high as those in the control group after two immunisations. So, 
using oligonucleotides as adjuvant, perhaps only one immunisation, instead of the commonly 
performed two immunisations schedule, can be enough to induce a protective level of antibodies. 
These results on the CpG-ODN in pigs confirm those previously seen in mice, clearly showing  
that CpG-ODN enhance the antigen-specific antibody responses in both species (Sato et al., 1996; 
Halpern et al., 1996). However, the effect on the antibody response in the present study is not 
sequence-specific and/or CpG-dependent since the same adjuvant effect was also observed in the 
GpC-supplemented group. This similar effect was observed in two successive experiments using 
different batches of oligodeoxynucleotides. This effect might be due to species differences as 
described by Hartman et al. (2000) or to an influence of the nucleotides flanking the CpG 
dinucleotide. Indeed Kamstrup and co-workers showed in an in vitro study that substitution of the 
flanking purines with pyrimidines or vice versa changed the immunostimulatory properties of the 
optimal sequence ATCGAT. So in the present study with pigs, the flanking sequences AG and TT 
might both be stimulating. The in vitro study of Kamstrup et al. also supported that the presence 
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of the CpG-dinucleotide is crucial for activating porcine PBMC. However, the present study in 
pigs clearly shows that this is not the case in vivo, indicating  that in vivo other factors than the 
presence of CpG-motifs influence the antigen-specific antibody responses. These factors might 
include differences in cell-populations activated in vivo as compared to the in vitro situation such 
as the dentritic cells (DC). DC cells are primary target cells for the CpG-ODN (Jakob et al., 1998; 
Sparwasser et al., 1998). CpG-ODN induce on DC-cells an enhanced expression of MHC-II 
molecules, CD80 and CD86 with better antigen processing and presentation towards Th cells. 
Moreover, DCs seem to be crucial cells for the induction of primary antibody responses. 
Differences in stimulated cell populations could have been due to breed or age-related changes. 
Indeed, the cellular distribution in different lymphoid organs, including blood, is in pigs age-
dependent (Bianchi et al., 1992; Yang et al., 1996; Rothkotter et al., 1999). Kamstrup and co-
workers used 6 to 10 months old mini-pigs while in the present study much younger conventional 
pigs (five weeks at moment of first immunisation) were used.  
Not only in the serum but also in the saliva and nasal secretions an earlier and higher OVA-
specific IgA response was observed in the ODN-supplemented groups. Again, this enhanced 
response was most obvious after the primary immunisation. Nearly all samples from both 
oligonucleotide groups were positive. After the second immunisation, this difference was less 
obvious even though the highest titers were found in the nasal secretions of the GpC-group. This 
indicates that even systemic administration of CpG or GpC-ODN, and not only oral 
administration can enhance the antigen-specific IgA response in mucosal secretions (Horner et al., 
1998). This effect was not due to an increased switch towards IgA because the IgA/IgG ratio did 
not differ between the CpG/GpC-groups and the control group.  
Besides its effect on the humoral response, the in vivo effect of both ODN-sequences was 
also analysed on the cellular (memory) response by measuring the antigen-specific proliferation of 
PBMC, spleen cells and cells from the local draining lymph node and by determining the cytokine 
mRNA expression in this lymph node. The CpG-sequence significantly enhanced the OVA-
specific as well as the ConA-induced proliferation in all tissues tested (PBMC, spleen cells or 
cells from draining lymph node) while this was not always the case for the GpC-ODN. This 
observation suggest that both sequences, used in this study, have the intrinsic capacity to trigger 
directly or indirectly via APC the MC to proliferate better. This capacity was more obvious for the 
CpG-sequence than for the GpC-ODN indicating that the presence of the CpG-motif is important 
when stimulating the cells in vitro with antigen and/or ConA. The observation that CpG-ODN 
enhance the antigen-specific proliferation is consistent with the observations of Lipford et 
al.(1997) who demonstrated that CpG-ODN may influence the signal threshold of antigen-reactive 
T cells in vivo and that this effect was due to the CpG-mediated activation of APC like DC and 
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macrophages. Moreover, it has been shown that CpG-ODN activate B cells and T cells (in the 
presence of APC and cytokines) in a polyclonal way (Liang et al., 1996). The observation that the 
CpG-ODN (and to a lesser degree the GpC-sequence) induced a higher OVA-specific 
proliferation might be due to more activated APC, and subsequently better antigen-presentation. 
Another explanation for this observation might be a different subset of T(h)-cells and/or cytokine-
profile in the cultures of in vivo CpG/GpC stimulated cells. 
The level of mRNA expression for the different cytokines (IL-6, IFN-γ, TGF-β and IL-10) 
displayed a lot of variation between animals within a group. Such heterogeneity has also been 
observed after in vitro stimulation of porcine PBMC (Kamstrup et al., 2001). There was no 
significant difference between the groups in IFN-γ, TGF-β and IL-10 mRNA expression. 
However, there was a significant decreased IL-6 mRNA expression in the CpG-ODN group as 
compared to the control group. Consequently, the increased levels of IgA antibodies in the CpG-
group were not accompanied by higher levels of IL-6 and TGF-β mRNA expression as we would 
expect from studies in mice and men (Beagley et al., 1989 ; Lebman et al., 1990). As IL-6 is a 
pro-inflammatory cytokine, mRNA-expression could have been low as measurements were done 
48 hours after the third immunisation. 
In conclusion this study shows that single immunisations in pigs with antigen, containing 
CpG and/or GpC-ODN can be used in vivo to enhance the antigen-specific antibody responses and 
cellular responses.  Indeed, a single immunisation containing ODN equals double immunisations 
without ODN and could render a booster immunisation redundant. Moreover, CpG-ODN have 
been shown to enhance the IgA in mucosal secretions which plays an important role in mucosal 
protection. Taken together these immunostimulating properties, ODN might be applicable in 
vaccines against infectious diseases in pigs. 
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CHAPTER 5 
PORCINE-SPECIFIC CpG-OLIGODEOXYNUCLEOTIDE ACTIVATES B-
CELLS AND INCREASES THEIR EXPRESSION OF MHC-II 
MOLECULES. 
 
5.1.Summary  
Two motifs namely A = 5’-GCTAGACGTTAGCGT-3’and B= 5’-TGCATCGATGCAG-3’ 
were synthesized by two different companies and tested in vitro for their capacity to stimulate 
porcine peripheral blood monomorphonuclear cells (PBMC). Motif B consisting of a nuclease-
resistant phosphorothioate guanosines at the 5’ and at the 3’-end [Bs] consistently enhanced 
significantly the proliferation of porcine PBMC in comparison with motif A. The latter motif did 
not induce any proliferation. Methylation of motif B diminished these responses although this was 
dependent of the company that synthesized this CpG-ODN. Four days of culture with motif [Bs] 
increased the percentage of B cells as well as B cell blasting. Moreover, this CpG-ODN also 
enhanced the expression of class II MHC in most cultures while there were no changes in 
percentage of macrophages or in the degree of expression of the macrophage marker. In 
conclusion, in this study it was shown that 5’-ggTGCATCGATGCAGggggg-3’ is a swine-
specific CpG-ODN. This motif activates porcine B-cells and deserves further evaluation in vivo as 
a potential immunostimulating adjuvant.  
 
5.2. Introduction 
 
The immune system of vertebrates recognizes unmethylated cytidine-phosphate-guanosine 
(CpG) dinucleotides as a danger signal (Krieg et al., 2001). These CpG’s are predominantly 
present in bacterial DNA. Recently it has been demonstrated that CpG-motifs are recognized by 
Toll-like receptor (TLR)-9 (Hemmi et al., 2000). Synthetic oligodeoxynucleotides (ODN) 
containing these CpG-motifs (CpG-ODN) have been extensively studied in vitro in mice and man 
for their immunostimulatory activity on different immune cells. For B cells, CpG-ODN have been 
shown to directly stimulate their proliferation and their immunoglobulin secretion, to increase the 
expression of MHC class II antigens and co-stimulatory molecules (Krieg et al., 1995) and to 
decrease apoptotic cell death (Yi et al., 1998). For macrophages and dendritic cells, activation 
with induction of IL-12, TNF-α, IFN-α and IFN-γ has been demonstrated (Jakob et al., 1998; 
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Stacey et al., 1996, Ballas et al., 1996, Cowdery et al., 1996). Activation of human T cells by 
CpG-ODN requires the presence of APC (Kranzer et al., 2000) while this is not the case in mice 
(Iho et al., 1999). It is known that a Th1 cytokine-based immune response is induced when CpG-
ODN are used as an adjuvant in vaccine formulation (Roman et al., 1997). Although it is believed 
that CpG-ODN recognition is conserved across mammalian species, there is evidence that the 
recognition of different CpG-motifs varies between species (Kanellos et al., 1999). Even within 
species two distinct CpG-motifs may activate different cell populations (Verthelyi et al., 2001). 
Today, there is limited information concerning the biological effects of CpG-ODN in pigs. 
Kampstrup et al., (2001) demonstrated in vitro that the TGCATCGATGCAG motif was optimal 
for proliferation of PBMC. This was accompanied with an enhanced secretion of IL-6 and IL-12. 
We demonstrated that the CpG-ODN GCTAGACGTTAGCGT, that has immunostimulatory 
properties in mice, is immunostimulating in pigs as well when used as an adjuvant for 
intramuscular immunisation (IM) (Van der Stede et al., 2002, Chapter 4). The present study was 
undertaken to screen different CpG-ODN sequences for their in vitro capacity to stimulate 
proliferation of PBMC from outbred conventional pigs and to identify the proliferating cell 
populations. 
 
Chapter5: Porcine specific CpG-ODN activates B-cells and enhances their MHC II expression 101 
5.3. Material and Methods 
 
5.3.1. Oligodeoxynucleotides 
 
Two motifs (motif A and motif B) of CpG-ODN were synthesized by two different 
companies (Biosource Europe (Nivelles, Belgium) and Eurogentec SA (Seraing, Belgium)). They 
are presented in Table 5.1. 
Table 5.1.: CpG-ODN (motif A and B) and its modifications used for in vitro proliferation assays. 
 
Motif Name2 ODN Euro1 ODN Bio1 Sequence Backbone -CH3¶ 
Motif-A A 565 572 GCTAGACGTTAGCGT O - 
 [AS] 459 7972 gg GCTAGACGTTAGCGTggggg SOS - 
 rev [AS] 259 7974 ggGCTAGAGCTTAGGCTggggg SOS - 
 Am 566 573 GCTAGAZGTTAGZGT O + 
 [AS]m 258 7973 gg GCTAGAZGTTAGZGTggggg SOS + 
 rev [AS]m 260 7975 ggGCTAGAGZTTAGGZTggggg SOS + 
Motif-B B 567 574 TGCATCGATGCAG O - 
 [BS] 261 7976 gg TGCATCGATGCAGggggg SOS - 
 [BS]m 262 7977 ggTGCATZGATCCAGggggg SOS + 
1the numbers were assigned based on the synthesis run in which the ODN were designed and produced 
by the company (Eurogentec and Biosource).2 ODNs are grouped according to sequence and 
backbone: A = motif A in its phosphodiester backbone, [As] = motif A in its phosphorothioate (S) 
backbone followed by its reversed (rev [As]) and the methylated form ([As]m). Phosphodiester 
nucleotides (O) are shown in upper case and phosphorothioate (S) nucleotides are shown in lower 
cases (g-stretch). Z = 5-methylcytosine.¶:methylation is indicated with + 
 
ODN’s that contain an unmodified phosphodiester bacbone are indicated as A and B while 
[AS] and [BS] have a SOS-backbone consisting of a nuclease-resistant phosphorothioate 
guanosines at the 5’ and the 3’-end and with a phosphodiester in the center. Reversed GpC-ODNs 
(rev [AS]) or methylated (Am, [AS]m, [BS]m and rev [AS]m) CpG-ODN were used as controls since 
they should be less immunostimulatory. The motif ATCGAT (motif B) was tested since Kamstrup 
et al., (2001) demonstrated in vitro that it was highly immunostimulatory for pig PBMC. The 
GACGTT motif (motif A) was in vitro shown to be immunostimulatory for mice and in vivo for 
pigs (Van der Stede et al., 2002, chapter 4). 
All ODN were diluted in TE buffer (10mM Tris, pH 7, and 1mM EDTA) at a concentration of 1 
mg/ml and stored at –20°C. For in vitro proliferation assays, the CpG-ODN were diluted to 
optimal concentrations in leukocyte medium (RPMI-1640 supplemented with penicillin (100 
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IU/ml), streptomycin (100 µg/ml), kanamycin (100 µg/ml), L-glutamin (200 mM), 
sodiumpyruvate (100mM), non-essential aminoacids (100mM), β-mercaptoethanol (5.10-5 M) and 
1% (vol/vol) serum of a colostrum-deprived piglet. 
5.3.2. Preparation of cells and cell culture  
 
Blood, from four weaned 5-8 weeks old outbred pigs of both sexes (Piétrain x Belgian 
Landrace) was sampled from the jugular vein on Alsever’s solution (50% vol/vol). PBMC were 
isolated by density gradient centrifugation using Lymphoprep (Invitrogen, Merelbeke, Belgium) 
as described previously (Van den Broeck et al., 1999a). After lysis of the erythrocytes in 
ammoniumchloride (0.8% [wt/vol]), the PBMC were washed 3 times and subsequently 
resuspended at the concentration of 4.106 cells/ml in leukocyte medium. 
 
5.3.3. Lymphocyte proliferation assays 
 
PBMC were brought into wells of flat bottem microtiter plates (Geiner Bio One) at 4 x 105 
cells/well in 200 µl leukocyte medium to which 20 or 10 µg/ml of an ODN with or without a 
suboptimal final concentration of concanavaline A (ConA) of 0.5 µg/ml. Each condition was 
tested in triplicate on cells of four different pigs. The cells were incubated for 72 h at 38°C in a 
humidified atmosphere with 5% CO2 after which one µCi of 3H-thymidine (Amersham ICN, 
Bucks, UK) was added for 18 h. Then, the cells were harvested onto glass fiber filtermats (Perkin 
Elmer, Life Science, Oosterhout, Netherlands). The radioactivity incorporated into the DNA was 
measured using a β-scintillation counter (Perkin Elmer). Stimulation indices (SI) were calculated 
as the quotient of the mean cpm of the stimulated PBMC (triplicates of cultures of cells with 
addition of ODN with or without ConA) over the mean cpm of the media control (neither ODN 
nor ConA). PBMC were stimulated with 0.5 µg/ml ConA as a positive control. 
 
5.3.4. Phenotypic analysis of ODN-stimulated PBMC 
 
The PBMC of two pigs were cultured for 4 days in 24-well plates (Nunc) at 1 x 107 
cells/well in 2 ml leukocyte medium alone, in leukocyte medium supplemented with 10 µg/ml of 
an ODN or with 10 µg/ml ConA. On days 0 and 4, the cells were stained for 15 min on ice in 100 
µl of staining medium (RPMI-1640 supplemented with 2% immunoglobulin free horse serum and 
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0,02 % sodium azide) with one of the following monoclonal antibodies (MAb): MAb specific for 
swine B cells (clone 28.4.1, α-IgM Van Zaane et al., 1987), swine monocytes and macrophages 
(clone 74-22-15, Pescovitz et al., 1984; Lunney et al., 1993), swine T cells (clone PPT3, α-CD3 , 
Yang et al., 1996) and swine SLA-DR (MHC II (clone MSA-3, Hammerberg et al., 1986) and a 
control MAb specific for penicillin (clone 19C9, Cliquet et al., 2001). Subsequently, the cells 
were washed twice with staining medium and resuspended in staining medium containing FITC-
conjugated antibody (sheep anti-mouse (Fab)2, Sigma-Aldrich). Cells were incubated for 45 min 
on ice, washed twice with staining medium and once with PBS (150 mM, pH 7.4). Flow 
cytometric analysis was conducted using a FACScalibur flow cytometer (Becton-Dickinson, San 
Jose, California) equipped with a 15-mW air-cooled argon ion laser with an excitation wavelength 
of 488 nm. Emission fluorescence was detected with a 530/30 nm bandpass filter for FITC. At 
least 10,000 cells were analysed per sample. Propidium iodide exclusion (FL3) was used to select 
for viable cells. Cells expressing a specific antigen are presented as the percent of the total 
number of viable analysed cells. 
 
5.3.5. Statistical analysis  
 
The data from the lymphocyte proliferation assays were analysed using the statistical 
software program SPSS. A one-way ANOVA was used to estimate the effect of ODN on 
proliferation. SI was used as the dependent variable and was log10 transformed and treatment was 
the factor. The Bonferroni adjustment for multiple comparisons was applied to evaluate the 
significant differences among the ODN-sequences (treatment). P < 0.05 was considered as 
statistically significant.  
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5.4. Results 
5.4.1. Immunostimulatory effects of ODN on porcine PBMC 
Both CpG-ODN motifs (A and B) and their modifications were synthesized in two different 
companies and screened for the ability to induce lymphocyte proliferation (Table 5.2.). 
Spontaneous proliferation (cpm of control medium cultures) varied between 197 (animal 2) and 
1224 cpm (animal 4). The cpm after addition of ConA (without ODN) varied between 6,341 and 
40,977. ODN [BS] (nrs 7976 and 261) consistently induced a proliferative response in PBMC 
with mean SIs significantly greater (P<0.05) than that induced by other ODNs (Fig. 5.1). For 
the ODN of Eurogentec (ODN 261), the SIs were even higher using a dose of 10 µg/ml than 
with 20 µg/ml while this was not the case for the same ODN of Biosource (ODN 7976). 
Surprisingly, methylation of CpG-dinucleotide in ODN 7976 by Biosource ([BS]m) still 
induced a significant proliferation using 20 µg/ml in comparison with other ODN (SI ranged 
from 4.7-21.3) (Fig. 5.1A). However, this was not the case using a dose of 10 µg/ml ODN (SI 
ranged from 1,4-3.9) (Fig. 5.1B). The mean SI of ODN 7977 was not significantly lower than 
the mean SI of ODN 7976 while ODN 262 of Eurogentec (equivalent of ODN 7977), showed 
significantly lower SIs than ODN 261. Here again proliferation was higher using 10 µg/ml 
ODN 262. All other ODN did not display any proliferation, except for motif B (ODN 574) in 
animal 1 and motif rev[As] (ODN 7972) in animal 4. 
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The same tendency was observed when the PBMC were stimulated with suboptimal 
concentrations of ConA and supplemented with 10 µg/ml ODN. Significantly higher SIs (P<0.05) 
were observed after addition of motif [Bs] (ODN 261) in comparison with all other ODNs except 
for [Bs]m (ODN 7977). Besides ODN 261, also ODN 7976 and their methylated forms (ODN 262 
and ODN 7977) showed consistently higher SIs in comparison with PBMC cultures stimulated 
with ConA only (Table 5.1.), but this was not statistically significant (Fig. 5.1C).  
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FIGURE 5.1: Mean SI ± SEM of porcine PBMC stimulated with 10 µg/ml ODN (Fig 5.1A) , 20 µg/ml 
ODN (Fig 5.1B) or ConA (0,5 µg/ml) + 10 µg/ml CpG-ODN (Fig 1C). The cells were incubated in 
triplicate for 72 hours, labelled with 3H-thymidine, and incubated for an additional 18 hours. The 
stimulation index (SI) was calculated by dividing the mean cpm of the stimulated wells by the mean cpm of 
the medium wells for each animal. For each treatment, the mean SI ± SEM was the mean of the SIs of 4 
animals. Fig. 1A:*The mean SI of ODN 7977, ODN 7976 and ODN 261 are significantly higher (P<0.05) 
than all other ODNs. Fig. 5.1.B: *The mean SI of ODN 7976 and ODN 261 are significantly higher 
(P<0.05) than all other ODNs. Fig. 5.1.C :*The mean SI of ODN 261 is significantly higher than all other 
ODNs except ODN 7977, 7976 and 262. The mean SI for ConA only (73,5 ± 24,5) is shown as a white bar. 
 
5.4.2. Phenotypic analysis of CpG-ODN-stimulated PBMC 
 
To define which cell types were responding to the immunostimulatory CpG-motifs, PBMC 
of 2 pigs were cultured for 4 days with 10 µg/ml ODN of Biosource or with ConA (T-cell 
activator). On day 0 the PBMC population included 64,2 to 70 % T cells (CD3+) and 13.9 to 19% 
B cells (IgM+). Fig. 5.2 presents the data for PBMC of one pig. After 4 days of culture with [Bs] 
(ODN 7976) an increase between 6.3 to 12.1 % (Fig 5.2) of IgM+B cells was observed while the 
increase was lower after 4 days of culture with [Bs]m (ODN 7977), with a range between 2 and 4.6 
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% (Fig 5.2), in comparison with medium alone. An increase of 3.5 % of activated B-lymphocytes 
was observed in one animal after culture with [Bs] (Fig. 5.2.). There was almost no increase in 
activated IgM+ B cells in cultures with other ODN (data not shown). The percentage of activated 
CD3+ T cells was 12.5 % (between 11.8%-13.2%) lower after 4 days of culture with [Bs] in 
comparison with medium alone while this decrease was lower (mean of 5%) with its methylated 
form [Bs]m. PBMC stimulated with ConA had a 81 % increase in activated T cells relative to 
medium alone, whereas almost no B cells could be detected in the ConA stimulated cultures. 
The increase in the percentage of MHC II+ cells ranged between 2 and 4.6 % after 4 days of 
culture with [Bs] in comparison with non-stimulated cultures (no addition of ODN, Fig. 5.3). This 
was not due to an increase of the percentage of activated MHC II+ cells since less activated MHC 
II+ cells were observed in ODN-activated cultures. There was however an increased mean relative 
fluorescence intensity for MHC II on the [Bs] stimulated cultures indicating an increased 
expression of MHC class II molecules (Fig. 5.3). 
There were no changes in percentage or in the degree of expression of the macrophage 
marker. 
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FIGURE 5.2: ‘Fluorescence-forward scatter profiles’ for IgM+  B-cells and CD3+ T-cells among ODN 
activated PBMC. PBMC stimulated with 10 µg/ml ODN 7976, with 10 µg/ml ConA or not stimulated. 
The percentage of IgM+ and CD3+viable cells in the upper right quadrant are defined as activated on 
the basis of increased cell size measured by forward angle light scatter (FALS). Green fluorescence 
(FL1) was used to identify surface IgM+ and CD3+ cells. 
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FIGURE 5.3: ‘Fluorescence-forward scatter profiles’ for MHC class II on PBMC 4 days after 
stimulation with 10 µg/ml ODN 7976, 10 µg/ml ConA or without stimulation (medium). The numbers 
in the upper quadrants present the percentage of MHC-II+ viable cells. The mean fluorescence intensity 
(MFI, FL1, log scale) is written between brackets. 
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5.5. Discussion  
 
Originally, it was believed that CpG-ODN recognition is conserved across several 
mammalian species. However, nowadays typical immunostimulatory CpG-ODN-sequences have 
been characterized for mice (Krieg et al., 1995), humans (Verthelyi et al., 2001) and primates 
(Hartmann et al., 2000). Recently, a phosphorothioate CpG-ODN containing the palindromic 
hexamer 5’-ATCGAT-3’ has been shown to induce optimal proliferation of porcine PBMC and 
induce secretion of IL-6, IL-12 and TNF-α (Kamstrup et al., 2001). Moreover, an in vivo study 
injecting pigs intramuscularly with 500 µg of the phosphodiester mice-specific CpG-ODN 
containing a 5’-GACGTT-3’ motif and ovalbumin (OVA) was able to enhance the OVA-specific 
antibody serum response as well as the OVA-specific IgA response in mucosal secretions. In 
addition, the motif induced a significant increase in the proliferation of spleen cells, lymph node 
cells and PBMC (Van der Stede et al., 2002). The present study evaluated this mice-specific motif 
A and swine-specific motif B in vitro in a lymphocyte proliferation assay by comparing them with 
control ODN in which the CpG-dinucleotide is reversed into GpC-ODN (rev[As] and rev[Bs] or in 
which the CpG-dinucleotide was methylated ([As]m and [Bs]m). Furthermore, the effect of the 
backbone modification, addition of a nuclease resistant (phosphorothioate nucleotides) leader and 
tail ([As] and [Bs]) was analysed. 
The ODN that induced the highest proliferation of PBMC from the 4 pigs was the one 
reported by Kamstrup et al. (2001) namely [Bs] (= 5’-TGCATCGATGCAG-3’). Our data indicate 
that the addition of G’s at the 5’- and 3’-end, even if these G’s are phosphodiester nucleotides, is 
required for activating PBMC since motif B (=5’-TGCATCGATGCAG-3’), in contrast with 
ODN D25 (=5’-GGTGCATCGATGCAGGGGGG-3’) as described by Kamstrup et al. (2001) 
didn’t induce any proliferative response. The addition of this G-stretch at both ends may be 
immuno-enhancing by helping the non-specific uptake of the ODN by APC (Pistesky and Reich 
1998; Wloch et al., 1998). Recently, it was shown in vivo that even a poly-G stretch at the 3’-end 
of the ODN strongly enhanced the uptake of CpG-ODN (Dalpke et al., 2002). However, Lipford 
and co-workers (2000) showed that extension of CpG-ODN with a poly-G strech at either 3’ or 5’ 
end impaired the TNF-α, IL-6 and IL-12 secretion by a macrophage cell line (J744). Yet, this G-
stretch, and not the CpG-motif itself, is responsible for direct costimulation of purified T cells 
subjected to TCR cross-linking (Lipford et al., 2000), for moderate B-cell proliferation (Liang et 
al., 1996) and for NK-cell activation (Ballas et al., 1996) and may account for better proliferation 
of the PBMC. 
The mice-specific phosphodiester motif A (=5’-GCTAGACGTTAGCGT-3’) did not 
induce any proliferation of porcine PBMC at any dose tested. This is a surprising finding as this 
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sequence and even its control GpC-ODN sequence enhanced the antigen-specific in vitro 
proliferation of PBMC after in vivo administration (IM injection of 500 µg, Van der Stede et al., 
2002). Moreover, the use of this ODN as adjuvant in an intramuscular vaccination of pigs with 
F4-fimbriae has been shown to reduce the faecal excretion of F4+ enterotoxigenic E. coli 
following (ETEC) challenge (Van der Stede et al., 2003 chapter 7). This indicates that CpG-ODN 
sequences which do not enhance in vitro proliferation can effectively been used in vivo as an 
adjuvant. As a consequence, in vitro proliferation assays may not be as conclusive to evaluate the 
immunostimulatory effect of CpG-ODN in vivo. Different cell populations may be activated in 
vivo compared to the in vitro situation. Dentritic cells (DC) for example, which are primary target 
cells for the CpG-ODN (Jakob et al., 1998; Sparwasser et al., 1998), are not in high frequency in 
the circulation (Carrasco et al., 2001). Nevertheless, our and Kampstrup et al. (2001) in vitro 
studies show that 5’-ggTGCATCGATGCAGggggg-3’is an interesting candidate to be analysed in 
vivo for its immunostimulatory properties and its capacity to protect against different infectious 
diseases. 
Considerable heterogeneity was observed in the response of the individual pigs to various 
CpG-ODN. Using conventional outbred pigs we observed lower proliferation using the same 
ODN as compared with the in vitro proliferation assays of Kamstrup et al. (2001) using NIH 
inbred minipigs. However, using these NIH inbred minipigs they observed also individual 
differences indicating no link between MHC II haplotype and CpG-ODN responsiveness. These 
individual differences are also observed in man, an other outbred population (Verthelyi et al., 
2001). 
Methylation of the CpG-dinucleotide normally reduces or eliminates the 
immunostimulatory capacity of the CpG-ODN. In the present study, methylation of [Bs] had 
different results depending on the company that synthesized the ODN: ODN 7977 still induced 
significant proliferation in a dose dependent way while this was not the case for ODN 262. This 
indicates that one must be careful interpreting effects of CpG-ODN with the same sequences but 
produced by different companies. Probably, the methylation in ODN 7977 was not as complete as 
it was in ODN 262. 
ODN [Bs] (7976) enhanced the percentage of IgM+ porcine B cells of MHC II+-cells and 
enhanced B-cell blasting (Fig.5.2). As a consequence there was a decrease in the percentage of 
porcine T cells This indicates that this CpG-motif induces porcine B cells to proliferate, as has 
been observed for mice-specific ODN in mice (Yi et al.,1998, Krieg et al., 1995). In mice it has 
been demonstrated that ODN-stimulated B cells resist apoptosis whereas the decrease in the 
number of IgM+ B cells in medium cultures is due to spontaneous B-cell death (Illera et al., 1993). 
Whether the effect of CpG-ODN on B cells occurs directly or indirectly via monocytes is not 
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clear. Depleting the monocytes in a bovine PBMC culture dramatically reduced the proliferative 
response induced by an optimal CpG-ODN sequence (Pontarello et al., 2002). This is in contrast 
with studies in mice (Krieg et al., 1995) and man (Hartmann and Krieg 2000). Results showed 
that [Bs] increased the percentage of MHC II+-cells as well as the expression of MHC II 
molecules on porcine PBMC. In pigs class II antigens are expressed on B cells, activated 
macrophages but also on a subset of CD4-CD8+ and CD4+CD8+ T cells (Lunney et al., 1987; 
Saalmüller et al., 1991). As, no difference in the percentage of macrophages (MAb 74-22-15) and 
a decreased percentage of CD3+-cells (all T cells) was observed, it is expected that clonal 
expanded B cells are responsible for the increased percentage of MHC II+-cells and the increased 
expression of MHC class II antigens. 
In conclusion, it was shown that motif B (5’-TGCATCGATGCAG-3’) in its 
phosphorothioate backbone is mitogenic for porcine B cells and increases their percentage as well 
as the expression of MHC class II molecules. Methylation of this motif reduces this effect 
although this may differ depending on the manufacturer. 
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CHAPTER 6 
ANTIGEN DOSE MODULATES THE IMMUNOGLOBULIN ISOTYPE 
RESPONSES OF PIGS AGAINST INTRAMUSCULARLY 
ADMINISTERED F4 FIMBRIAE 
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6.1. Abstract 
 
Parenteral immunisation normally induces a systemic antibody response characterized by 
high IgG and low IgA responses. In the present study, the effect of different doses of F4-fimbriae 
on the isotype-specific antibody response after intramuscular immunisation was studied in pigs. 
Pigs were injected twice with a 9 weeks interval with either 1, 0.1 or 0.01 mg of F4-ETEC 
fimbriae. The dose of 1mg F4 induced significantly lower primary F4-specific IgG and IgM 
responses than the doses of 0.1 and 0.01 mg F4 but primed for an enhanced F4-specific IgM 
serum antibody response after the booster immunisation. Furthermore, the dose of 0.1 mg induced 
the highest F4-specific IgA serum response which was significantly higher than after injection 
with 0.01 and 1mg F4. Moreover, both lower doses (0.1 and 0.01 mg) showed a higher number of 
F4-specific IgA and IgG antibody secreting cells (ASC) in the local draining lymph nodes of the 
pigs. This study demonstrated that low doses of purified F4-ETEC fimbriae, especially the 0.1 mg 
dose, are optimal for inducing F4-specific IgA responses after IM immunisation. 
 
6.2. Introduction 
 
Enterotoxigenic Escherichia coli (ETEC) that express F4 (K88) fimbriae are an important 
cause of neonatal diarrhea in newborn and post-weaning diarrhea (PWD) in newly-weaned piglets 
(Klemm et al., 1985; Cox et al., 1987). These F4-fimbriae mediate adhesion to the brush border 
receptors on porcine intestinal epithelial cells, the initial step in the establishment of the enteric 
infection (Nagy et al., 1985). The F4-fimbriae are proteinaceous filamentous adhesins that are 
expressed on the surface of the bacteria. Three serological variants of F4 exist namely: F4ab, F4ac 
and F4ad (Guinée et al., 1979; Mooi et al., 1984; Gaastra et al., 1986). However, F4ac is most 
commonly associated with diarrhea in pigs (Gonzalez et al., 1995; Westerman et al., 1988). Rutter 
and co-workers (1972) were the first to show that neonatal diarrhea can be prevented by passively 
protecting the piglets via parenteral (intramuscular) immunisation of pregnant dams with fimbriae. 
This was confirmed by others using commercial vaccines, containing a combination of heat- or 
formalin-killed E. coli bacteria, LT enterotoxin and purified fimbriae (Nagy et al., 1985; Moon et 
al., 1993; Osek et al., 1994,). At weaning however, this maternal protection stops and pigs 
become susceptible again for F4+-ETEC and can develop PWD. In order to protect the piglets 
against PWD, the induction of an acquired mucosal immunity is necessary. This protection is 
given by IgM, IgA and IgG antibodies against fimbriae and/or enterotoxins (Porter et al., 1974; 
Bianchi et al., 1992).  
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It was shown that oral administration of F4ac fimbriae induced a protective mucosal 
immune response in 6-week-old weaned piglets bearing the F4-receptor on their enterocytes (Van 
den Broeck et al., 1999a). However, mucosal immunity will be difficult to induce in young pigs in 
the presence of passively transferred lactogenic antibodies from the sow. Therefore, parenteral 
vaccination of piglets during the suckling period could be more ideal. It was shown that 
intramuscular immunisation of piglets with 1 mg of crude F4 fimbriae in incomplete Freund’s 
adjuvant evoked an IgA serum antibody response only slightly lower than that following an ETEC 
infection (Van den Broeck et al. 1999b).  
In the present study, a great effect of the dose of intramuscularly injected F4-antigen was 
seen on the isotype-specific antibody response in serum and in the local draining lymph node. 
 
6.3. Materials and Methods 
6.3.1. Pigs 
 
Nine conventionally reared pigs (Belgian Landrace x Piétrain) from 1 litter on 1 closed farm 
were seronegative for antibodies against F4 as determined by ELISA. They were weaned at the 
age of 5 weeks and immediately housed in isolation units where they obtained water and food ad 
libitum. 
 
6.3.2. Purification of F4-fimbriae 
 
The fimbriae were purified as described by Van den Broeck and co-workers (1999c). 
Briefly, fimbriae were isolated by homogenising a bacterial suspension of strain E.coli GIS 26 
(O149:K91: F4ac, LT+Sta+STb+) using an Ultra Turrax at 24,000 rpm for 20 min. The 
solubilized fimbriae were precipitated with 40 % (wt/vol) ammonium sulphate. The pellet was 
dialysed against PBS (150 mM, pH 7,4) and thereafter the fimbriae were further purified by 
by anion exchange chromatography using a Bio-Scale Q5 column (BIO-RAD Laboratories, 
Eke, Belgium). The total protein concentration was determined using the Bicinchoninic Acid 
Protein Assay Kit (SIGMA, Sigma-Aldrich, Bornem, Belgium) and purity was assessed by 
electrophoresis on SDS-12% polyacrylamide slab gels according to Laemmli et al.(1970) 
using the BIO-RAD Mini-Protean II Electrophoresis cell. These purified F4-fimbriae were 
used to immunise the pigs. 
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6.3.3. Experimental design 
 
Nine pigs were intramuscularly (IM, m. gastrocnemius) immunized at the age of 8 weeks 
with different doses of F4-fimbriae and divided into 3 groups. The pigs received either 1mg (n=3, 
1 mg group), 0.1 mg (n=3, 0.1 mg group) or 0.01 mg (n=3, 0.01 mg group) purified F4-fimbriae 
supplemented with 2 µg of 1α,25(OH)2D3. The 1α,25(OH)2D3 has been able to enhance the IgA 
serum response against human serum albumin (HSA) and to increase the number of HSA-specific 
IgA and IgG ASC in the local draining lymph node (Van der Stede et al., 2001). The F4-fimbriae 
were dissolved in 0.5 ml PBS which was suspended 1/1 (vol/vol) in incomplete Freund’s adjuvant 
(IFA, DIFCO Laboratories). The steroid compound 1α,25(OH)2D3 (ALEXIS Biochemical’s, 
Zandhoven, Belgium) was dissolved in absolute ethanol as a stock solution (8 µg/ml) and stored 
at -20°C until used. It was mixed immediately with the F4 antigen and IFA at moment of the IM 
immunisation. 
All these animals received a booster immunisation 66 days post primary immunisation (ppi) 
with the same dose of F4-fimbriae suspended in IFA. 
The immune response after the intramuscular immunisations was evaluated by determining 
the F4-specific antibody titers in serum (IgM, IgA, IgG), weekly or twice a week until 7 weeks 
post secondary immunisation (psi). Furthermore ELIspot assays were performed on MC of the 
local draining lymph nodes to localize and quantify the numbers of F4-specific IgM, IgA and IgG 
antibody-secreting cells (ASC) between 32 (one animal of each group) and 38 days psi (all other 
animals n= 6). 
 
6.3.4. Samples 
 
6.3.4.1. Serum 
 
Blood was sampled from the jugular vein at different time points ppi and psi as shown in 
Fig 6.1. Serum was collected and inactivated at 56°C during 30 min and subsequently treated with 
kaolin (Sigma Aldrich, Bornem, Belgium) as described by Van den Broeck et al (1999b). Final 
serum dilutions of 1/10 (vol/vol) were prepared in ELISA dilution buffer (PBS, 150 mM, pH 7.4) 
+ 0.05% (vol/vol) Tween® 20 + 3% (wt/vol) bovine serum albumin (BSA)) whereafter the diluted 
samples were stored at –20°C until use in ELISA. 
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6.3.4.2.Lymph node monomorphonuclear cells 
 
All pigs were euthanatized by intravenous injection of an overdose pentobarbital (24mg/kg; 
Nembutal, Sanofi Sant Animale, Brussels, Belgium) followed by exsanguination. Subsequently 
the popliteal lymph nodes were aseptically collected. After removing surrounding fat, the MC 
were isolated by gently teasing the tissues apart. The MC were collected in RPMI 1640 (Gibco, 
BRL) on ice and the erythrocytes were lysed with ammonium chloride (0.8% [wt/vol]). After 
centrifugation (380g, 4°C, 10 min), the pelleted cells were washed and resuspended in leukocyte 
medium (RPMI-1640 supplemented with penicillin (100 IU/ml), streptomycin (100 µg/ml), 
kanamycin (100 µg/ml), glutamine (200 mM), sodiumpyruvate (100 mM), non-essential 
aminoacids (100 mM) and 10% [vol/vol] fetal calf serum (FCS, Gibco BRL, Life Technologies, 
Merelbeke, Belgium) at the concentration of 1.107 cells/ml. 
6.3.5. Titration of F4-specific serum antibodies 
 
F4-specific IgM, IgA and IgG titers were determined by an indirect ELISA as described by 
Van den Broeck and co-workers (1999b). Briefly, the wells of a 96-well microtitre plate (NUNC, 
Polysorb Immuno Plates, Gibco BRL) were coated with a F4-specific monoclonal antibody 
(MAb, IMM-01) at a concentration of 1 µg/ml PBS. After 2 hours of incubation at 37°C, the 
remaining binding sites were blocked overnight at 4°C with PBS supplemented with 0.2 % 
Tween® 80 (Merck Eurolab, Leuven, Belgium). Subsequently, F4 fimbriae were added to the 
wells at a concentration of 30 µg/ml in ELISA dilution buffer (PBS, pH 7.4 + 0.05% [vol/vol] 
Tween® 20 + 3 % BSA), and incubated for 1 hour at 37°C. Then, the treated sera were added in 
series of twofold dilutions in ELISA dilution buffer, starting at a dilution of 1/10, and the plates 
were incubated for 1 hour at 37°C. Thereafter, biotinylated-swine-specific IgM, IgA and IgG 
MAb (Van Zaane et al., 1987) were added and the plates were incubated for 1 hour at 37°C 
followed by 1 hour incubation at 37°C with peroxidase-conjugated streptavidin. Between each 
step, the plates were washed with washing buffer (PBS + 0.2% [vol/vol] Tween® 20). Finally, 
ABTS-solution, containing H2O2, was added and after 30 min incubation the optical density was 
measured at 405 nm (OD405).  
The antibody titer was determined as the inverse of the highest dilution that still had an 
OD405 higher than the cut-off value. The cut off value was determined by calculating the mean 
plus 3 times the standard deviation of the optical densities of the 1/10 diluted samples measured at 
day 0. The cut off values were 0.337, 0.280 and 0.250 for F4-specific IgM, IgA and IgG 
respectively. 
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6.3.6. ELIspot assay for F4-specific IgA, IgG and IgM antibody secreting cells (ASC) 
 
The ELIspot test was performed as previously described by Van den Broeck and co-workers 
(1999b). Briefly, coating and blocking of the plates were similar to the F4-specific serum ELISA. 
Subsequently the MC cell suspensions (107 cells/ ml leukocyte medium) were added in five wells 
(100 µl/well), after which the plates were incubated for 3 hours at 37°C in a humidified 5% CO2 
atmosphere. The cells were removed by three subsequent washes with washing buffer. Thereafter, 
the plates were incubated with the swine-specific IgA, IgM and IgG MAb (Van Zaane et al., 
1987) coupled to peroxidase for 1 hour at 37°C. Unbound conjugates were washed away by 3 
washes with washing buffer. The spots were developed in a substrate solution consisting of 4 
volumes of 3-amino-9-ethylcarbozole (AEC) working solution (0.67 ml AEC stock solution 
(0.4%,[wt/vol] in dimethylformamide) in 10 ml Na-acetate (0.1 M, pH 5.2) + 10µl 30% H2O2) 
and 1 volume of 3% [wt/vol] low-melting point agarose gel (BIOzym, Landgraaf, The 
Netherlands)). Spots were counted after overnight incubation in the dark at room temperature. For 
each MC suspension, spots in 5 wells (106 MC/well) were counted, to obtain the number of 
isotype-specific ASC per 5 x 106 MC. 
 
6.3.7. Statistical analysis 
 
Differences in log2 antibody serum titers (IgM, IgA and IgG) between the groups were 
tested for statistical significance using General Linear Model (SPSS 7.5 for windows, General 
Linear Model: Repeated Measures Analysis of Variance). Differences in the number of F4-
specific ASC 32 to 38 days psi were tested for statistical significance by a one-way ANOVA test. 
Statistical significance was assessed at a P value of < 0.05. 
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6.4. Results 
6.4.1. Effect of doses of F4 fimbriae on serum antibody responses 
The doses of 0.1 and 0.01 mg purified F4 induced a significantly (P<0,05) higher F4-
specific IgG and higher IgM and IgA responses after the first immunisation in comparison with 
the 1mg dose group (Fig. 6.1). The IgM titer peaked 10 days ppi in all groups and was highest in 
the 0.01 mg group (with P<0.05 at 15 days ppi) followed by the 0.1 mg group and then declined 
to baseline values from 25 days ppi onwards. The IgG titer in both lower dose groups reached its 
peak 5 days later, with geometric mean titers (GMT) ranging from 640 (29.3) to 2560 (211.3) and 
thereafter they declined until the second immunisation. Both lower dose groups showed also a 
primary IgA response which was highest for the 0.1 mg group. This group showed a gradually 
increase of the F4-specific IgA titer until the moment of the booster immunisation while in the 
0.01 mg group the IgA titer peaked at 25 days ppi and declined slowly until the moment of the 
second immunisation. No IgA serum antibody response could be detected in the 1 mg group.  
In contrast with the first immunisation, the second immunisation with 1 mg F4 induced a 
strong IgM, IgA and IgG booster response while lower doses induced an IgA and IgG but no IgM 
booster response. Animals that received 1mg purified F4 antigen showed a great increase (mean 
GMT from 24-210.32) of the F4-specific IgM with a peak 8 days psi, which was significantly higher 
(P<0.05) than for both lower-dose groups. This IgM titer almost disappeared 30 days psi. All 
three groups showed an IgG and IgA booster response with their peak 12 days psi. As for the IgM 
response, the 1mg group showed a significant increase (>500-fold) increase of the F4-specific IgG 
titer and a 30-fold increase of the F4-specific IgA titer. The 0.01 mg group displayed a 150-fold 
increase of the IgA titer and a 6-fold increase of the IgG titer. The 0.1 mg group showed the 
highest increase ( ± 320-fold) of the F4-specific IgA titer and a 25-fold increase of the IgG titer. 
The F4-specific IgA titers in the 0.1 mg group were significantly higher (P<0.05) at some time 
points (8, 12, 15 and 22 days psi) than in the other groups. Both, the F4-specific IgA and IgG 
titers, remained high until euthanasia 32 to 38 days psi. 
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6.4.2. Effect of dose on the number of F4-specific ASC in the local draining lymph node 
 
Between 32 and 38 days psi all pigs were euthanatised for enumerating the numbers of F4-
specific IgM, IgG and IgA ASC in their local draining lymph nodes (Table 6.1.). Slightly higher 
numbers of F4-specific IgM ASC were detected in the 0.1 mg group (mean 15 IgM ASC) than in 
the 1 mg group (mean 12 IgM ASC) and the 0.01 mg group (mean 7 IgM ASC). In contrast, the 
number of F4-specific IgG ASC was highest in the 0.01 mg group (mean of 709 IgG ASC) 
followed by the 0.1 mg group (mean of 425 IgG ASC) and the 1mg group (mean of 260 IgG ASC 
and significantly lower than the 0.01 mg group). Although statistically not significantly different 
from the other groups, the highest F4-specific IgA ASC were detected in the 0.1 mg group. 
 
TABLE 6.1.: F4-specific IgM, IgG and IgA ASC in local draining lymph node (Lnn. popliteus) 32 to 
38 days after a second intramuscular immunisation (IM) with different doses of F4 fimbriae. 
 
 Number of F4-specific ASC in local draining lymph node per 5.106  MC : 
 IgM  IgG  IgA 
Immunisation dose    Totala     Total     Total 
               
1 mg (n=3) 17 14 7 38  192 178 408 778  7 19 57 83 
0.1 mg (n=3) 1 13 31 45  387 252 637 1276  63 46 23 132 
0.01 mg (n=3) 19 0 3 22  862 804 462 2128  20 0 65 85 
a : sum of the number of F4-specific isotype-specific ASC of three animals. 
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6.5. Discussion 
 
The present study describes the effect of different doses of intramuscularly injected F4 
antigen on the isotype-specific antibody response in pigs. The first injection with F4-fimbriae 
induced a primary antibody response with low IgM and IgA titers peaking between 10 and 25 
days post immunisation and IgG titers reaching the highest level 11 to 23 days post immunisation. 
This is in accordance with a previous study in which 5-week-old piglets were injected with 1 mg 
crude F4 antigen (Van den Broeck et al., 1999a) containing approximately 0.74 mg pure F4 (Van 
den Broeck et al., 1999b). In the present study however, a remarkable dose effect was seen using 
purified F4. One mg of purified F4 induced lower antibody responses than 0.1 and 0.01 mg F4. 
That 0.01 mg F4 induced a high and quickly appearing primary IgG serum antibody response with 
even the highest numbers of IgG ASC in the local draining lymph node indicates that F4 is a very 
potent antigen. However, increasing the dose above the range of 1mg purified F4-antigen 
suppressed the primary antibody response. The reason for this suppression is not clear. 
Apparently, the antibody response against IM injected F4-fimbriae seems to differ between 
species. Intramuscular injection of 1 mg purified F4 induced significant-F4-specific IgG titers in 
chickens (Yokoyama et al., 1992) while 5 µg seems to be the ‘optimal’ dose for mice (Bianchi et 
al., 1996). That 1 mg crude F4 used by Van den Broeck et al (1999a) did not induce such low IgG 
and IgA responses could have been due to the lower amount of pure F4 or contamination with 
LPS that activate macrophages, dendritic cells and induce the release of inflammatory cytokines 
(Raetz 1993). Moreover, Van den Broeck and co-workers injected IM in the neck. This 
localization was shown to induce better IgA responses than injection in the back (Vanderpooten et 
al., 1997). In the present study, pigs were injected in the m. gastrocnemius to have a strictly 
systemic response. 
The second intramuscular immunisation resulted again in remarkable differences between 
the 1mg group and the lower dose groups in IgG and IgM responses. One mg induced a 
significantly higher IgM response and a significant increase in IgG so that a serum IgG titer 
comparable to the titers in both lower dose groups was obtained 12 days later. In the local 
draining lymph node, however, the number of F4-specific IgG ASC was still the lowest in the 
1mg group. A reason for these high IgM responses can be the nature of the F4-antigen. As the F4-
antigen is composed of identical repeating FaeG protein subunits (Oudega et al., 1989), the F4-
antigen might act as a TI-2 antigen (T-cell independent antigen, Vos et al., 2000). In low 
concentrations, TI-2 can also induce a T-helper dependent antibody response. This could explain 
the strong IgG responses seen in the lower dose groups after the first immunisation and is 
consistent with the high antigen-specific proliferation induced in MC of 4-week old IM primed 
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(100 µg F4-fimbriae) piglets (Van der Stede et al., 2003 chapter 7). In high concentrations 
however, these TI-2 antigens can even suppress or block the B cells, which could explain the low 
IgM and IgG response following the first injection. However, this blocking of the B cells was not 
complete as strong IgM responses were seen after the second immunisation. Another explanation 
for this IgM response might be the formation of antigen-antibody complexes upon use of high 
doses of F4-fimbriae. Such complexes can be entrapped by complement receptors on B cells or 
macrophages which can lead to accumulation of antigen in the local draining lymph node and in 
turn may attract more IgM+ antigen-specific B cells (Tite et al., 1979; Ochs et al., 1996). The high 
IgM responses against F4 are not exceptional as has been shown in several studies. Bianchi et al 
(1996) showed that intramuscular immunisation of 4 week-old piglets with 2.109 killed F4ac+ 
bacteria induced a low primary IgA, IgM and IgG serum antibody response with a peak 5-10 days 
post immunisation. Oral challenge of these piglets with live F4ac+-ETEC resulted in a strong 
systemic IgM as well as IgG booster response. In addition, Van den Broeck et al (1999a) showed 
that oral challenge with crude F4 (3 successive days (2.3mg F4/day/pig) of 18 weeks old IM 
primed pigs resulted in high numbers of F4-specific IgM ASC in the peripheral blood. Also 
combinations of oral and parenteral administration with F4 resulted in high IgM antibodies in the 
colostrum (Chidlow et al., 1979) preventing piglets from neonatal diarrhea. Although, whole 
bacteria cannot be compared with F4-proteins, we suppose that high doses of F4-fimbriae result in 
high IgM responses and is consistent with the results in the present study. It indicates that at least 
more IgM+-B cells are stimulated by high doses of F4-fimbriae. 
Fimbriae-specific serum IgA may be a useful indicator for mucosal immune responses 
against fimbriae (Sarrazin et al., 1997; Van den Broeck et al., 1999a). Moreover, it has been 
shown that a polymeric IgA response in serum can be produced by parenteral immunisation 
(Mascart-Lemone et al., 1987). The F4-specific serum IgA was significantly higher after two IM 
injections with 0.1 mg. In contrast, the IgA response was again lower in the 1mg group following 
the second immunisation as could be seen in serum and the local draining lymph node indicating 
that this dose is not optimal for induction of lactogenic immunity in sows by intramuscular 
immunisations. This indicates that, besides the route of immunisation (Vanderpooten et al., 1997; 
Todryk et al., 1998), also the antigen dose appears to be essential for a good IgA response. It is 
conceivable that IM injection of different doses F4 induces distinct patterns of cytokines that 
promote respectively different T-lymphocyte functions suppressing or stimulating IgA, IgM 
and/or IgG responses. In mice, immunisation with high doses of soluble protein (high ligand 
density) results in Th1 differentiation, whereas low doses tend to modulate towards Th2-type 
responses (Constant et al., 1997) which have been shown to promote the expansion of IgA-
producing B-cell (Romagnani, 1997). In conclusion, these results stress the importance of the F4-
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antigen dose for modulation of immune responses and consequently construction of vaccines 
against E. coli. 
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7.1. Abstract 
 
In this study it was analysed whether IM immunisation of piglets with F4 during the 
suckling period could protect against oral challenge with F4+-E. coli and whether addition of 
1α,25(OH)2D3 or CpG-ODN could improve this protection. 
F4-seronegative F4-receptor positive pigs were divided into four groups of 5 pigs each. The 
pigs were intramuscularly injected with F4 fimbriae only or supplemented with 1α,25(OH)2D3 
(D3-group) or CpG-ODN (CpG-group). The control group received PBS in IFA. Seven days after 
the second immunisation, all pigs were intragastrically inoculated with 1. 1010 CFU of F4+-E. coli. 
All F4-injected groups, showed a reduced faecal excretion of F4+-E. coli. However, this reduction 
was only statistically significant in the D3-group 2 days post challenge. Pigs in the latter group 
showed a secondary antibody response upon challenge, indicating that F4-primed memory B cells 
were present in the gut-associated lymphoid tissues at that moment. 
CpG-ODN, on the other hand, did not enhance the F4-specific antibody response. However, 
CpG-ODN significantly increased the F4-specific as well as mitogen-induced proliferation of 
pheripheral blood monomorphonuclear cells indicating a direct or indirect overall effect on T-
lymphocytes. In conclusion, supplementation with 1α,25(OH)2D3 or CpG-ODN improved 
protection against an F4+-E. coli infection. This protection was most obvious for 1α,25(OH)2D3 
and indicates its potential use in veterinary vaccines against enteropathogens.  
 
7.2. Introduction 
 
Enterotoxigenic Escherichia coli (ETEC) causes neonatal and post-weaning diarrhoea 
(PWD) in pigs resulting in high economic losses in many piggeries. ETEC involved in neonatal 
and PWD can produce F4 and/or F18 fimbriae and LT, STa and/or STb (Nagy et al., 1999). The 
F4+- E. coli strains seem to be the predominant serotype in most countries (Hampson 1994). 
Neonatal infections can be prevented effectively by passive colostral and lactogenic immunity that 
can be obtained and increased by vaccination of the sows (Rutter et al., 1974; Deprez et al., 1986; 
Moon et al., 1988). In contrast, no vaccines are available for PWD. Besides the weaning itself, 
other factors are involved in the PWD-complex such as mixing of the pigs, changes in 
environmental temperature, humidity and diet (Miller et al., 1984; Kelly et al., 1990; Scheepens et 
al., 1994; Jones et al., 2001). Furthermore, weaning is accompanied with the disappearance of the 
lacteal protection provided by the milk antibodies of vaccinated or naturally infected dams. These 
protective antibodies inhibit the adhesion of ETEC to brush border receptors of small intestinal 
epithelium of pigs and can neutralise the enterotoxins produced by ETEC. So, to protect piglets 
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against PWD the induction of an active mucosal immune response is required. Secretory IgA 
(sIgA) antibodies play an important role in this protective immunity (McGhee et al., 1992). It has 
been shown that the steroid hormone 1α,25(OH)2D3 (Van der Stede et al., 2001) and CpG-
oligodeoxynucleotides (Van der Stede et al., 2002) can enhance the antigen-specific IgA response 
in serum as well as in mucosal secretions after IM immunisation. Consequently, CpG-ODN and 
1α,25(OH)2D3 look promising candidate adjuvants for veterinary vaccines. 
1α,25(OH)2D3,  the active metabolite of vitamin D, is a lipophilic steroid hormone and acts 
through binding and activation of the nuclear vitamin D3 receptor which influences the 
transcription of numerous genes (Carlberg et al., 1998). In mice, it was also shown that 
1α,25(OH)2D3 modulated a systemically induced immune response towards a mucosal immune 
response with enhanced homing of antigen-specific IgA and IgG antibody secreting cells (ASC) 
to the lamina propria of the intestine and lungs (Daynes et al., 1994, Daynes et al., 1996). This 
modulation was accompanied with an enhanced production of IL-4 and IL-10 (Th2-cytokines). In 
cattle, 1α,25(OH)2D3 increased milk IgA, IgM and IgG and IgG1 serum antibodies but decreased 
serum IgG2 serum antibodies (Reinhardt et al., 1999) while in sheep 1α,25(OH)2D3 enhanced both 
IgG1 and IgG2 serum antibodies with moderate effects on the IgA response (Scheerlinck et al., 
2001). In general, the steroid hormone 1α,25(OH)2D3 is classified as a Th2-immunomodulating 
adjuvant. 
In contrast CpG-ODN are classified as Th1-modulating adjuvants in mice and man (Roman 
et al., 1997). CpG-ODN directly activate monocytes, macrophages and dendritic cells to secrete 
IL-12, TNF-α and IFN-α (Ballas et al., 1996; Stacey et al., 1996). These cytokines enhance NK-
activity with the production of IFN-γ (Cowdery et al., 1996). In vitro studies in mice have been 
shown that CpG-ODN directly stimulate B cell proliferation inducing the secretion of 
immunoglobulins, IL-6 and IL-10 (Krieg et al., 1995; Yi et al., 1996; Redford et al., 1998; Brown 
et al., 1998) and modulate these B-lymphocytes towards production of IgG2a. Also immune cells 
(monomorphonuclear cells) of other species like cattle, sheep (Pontarollo et al., 2002) and pigs 
(Kampstrup et al., 2001) are activated in vitro by CpG-ODN. 
The aim of the present study was to evaluate whether IM immunisation of piglets with F4 
during the suckling period could protect against oral challenge with F4+-E. coli and whether 
addition of 1α,25(OH)2D3 or CpG-ODN could improve this protection. 
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7.3. Material and methods 
7.3.1. Animals 
 
Twenty conventional pigs (Belgian Landrace x Piétrain) derived from three different litters 
on 1 closed farm were used in the experiment. These pigs were F4 seronegative as determined by 
ELISA. During the suckling period the pigs remained with their dams on the farm. At 29 days of 
age they were weaned, transported to the faculty where they were housed in isolation units and 
obtained water and food ad libitum. 
7.3.2. Bacterial inoculum 
The E. coli strain GIS 26 (O149:K91:F4ac, LT+STa+STb+) was cultured during 24 hours on 
Brain Heart Infusion Agar (Oxoid, Unipath, Drongen, Belgium) and bacteria were collected by 
washing the agar with phosphate-buffered saline (PBS, 150mM, pH 7,4) Subsequently, the 
bacteria were washed once with PBS and the concentration was determined by measuring the 
optical density at 660 nm (OD660). An OD660 of 1 equals 109 bact/ml, as determined by counting 
the colony forming units (CFU). The concentration of the suspension was adjusted to 109 
bacteria/ml. The production of F4-fimbriae was tested by agglutination using a F4a-specific MAb 
(IMM-01). The production of Escherichia coli heat-lable enterotoxin was tested using the VET-
RPLA kit (TD920, Oxoid, Unipath, Drongen, Belgium).  
7.3.3. Purification of F4 (K88ac)-fimbriae 
 
The fimbriae were purified as described by Van den Broeck and co-workers (1999). Briefly, 
the bacteria were cultured in Tryptone Soya Broth (Difco Laboratories, Biotrading, Bierbeek, 
Belgium) at 37°C for 18 hours. Subsequently the bacteria were collected by centrifugation (3,000 
x g, 30 min) and washed in PBS, after which the fimbriae were isolated by homogenising the 
bacterial suspension followed by a precipitation with 40 % (wt/vol) ammonium sulphate. The 
pellet was dialysed against PBS and hereafter the fimbriae were further purified by anion 
exchange chromatography using a Bio-Scale Q5 column (BIO-RAD Laboratories, Eke, Belgium). 
The F4-fimbriae solution was filter sterilised and the total protein concentration was determined 
using the Bicinchoninic Acid Protein Assay Kit (SIGMA, Sigma-Aldrich, Bornem, Belgium). 
Purity was assessed by electrophoresis on 12% SDS-polyacrylamide slab gels as described and 
contained mainly the major subunits of 27.5 kDa (Laemmli 1970). The purified F4-antigen was 
used to immunize the pigs and for in vitro proliferation assays. 
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7.3.4. Experimental design   
7.3.4.1. Immunisations 
The pigs of the 3 different litters were allocated at random into 4 groups of 5 piglets each. 
The pigs were intramuscularly (IM, in the neck) injected at 8 and 25 days of age with 100 µg of 
F4 in incomplete Freund’s adjuvant (IFA, F4-group), 100 µg F4 in IFA supplemented with either 
2 µg of 1α,25(OH)2D3 (D3-group) or 500 µg of CpG-ODN (CpG-group). The control group 
received PBS in IFA. 
The D3-, CpG and F4-group received F4 dissolved in 0.5 ml PBS and 1/1 (vol/vol) 
suspended in incomplete Freund’s adjuvant (IFA, DIFCO Laboratories) with or without their 
specific supplement. The steroid compound 1α,25(OH)2D3 (Sigma-Aldrich, Bornem, Belgium) 
was dissolved in absolute ethanol as a stock solution 40 µg/ml and stored at -20°C until used. 
CpG-ODN (5’GCT-AGA-CGT-TAG-CGT-3’) had a phosphodiester backbone and were stored at 
–20°C (Biosource Europe) at a concentration of 10 mg/ml sterile DEPC treated water. 
Eight days post the second immunisation (dpsi, age of 33 days), all pigs were 
intragastrically infected with the GIS26 strain as further described. 
The effects of the IM immunisations upon the F4+-E. coli-challenge were evaluated by 
analysing (i) weight gain (ii) faecal F4+-E. coli excretion, (iii) F4-specific antibody response and 
(iv) F4-specific proliferation of PBMC.  
All pigs were weighed at moment of the first IM immunisation (8 days of age), a week 
before challenge, at moment of challenge infection (33 days of age) and 7 and 14 days later (47 
days of age). The average daily weight gain (ADWG) was calculated at moment of challenge (= 
(weight (kg) on day 33)-(weight on day 8)) and 14 days post challenge (dpc) (= (weight on day 
47)-(weight on day 33)) to compare the growth of the different groups during the challenge 
infection. 
In order to know the F4-receptor status (F4R) of the pigs, they were euthanatized 15 dpc by 
an intravenous injection of pentobarbital (24 mg/kg; Nembutal, Sanofi Sante animale, Brussels, 
Belgium). Thereafter small intestinal villi were collected for determining the presence of the F4R.  
 
7.3.4.2. Challenge with virulent F4+-E. coli GIS 26 
 
The pigs were treated three days with florfenicol (Nuflor, Schering-Plough, Brussels, 
Belgium) in PBS (300 mg in 5 ml PBS/animal/day) in order to decrease colonisation resistance by 
the normal gut flora. Before the challenge, the pigs were deprived of food and water for 12 hours 
whereafter the acidic gastric pH was neutralized with 62 ml NaHCO3 (1,4 % (wt/vol) in distilled 
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water) to increase the survival of the bacteria during the passage through the stomach (Cox et al., 
1991). Fifteen minutes later, the pigs were intragastrically infected with 1010 F4+-E. coli. 
 
7.3.5.. Samples 
7.3.5.1. Serum 
 
On days 0 (first immunisation 8 days of age), 10, 17, 25, 29, 33 and 40 of the experiment 
blood was sampled from the jugular vein, serum was collected and inactivated at 56°C during 30 
min and subsequently treated with kaolin (Sigma-Aldrich, Bornem, Belgium) to decrease 
background reading in ELISA (Arnouts 1994). Therefore, 4 volumes of a kaolin suspension (25% 
(wt/vol) in PBS) were added to 1 volume of serum and incubated for 30 min at room temperature. 
The suspension was centrifuged at 5,500 x g for 10 min and the supernatant was diluted in ELISA 
dilution buffer (PBS + 0,2% (vol/vol) Tween 20 + 3% (wt/vol) bovine serum albumin (BSA)), 
yielding a final serum dilution of 1/10. 
 
7.3.5.2. Faeces 
Faecal samples were collected daily from day 0 till 7 dpc. The prevalence and severity of 
the diarrhoea were noted by visually scoring the consistency of the faeces on a scale of 0 to 3 as 
described by Cox et al (1987) : 0 = no diarrhoea (normal faeces); 1 = slight (pasty faeces); 2 = 
moderate (semi liquid faeces); 3 = severe diarrhoea (watery faeces). 
 
7.3.5.3. Peripheral blood monomorphonuclear cells (PBMC) 
 
Blood was collected from the jugular vein 4 dpsi and 14 dpc on an equal volume of 
Alsever’s solution. PBMC were isolated by density gradient centrifugation on Lymphoprep 
(Invitrogen, Merelbeke, Belgium). After lysis of the erythrocytes in ammonium chloride (0.8% 
[wt/vol]) and subsequent centrifugation (380 x g for 10 min at 4°C), the PBMC were washed and 
resuspended at the concentration of 4.106 cells/ml in leukocyte medium (RPMI-1640 
supplemented with penicillin (100 IU/ml) and streptomycin (100 µg/ml), kanamycin (100 µg/ml), 
L-glutamin (200 mM), sodiumpyruvate (100mM), non-essential aminoacids (100mM), β-
mercaptoethanol (5.10-5 M) and 1% (vol/vol) serum of a colostrum-deprived piglet). The cells 
were used for analysis of F4-specific proliferation. 
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7.3.6. ELISA for F4-specific IgG, IgA and IgM serum antibodies 
 
F4-specific IgM, IgA and IgG titers were determined in an indirect ELISA as described by 
Van den Broeck et al (1999). Briefly, the wells of a 96-well microtitre plate (NUNC, Maxisorb 
Immuno Plates, Gibco BRL) were coated with a F4-specific MAb (IMM-01) at a concentration of 
1 µg/ml coating buffer (PBS, 150mM, pH=7,4). After 2 hours of incubation, the remaining 
binding sites were blocked overnight at 4°C with PBS supplemented with 0.2 % (vol/vol) 
Tween®80 ( Merck Eurolab, Leuven, Belgium). Subsequently, purified F4 was added to the wells 
at a concentration of 30 µg/ml in ELISA dilution buffer (PBS, pH 7.4 + 0.05% [vol/vol] Tween® 
20 + 3 % BSA) for 1 hour at 37°C. Then, the pretreated sera were added in series of twofold 
dilutions in ELISA dilution buffer, starting at a dilution of 1/10. The plates were incubated for 1 
hour at 37°C. Thereafter, biotinylated-swine-specific IgM, IgA and IgG MAb (Van Zaane et al., 
1987). were added and plates were incubated for 1 hour at 37°C followed by 1 hour incubation at 
37°C with peroxidase-conjugated streptavidin. Between each step, the plates were washed with 
PBS + 0.2% [vol/vol] Tween® 20. Finally, the ABTS solution (Roche Diagnostic, Brussels, 
Belgium), containing H2O2, was added and after 30 min incubation the optical density was 
measured at 405 nm (OD405).  
The antibody titer was determined as the inverse of the highest dilution that still had an 
OD405 higher than the cut-off value. The cut off value was determined by calculating the mean 
OD405 plus 3 times the standard deviation of the optical densities of the 1/10 diluted samples 
measured at day 0. The obtained cut-off values were 0.26, 0.32 and 0.4 for F4-specific IgM, IgG 
and IgA respectively. 
 
7.3.7. Faecal excretion of F4+ E. coli. 
 
The faeces was examined for the presence of F4+-E. coli by preparing a 1% (wt/vol) 
suspension in PBS at 4°C. Subsequently 50 µl of four serial 10-fold dilutions in PBS were plated 
out on sheep blood agar plates (Difco Laboratories). After 24 hours incubation at 37°C the 
colonies were blotted onto polyvinylidene fluoride membranes (Gelman Science, Leuven, 
Belgium) during 2 hours at room temperature. Subsequently, the remaining binding sites were 
blocked overnight with blocking solution (5% (wt/vol) nonfat dry milk in PBS). After rinsing the 
membranes in PBS, a peroxidase-conjugated F4-specific MAb (IMM-01) was added for 1 hour at 
room temperature. The membranes were rinsed again whereafter the substrate solution (0.67 ml of 
AEC stock solution (0.4% (wt/vol) in dimethylformamide) in 10 ml sodium acetate (0.1 M, pH 
5.2) + 10 µl 30 % H2O2) was added. The enzymatic reaction was stopped after 15 min by rinsing 
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the membranes in PBS and the brown-red dots were counted. The results are presented as the 
mean number (log10) of F4+-E. coli per gram faeces ± SEM (Figure 7.1). 
7.3.8. F4-specific proliferation assay 
 
The lymphocyte proliferation test was performed by adding F4-fimbriae (final 
concentration 10 µg/ml) or medium to the wells of a 96-well flat-bottom microtitre plate (Nunc) 
containing 4 x 105 PBMC/well (final volume of 200 µl). To evaluate the proliferative capacity of 
the cells, concanavalin A (ConA, final concentration 10µg/ml) induced proliferation was used as a 
control. Each stimulation was performed in triplicate. The cells were incubated at 38°C in a 
humidified atmosphere with 5% CO2. After 72 hours the cells were pulse-labeled with 1 µCi/well, 
of [3H]-thymidine (Amersham ICN, Bucks, UK) and 18 hours later the cells were harvested onto 
glass fiber filters (Perkin Elmer, Life Science, Brussels, Belgium) The radioactivity incorporated 
into the DNA was measured using a β-scintillation counter (Perkin Elmer, Life Science, Brussels, 
Belgium). The results are presented as the mean counts per minute (cpm) calculated by 
substracting the background cpm (medium) from the cpm of F4-stimulated cultures. 
 
7.3.9. In vitro villous adhesion assay for the F4R using F4+ E. coli  
 
In order to determine the presence of the F4R on the small intestinal villous enterocytes, an 
in vitro villous adhesion assay was performed. Collection of the small intestinal villi was 
performed as described by Cox and Houvenaghel (1987;1993). The in vitro villous adhesion assay 
was based on the technique described by Girardeau (1980). 
 
7.3.10. Statistical analysis 
 
Differences between the groups in mean log2 antibody serum titers (IgM, IgA and IgG) and 
F4+-E. coli shedding in faeces were tested for statistical significance using General Linear Model 
(Repeated Measures Analysis of Variance, SPSS 7.5 for Windows). Differences in the frequency 
of F4+-E. coli excreting animals were tested for statistical significance using a chi-square test 
(Pearson). Differences between groups in cell proliferation assays and faecal score were analysed 
for statistical significance using the Kurskal-Wallis test. Differences in the the ADWG between 
the groups was tested for statistical significance using a two-sample t test. P < 0.05 was 
considered as statistically significant. 
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7.4. Results 
 
7.4.1. Faecal shedding of F4+- E. coli  
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 7.1: Mean faecal excretion of F4+-E. coli/gram faeces (log10± SEM)/group/day until 7 days 
post challenge (dpc). Pigs were IM injected two times (at the age of 8 and 25 days) with F4-fimbriae 
with or without different immunomodulators (1α,25(OH)2D3 and CpG-ODN) and intragastrically 
infected with 1.1010 F4+-E. coli one week later. Significant difference (p<0.05) between control group 
and D3-group 2 dpc is indicated with an asterisk. 
 
 
Before challenge (Day 0) all animals had no F4+-E. coli excretion and showed no diarrhoea 
(faecal score = 0, not shown). In the control group, a peak in the faecal F4+-E. coli excretion 
(mean  F4+-E. coli/gram faeces of 107,8) was seen 2 dpc followed by a gradual decrease. Seven 
dpc no F4+-E. coli could be isolated from the faeces of all pigs. All F4-vaccinated groups showed 
a reduced F4+-E. coli excretion but this was only significant for the D3-group 2 dpc (Figure 7.1). 
A significantly lower faecal score was observed in the CpG-group in comparison with the control 
group 2 dpc (Table 7.1.). At that moment a significantly higher (P<0,05) number of F4+-E. coli 
excreting animals was observed in the control group in comparison with the D3-group (Figure 
7.2). No statistical difference was observed between the F4-group and the ‘supplemented’ groups. 
The duration of F4+-E. coli excretion (6 days) was not significantly different between the groups. 
 
 
 
0 
2 
4 
6 
8 
10 
0 1 2 3 4 5 6 7
CpG 
D3 
F4 
PBS 
dpc
* 
134    Chapter 7 
  
0%
20%
40%
60%
80%
100%
0 1 2 3 4 5 6 7
dpc
%
 F
4+
 E
TE
C
-e
xc
re
tin
g 
an
im
al
s
PBS-group
F4-group
D3-group
CpG-group
 
FIGURE 7.2: % of F4+-E. coli excreting animals until 7 days post challenge (dpc). Significant 
difference (P<0.05, two-by-two table) was found between the D3-group and the control group 2 dpc. 
 
 
TABLE 7.1. : The daily faecal score for each individual animal in the different treatment groups. Pigs 
were intramuscularly (IM) injected at the age of 8 and 25 days old and infected 8 days later with 1.1010 
F4+-ETEC.  
  Faecal scorea  
groups Pig 1 dpc* 2 dpc 3 dpc 4 dpc 5 dpc 6 dpc 7 dpc Total faecal score/group 
during observation period 
PBS  1 1b 0a 3 1 1 0 1  
 2 2c 1 1 1 1 0 0  
 3 1 1 0 2 2 1 0  
 4 2 1 1 1 1 1 1  
 5 3d 1 0 1 0 0 0 33 
          
F4  6 0 0 0 1 0 1 1  
 7 3 2 3 3 3 1 0  
 8 0 0 0 1 1 0 0  
 9 0 0 0 1 0 1 1  
 10 1 0 1 0 0 1 1 27 
          
D3 11 0 1 1 0 1 1 1  
 12 1 0 0 0 0 0 0  
 13 2 0 0 0 0 0 0  
 14 1 1 0 1 1 1 0  
 15 1 1 1 1 †b   17 
          
CpG 16 0 0 1 0 1 1 1  
 17 1 0 0 1 0 1 0  
 18 1 0 1 0 1 0 0  
 19 1 0 1 1 1 0 0  
 20 1 0 1 1 1 0 0 18 
          
aFaecal score:  0: normal faeces ; 1: pasty faeces ; 2: semi liquid faeces; 3: watery faeces. 
†b: pig died of bronchopneumonia.*:days post challenge. 
     * 
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7.4.2. Humoral immune responses 
 
All pigs were F4-seronegative prior to the start of the experiment. The kinetics of the F4-
specific serum antibody responses is shown in figure 7.3. The control group showed no antibody 
response before challenge infection, even though a slight increase in baseline values occurred just 
before challenge. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 7.3: Kinetics of the F4-specific IgM, IgA and IgG serum response following 2 IM immunisations 
and challenge infection with F4+-E. coli. Pigs in each group (n=5) were injected on two occasions with PBS 
in IFA (○) or 100 µg F4-fimbriae in IFA (♦) with or without supplementation of 2 µg of 1α,25(OH)2D3 (■) 
or 500 µg of CpG-ODN (▲). The antibody titers are plotted as mean log2 titers ± the SEM. and significant 
differences (P<0,05) are indicated with a, b and c. 
a: statistical difference between the F4-group (♦) and the control group (○). 
b: statistical difference between the D3-group (■) and the control group (○). 
c: statistical difference between the CpG-group (▲) and the control group (○). 
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Following vaccination the F4-specific IgM antibody titers peaked 10 days post primary 
immunisation (dppi) in all 3 F4-immunised groups, whereafter it decreased again to reach baseline 
values 25 dppi. Seventeen dppi, the IgG antibody titer in the F4-immunised groups was 
significantly higher (P<0.05) than the control group and remained significantly higher after the 
booster immunisation. After the F4+-E. coli challenge, 3 out of 5 control animals showed an IgM 
and IgG antibody response, while low IgM and decreased IgG responses were seen in the F4-
immunised groups (no apparent booster response). 
Following the IM immunisations an increase of the F4-specific IgA-titers was also observed 
in the F4, D3 and CpG-group but was only statistical significantly different from the control group 
in the F4-group (from 17 dppi onwards). The F4+-E. coli challenge resulted in a strong increase of 
the IgA titer in the D3-group with significantly higher (P<0,05) IgA titers than in the control group 
0, 4 and 7 dpc. After the E. coli challenge, the control group showed a good increase of the of the 
IgA titer (24-26,12) to reach a plateau 7 dpc. 
7.4.3. F4-specific proliferation. 
 
The lymphocyte proliferation in response to F4-fimbriae and ConA were analysed 4 dpsi 
(Figure 7.4A) and 14 dpc (Figure 7.4B). Spontaneous proliferations (mean cpm of control 
medium cultures ± SEM) was 537 ± 70 cpm (4 dpsi) and 254 ± 52 cpm (14 dpc). 
Four dpsi, the F4-specific proliferation was significantly higher (P<0,05) in the CpG-group 
than in all other groups and significantly higher in the F4 and D3 group than in the control group. 
ConA-induced stimulation resulted in high proliferation in all groups with the highest 
proliferation seen in the CpG-group that was significantly higher than in the control and D3-group 
(Figure 7.4A).  
Fourteen dpc the F4-specific proliferation in the control group was still significantly 
lower (P<0,05) than in the other vaccinated groups. There were no significant differences 
between the F4-vaccinated groups. Again, the ConA-induced proliferation was significantly 
higher (P<0,05) for the CpG-group than for the other groups, whereas the F4- and D3-group 
had significantly higher ConA-induced proliferations than the control group (Figure 7.4B). 
 
 
 
 
 
 
Chapter7:Reduced faecal excretion of E. coli after IM injection with 1,25(OH)2D3 and CpG-ODN     137 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 7.4: F4-specific (10 µg/ml final concentration) and ConA-induced proliferation (10 µg/ml 
final concentration) proliferation of PBMC 4 dpsi (A) and 14 dpc (B). Results are presented as mean 
cpm ± SEM. Bars with a different letter are significantly different (p<0,05). 
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7.4.4. Weight gain 
 
The mean body weight increased from 3,45 kg ± 0,41 kg at the start of the experiment to 
8,37 ± 1,0 kg at moment of challenge to 16,17 ± 1,48 kg 14 dpc. No significant differences 
(P>0.05) between the experimental groups were observed. The ADWG between the first 
immunisation and the challenge 25 days later was + 0.211 ± 0.05 kg for the control group, + 0.211 
± 0.04 kg for the CpG, + 0.200 ± 0.03 kg for the F4 and +0.193 ± 0.03 kg for the D3-group. 
Fourteen dpc, the ADWG was + 0.612 ± 0.126 kg for the D3-group, + 0.593 ± 0.08 kg for the F4-
group, + 0.562 ± 0.09 kg for the CpG-group and + 0.519 ± 0.06 kg for the control group. There 
were no significant differences (P>0.05) between the groups. A decrease in the mean daily weight 
gain was seen in all groups following weaning with an overall increase of 227 ± 36 g the week 
before weaning to 100 ± 69 g the week after weaning. 
 
7.5. Discussion 
 
At weaning piglets become deprived of lactogenic antibodies and need an active mucosal 
immunity to protect them against enteropathogenic microorganisms. However to obtain protection 
immediately post-weaning, piglets have to be immunised during the suckling period. In the 
present study it was analysed whether IM immunisation of piglets with F4 in IFA during the 
suckling period could protect against oral challenge with F4+-E. coli and whether addition of 
1α,25(OH)2D3 or CpG-ODN could improve this protection. 
Intramuscular immunisation with F4 fimbriae was able to reduce F4+-E. coli excretion in 
faeces upon challenge with F4+-E. coli. Addition of CpG-ODN and 1α,25(OH)2D3 reduced even 
more the E. coli excretion which was statistically significant for 1 α ,25(OH)2D3 on day 2 post 
challenge. All of the non-immunised (control) pigs excreted F4+ E. coli and 60 % developed a 
transient and severe diarrhoea (semi liquid to watery diarrhoea) within 2 days post challenge, 
which is in agreement with previous observations (Cox et al., 1991). Pigs can excrete high 
numbers of F4+-E. coli in the absence of diarrhoea: post-weaning diarrhoea is a multifactorial 
disease complex in which F4+-E. coli is one of the factors. The number of excreting and 
diarrhoeic pigs in all F4-immunised groups was lower than in the control group. This was not due 
to the lack of specific receptors as all pigs in this study expressed the F4R. Best protection, as 
evaluated by the excretion of F4+-E. coli and the degree of diarrhoea after challenge, was obtained 
by adding 1 α ,25(OH)2D3 to the antigen. 
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In order to evaluate the supplementation of 1α,25(OH)2D3 or CpG-ODN on the humoral 
immunity, the F4-specific serum antibody responses were measured. After IM immunisation 
similar F4-specific serum IgM and IgG responses were observed, whereas the animals that 
received only F4 displayed the highest serum IgA responses. Van den Broeck et al (1999) 
demonstrated that the F4-specific IgA serum titer is a useful measure for the mucosal immune 
response in piglets after an oral immunisation since they are induced at the gut-associated 
lymphoid tissue (GALT). The IgA response after an intramuscular immunisation of pigs is mainly 
induced in systemic lymphoid tissues so that the F4-specific IgA titer is less correlated with the 
IgA in the gut mucosa. However, some of the dimeric serum IgA will be secreted at the mucosal 
surfaces what could explain the protection observed in the F4-group. Furthermore, studies have 
shown that non-mucosal immunisations can induce antigen-specific IgA ASC which are capable 
of homing to mucosal tissues (Quiding-Jabrink et al., 1997; Kantele et al., 1997). Although, the 
number of antigen-specific IgA ASC in the GALT were not enumerated in the present study, an 
increased homing of antigen-specific IgA ASC to the gut-associated lymphoid tissue (Peyer’s 
Patches) has been observed in previous studies following intramuscular immunisation with 
antigen and 1α,25(OH)2D3 (Chapter 3). Similar observations have been made in mice where 
subcutaneous injections with hepatitis B surface antigen together with 1α, 25(OH)2D3 induced 
increased numbers of IgA and IgG ASC in lamina propria of lungs and intestines (Daynes et al., 
1994; 1996). This was at least partly due to the migration of antigen-pulsed dendritic cells from 
the local draining lymph nodes towards the Peyer's patches, where the activation and 
differentiation of antigen-specific B cells is initiated (Enioutina et al., 1999;2000). This might 
explain the protection as well as the booster IgA serum response using 1α, 25(OH)2D3 upon F4+-
E. coli challenge. 
In the present study, neither 1α,25(OH)2D3 nor CpG-ODN enhanced the F4-specific serum 
antibody responses, whereas significant increases did occur with these immunomodulators when 
HSA (Van der Stede et al., 2001) or ovalbumin (Van der Stede et al., 2002) were used as 
immunizing antigens. This could be due to the nature of the F4-antigen that consists of repetitive 
epitopes of identical FaeG protein subunits (Oudega et al., 1989) and induces already potent 
immune antibody responses difficult to ameliorate with 1α,25(OH)2D3 or CpG-ODN.  
Remarkably, the combination of F4-fimbriae in IFA even reduced the faecal F4+-E. coli 
excretion although this reduction was not significant as compared to the control group. The 
mechanism for this reduction is not clear but the high serum IgA titers could be involved. F4 
suspended in IFA is good for inducing high serum antibody titers. IFA and other water in oil 
adjuvants are excellent stimulators of the humoral as well as cellular immunity (Lindblad et al., 
2000). 
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In order to analyse the effect on cellular (memory) immunity, lymphocyte proliferation 
assays were performed. All immunized groups showed F4-specific proliferations, which were 
however significantly higher in the CpG-group than in all other groups. Also in a previous study, 
with CpG-ODN primed animals, enhanced OVA-specific as well as mitogen-induced proliferation 
were observed (Van der Stede et al., 2002). So, it appears that CpG-ODN have the intrinsic 
capacity to trigger directly or indirectly via APC the lymphocytes for better proliferation. This is 
consistent with the observations of Lipford et al (1997) who demonstrated that CpG-ODN may 
influence the signal threshold of antigen-reactive T cells in vivo and that this effect was due to the 
CpG-mediated activation of antigen-presenting cells like dendritic cells and macrophages. CpG-
ODN priming enhanced also the antigen non-specific proliferation as evidenced in the ConA 
stimulations. This is in accordance with the polyclonal activation of B- and T cells (in the 
presence of APC and cytokines) by Liang et al. (1996). As the effect of CpG-ODN on the cellular 
immunity was uniformly immunoenhancing this was not the case with 1α,25(OH)2D3 where a 
high variability in proliferation was observed among the animals. However, the mean proliferation 
of 1α,25(OH)2D3 injected animals was still higher than with F4 only. The enhanced cellular 
immunity perhaps contributed to protection. Further  studies are required to fully characterize the 
role of cellular immunity in F4+-E. coli infections. No indications of homing of F4-specific IgA 
ASC towards the GALT were obtained after IM immunisation with CpG-ODN, but secretion of 
F4-specific serum IgA could be involved in the decreased faecal excretion of F4+-E. coli. 
In conclusion, intramuscular immunisations of suckling piglets with F4-fimbriae reduced 
the F4+ E. coli excretion upon challenge. In addition, supplementation of 1α,25(OH)2D3 improved 
significantly this reduction and was correlated with the presence of a secondary (mucosal) IgA 
response. Conversely, addition of CpG-ODN correlated with significantly higher T-cell 
proliferation. These results indicate that 1α,25(OH)2D3 and CpG-ODN have a potential to 
improve veterinary vaccines against enteropathogens. 
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CHAPTER 8 
 GENERAL DISCUSSION, CONCLUSIONS AND PERSPECTIVES 
 
Since most pathogens either replicate at a mucosa or at the mucosal barrier before entering 
the body, mucosal immune mechanisms are the first step in defense against these pathogens. 
Vaccines that activate mucosal immune mechanisms are therefore superior to other vaccines in 
affording protection against these pathogens. The best route for inducing protection in the 
intestinal mucosal tract is the oral route. However, only few oral vaccines are available. Soluble 
antigens mostly do not induce protection via this route even so inactivated bacteria. Protection can 
be obtained with attenuated enteropathogens but then these strains still induce clinical signs 
(Moon et al., 1993). A major hurdle in delivering antigen via mucosal surfaces is that most 
antigens are poorly immunogenic and induce a state of hypo- or unresponsiveness, called oral 
tolerance (Strobel and Mowat 1998). 
Studies in mice have demonstrated that systemic injection of antigen in the presence of 
1α,25(OH)2D3 as immunomodulator could be modulated towards a mucosal immune response 
with the appearance of IgA antibody secreting cells in the mucosa and of sIgA in intestinal 
mucosal secretions (Daynes et al., 1994, 1996; Enioutina et al., 1999, 2000).  
The aim of the present PhD-thesis was to determine if an intramuscular immunisation in 
pigs, which normally induces a systemic immune response, could result in a mucosal immune 
response using 1α,25(OH)2D3 and CpG-oligodeoxynucleotides (CpG-ODN) and whether this was 
correlated with Th2-responses. Indeed, 1α,25-dihydroxyvitamin D3 has been classified as a Th2-
modulating adjuvant. Th2-like cytokines are considered to be major helpers for IgA responses. On 
the other hand, CpG-ODN are known as Th1-modulating adjuvants but are also able to stimulate 
directly B cells. 1α,25-Dihydroxyvitamin D3 and CpG-ODN belong to two different classes of 
adjuvants: 1α,25(OH)2D3 belongs to the class of cytokines and hormones and the CpG-ODN 
belong to the ‘bacterial products’ such as bacillus Calmette-Guérin (BCG) and monophosphoryl 
lipid A (Edelman, 2000). Their immunomodulating effects and their possible role in the induction 
of active (mucosal) immunity are discussed in chapter 1. 
Hereto, different immune parameters such as the antigen-specific isotype-specific serum 
antibody response, antigen-specific IgA titers in mucosal secretions, antigen-specific lymphocyte 
proliferation, phenotypic analysis of the lymphocyte subsets and cytokine-profiles (Th1/Th2) 
were evaluated after IM immunisation of antigens supplemented with or without 1α,25(OH)2D3 or 
CpG-ODN. Furthermore, in order to evaluate the protective capacity of an induced mucosal 
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immune response, a challenge experiment was performed with F4-fimbriae as immunogen and 
F4+-enterotoxigenic Escherichia coli (ETEC) as challenge strain (Chapter 7). F4-fimbriae are 
proteinaceous surface antigens composed of repeating subunits and play a role in the pathogenesis 
of PWD in pigs as they allow the bacteria to adhere to specific receptors on the brush border of 
enterocytes with subsequent colonization of the small intestine (Jones and Rutter, 1972). Other 
antigens used in the present thesis were HSA and OVA (Chapter 2, 3 and 4). 
 
8.1. The immunomodulating effects of 1α,25(OH)2D3 after IM immunisation of pigs 
 
8.1.1. Humoral responses 
 
To analyse the effect of 1α,25(OH)2D3 on the antibody response, IFA with or without 
1α,25(OH)2D3 was injected intramuscularly in piglets. Analysis of the HSA-specific serum 
antibody response and HSA-specific antibody-secreting cells (ASC) demonstrated that the steroid 
hormone was able to enhance the HSA-specific serum IgA response as well as the number of 
HSA-specific IgA ASC in the local draining lymph node. In addition 1α,25(OH)2D3 also 
enhanced the number of antigen-specific IgG ASC in the local draining lymph node (Chapter 2). 
However, the effect of 1α,25(OH)2D3 on the antigen-specific IgM, IgG, IgG1 and IgG2 serum 
antibody response was not consistently higher in comparison with the control animals and varied 
between the studies. This could have been due to a different site of immunisation in the different 
studies. Indeed, it has been shown in pigs that injection at sites of which the draining lymph nodes 
also drain draining parts of the mucosal immune system increases IgA responses (Vanderpoorten 
et al., 1997). So, immunisation in the m. gluteobiceps (Chapter 2) and neck (Chapter 4 and 7) both 
draining parts of respectively the rectum and mammary glands may be beneficial for inducing IgA 
responses in comparison with IM immunisation in the m. gastrocnemius (Chapter 3 and 7). So the 
effect of 1α,25(OH)2D3 in modulating towards IgA responses is best studied after IM injection in 
the periphery (m. gastrocnemius). The adjuvant influence upon IM immunisation was 
consequently best demonstrated in chapter 3 in which the steroid hormone modulated towards IgA 
as it was the only antibody isotype that was enhanced after IM injection. That the number of IgA 
ASC was enhanced by 1α,25(OH)2D3 in pigs was similar to observations observed in mice 
(Daynes et al., 1994, 1996) but different from man (Kriezel et al., 1999). In sheep a slide increase 
of the serum IgA titer was observed (Scheerlinck et al., 2001). Due to its depot effect, IFA 
provides a good lipophylic ‘vehicle’ capable to store and transport the emulsified antigen and the 
steroid hormone with subsequent slow release of antigen (Cox et al., 1997). Besides inducing 
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significant antibody responses, IFA also stimulated the cellular immune response as we observed 
significant proliferation of the MC (Chapter 3 and 7). 
Using 1α,25(OH)2D3, also higher antigen-specific IgA titers in mucosal secretions (saliva, 
faeces and nasal secretions) were obtained. This could be the result of diffusion of dimeric IgA 
out of the serum into the mucosal tissues and/or due to locally produced dimeric IgA by ASC 
originating from systemic lymphoid tissue. Subsequently, this dimeric IgA can be secreted as 
sIgA at the mucosal surfaces (McGhee et al., 1992). According to Coffin and co-workers (1997, 
1998) there are a number of mechanisms by which intramuscular immunisation may induce 
production of antigen-specific IgA in the gut-associated lymphoid tissue (GALT and/ or MALT). 
Firstly, the antigen may reach the GALT via the by blood and stimulate an immune response after 
processing by intestinal antigen presenting cells. Secondly, antigen-specific IgA-ASC may be 
generated in the draining lymph nodes and home to the GALT. Thirdly, activated antigen-specific 
B-lymphocytes may be generated in draining lymph nodes, disseminate to the GALT and, in the 
presence of cytokines supportive for IgA production, differentiate into IgA ASC. Fourthly, 
antigen presenting cells capable of presenting antigen-specific peptides may be generated in 
draining lymph nodes and home to the GALT. Localization of the HSA-specific ASC in different 
lymphoid tissues revealed that the highest numbers of ASC were found in the systemic lymphoid 
tissues (local draining lymph node > spleen > bone marrow) indicating that lymphocytes activated 
in the ‘periphery” preferentially migrate to systemic lymphoid tissues. The activation in the local 
draining lymph node is enhanced by 1α,25(OH)2D3 which is consistent with the enlarged local 
draining lymph node observed in some of the pigs. The presence of significant numbers of HSA-
specific ASC in the Peyer’s patches as well as antigen-specific IgA in mucosal secretions (saliva, 
nasal secrete and rectal content) using 1α,25(OH)2D3 suggests either that some antigen-specific B 
cells reach mucosa-associated lymphoid tissues or that either antigen or antigen-presenting cells 
carrying antigen reach these sites. That in pigs only few antigen-specific ASC were detected in the 
small intestinal lamina propria and significant numbers in the Peyer’s patches is an argument in 
favor of one of both mechanisms. In mice, homing of antigen-presenting cells (DC’s), due to 
1α,25(OH)2D3, has been described (Enioutina et al., 1999,2000). 
8.1.2. Cellular responses and Th1/Th2 bias. 
 
The hallmark for the mucosal immune system is the production of sIgA. Historically, in 
mice Th2-cytokines are considered to be the best ‘helpers’ for IgA responses. However, sIgA 
release may also be induced in Th1-dominated responses, as observed with intracellular pathogens 
such as Salmonella in the gastrointestinal tract or influenza virus in the upper respiratory tract. 
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Furhtermore, TGF-β (secreted by Th3-cells) has been reported to be the most crucial sIgA “switch 
factor” (Lebman et al., 1990). Thus, either Th1, Th2 or Th3 cells or a combination of these cell 
types can support antigen-specific sIgA responses.  
Therefore, in pigs in vivo mRNA expression of Th1-like (IFN-γ, IL-2), Th2-like (IL-4, IL-
10), inflammatory (IL-6) and Th3-like (TGF-β) cytokines by MC of the local draining lymph 
nodes was measured to analyze the effect of 1α,25(OH)2D3 on the cytokine profile. After a first 
IM immunisation 1α,25(OH)2D3 treated piglets showed an increased IL-10 mRNA, traces of IL-4 
and a significant lower IL-2 mRNA response than non-steroid treated piglets. Furthermore, low 
IFN-γ mRNA was seen in treated and non-treated piglets. This cytokine profile is indicative for a 
Th2-like response and is similar to what was observed in mice (Daynes et al., 1994, 1996). Such a 
Th2-microenvironment promotes IgA B-cell maturation and results in downregulation of the Th1-
like cytokines (IL-2, IFN-γ) as described in mice (Adorini et al., 2001) and man (Lemire et al., 
1995). TGF-β, the most crucial sIgA switch factor did not seem to be crucial for the effect of 
1α,25(OH)2D3  since there was no change between treated and non-treated pigs the first two days 
after the IM immunisation. Ten days after the primary immunisation TGF- β mRNA could not be 
detected in the steroid-treated group. After the second immunisation, the cytokine profile seemed 
to be, in several aspects, the opposite of this after the first immunisation. IL-2 mRNA expression 
was higher in the 1α,25(OH)2D3  treated pigs and IL-10 mRNA was lower. However IFN-γ was 
also significantly lower in the treated pigs, so that this response is not indicative for a Th2-like 
cytokine response nor for a Th1 like cytokine response.  
The Th1/Th2 paradigm stands for down regulation of Th2 cytokines by a Th1-cytokine 
profile whereas a Th2-cytokine profile down regulates Th1 cytokines. In the present study this is 
true for IL-2 (Th1-like) and IL-10 (Th2 like) since a high IL-2 mRNA expression was 
accompanied by a low IL-10 mRNA expression and vice versa. This is consistent with what is 
observed in mice and man (Mosman et al., 1996). However, the same is not true for IFN-γ (Th1-
like) and IL-4 mRNA expression, since high IL-2 mRNA expression was accompanied with low 
IFN-γ mRNA-expression and high IFN-γ mRNA expression was accompanied with low IL-2 
mRNA expression whereas IL-4 mRNA expression was consistently low. IL-10 and IL-2 are 
important cytokines for clonal expansion of activated B cells. Furthermore, IL-4, IL-5 and IL-6 
are involved in the differentiation towards IgA producing B cells and the IgA secretion. Injection 
with 1α,25(OH)2D3 did not enhance IL-4 and IL-6 and there are no tools available for measuring 
porcine IL-5. From the results, we can conclude that 1α,25(OH)2D3 did not favor a Th2 
microenvironment to the same extent as seen in mice. In fact only an increase of IL-10 was seen 
and then only after the first immunisation. That the increased expression of IL-10 mRNA is 
accompanied with a low IL-2 mRNA and vice versa could suggest that IL-10 may block the 
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transcription of IL-2 (Th1-like). In contrast to what is described by Blecha (2001), there was no 
evidence of a consistent down regulation of IFN-γ by IL-10 since high amounts of IL-10 mRNA 
in non-steroid treated pigs were accompanied by high IFN-γ mRNA expression. 
That 1α,25(OH)2D3 induces a different cytokine-profile after a first immunisation than after 
the second suggests that the effect on cytokines depends on the differentiation and activation 
status of the cells (naïve versus memory cells). In pigs, it is not clear which lymphocyte 
populations are affected by 1α,25(OH)2D3. In the present study only CD25+-cells (IL-2R+-cells) 
were increased as a result of steroid treatment. In pigs, CD25+-cells may be either monocytes, 
macrophages, T- and/or B cells (Denham et al., 1994; Lunney et al., 1987, 1994). No changes 
were observed in the percentage of CD2+ (most T cells) CD4+ (Th cells), CD8+ (CTL-cells) and 
IgM+-cells (B cells). Therefore it cannot be excluded that macrophages and/or dendritic cells are 
the primary target of 1α,25(OH)2D3 as observed in mice and man (Lemire et al., 1995, Enioutina 
et al., 1999, 2000, Adorini et al., 2001). 
 
8.2. The immunomodulating effects of CpG-ODN after IM immunisation of pigs 
8.2.1. Humoral responses 
 
In chapter 4 it was shown that CpG-ODN sequence 5-GCT-AGA-CGT-TAG-CGT-3’ as 
well as the reversed GpC-ODN sequence 5’-GCT-AGA-GCT-TAG-GCT-3’ significantly 
enhanced the primary serum antibody responses, the OVA-specific IgA titers in saliva and nasal 
secretions as well as the antigen-specific and ConA-induced proliferation of MC in different 
lymphoid tissues. The enhanced IgA response might be interesting for protection against mucosal 
infections as discussed in 8.3. The CpG-ODN as well as the GpC-ODN had a phosphodiester 
backbone and were shown to be most stimulatory in mice (Krieg et al., 1995, Klinmann et al., 
1999). The enhanced IgA response in pigs is a remarkable finding, as it has later been 
demonstrated in vitro by us (Chapter 5) as well as by others (Kamstrup et al., 2001) that this 
‘mice-specific CpG-ODN’ did not had any effect on proliferation of porcine lymphocytes. 
Therefore, in vitro proliferation assays may not be as sensitive, comparing to in vivo studies, to 
evaluate the immunostimulatory effect of CpG-ODN. The dose of 500 µg used in vivo and the 
presence of other cell populations in vivo than in vitro might explain the immunostimulatory 
effects of both ODNs. Also species differences could be important. In chickens, a dose of 50 µg 
of the GpC-ODN caused a decreased antibody response in comparison with the CpG-sequence 
(Vleugels et al., 2002). All these results indicate that CpG-ODN are promising adjuvants for 
enhancing the antibody responses (including IgA responses) after IM immunisation. They could 
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even skip booster immunisations. Indeed, a single injection of OVA combined with CpG-ODN 
resulted in antibody titers, which were as high as the titers in the control group after two 
immunisations.  
8.2.2. Cellular responses and Th1/Th2 bias  
 
In vitro studies with porcine peripheral monomorphonuclear cells (Chapter 5) clearly 
showed that 5’-ggTGC-ATC-GAT-GCA-Gggggg-3’ was the optimal sequence to induce 
proliferation. These CpG-ODN exerted effects on B-lymphocytes and enhanced the percentage of 
cells with MHC class II expression as well as the degree of expression following in vitro 
stimulation. A (polyclonal) B-cell proliferation is also observed in other species such as mice 
(Krieg et al., 1995), humans (Hartmann et al., 2000) and cattle (Brown et al., 1998 ; Pontarollo et 
al., 2002). In contrast, the CpG-ODN which was immunostimulatory in our in vivo study (Chapter 
4) did not induce any proliferative responses. Following in vivo administration, these CpG-ODN 
significantly enhanced OVA-specific proliferation as well as the ConA-induced proliferation of 
MC from blood, spleen and the local draining lymph node. So, even though these non-optimal 
CpG-ODN had no direct effect on MC in vitro they had an effect when given in vivo. That ConA-
induced proliferation was enhanced (Chapter 4) in the CpG-ODN injected pigs suggest that CpG-
ODN also activate T cells as observed in mice (Lipford et al., 1997, Liang et al., 2000). This could 
occur directly or indirectly via activation of B cells or APC by upregulation of cell-surface 
molecules or enhanced secretion of cytokines (Lotz et al., 1996). Indeed, in mice (Roman et al., 
1997) and man (Hartmann et al., 2000). CpG-ODN are known to be Th1-modulating adjuvants 
with increased secretion of IFN-γ and IL-12. CpG-ODN as well as GpC-ODN significantly 
decreased the mRNA expression of IL-6 (proinflammatory as well as Th2 (Mosmann and Sad., 
1996)) while there was a tendency for a higher IFN-γ (Th1-like) mRNA-expression. Furthermore, 
CpG-ODN, but also GpC-ODN, preferentially lead to the secretion of IgG2 antibodies in 
comparison with pigs which did not receive these oligonucleotide sequences. Only the IgG2 
response was significantly higher and not the IgG1 response. In mice, Th1-modulating adjuvants 
stimulate the secretion of IgG2a antibodies (Krieg et al., 1995). It should be stressed that the 
Th1/Th2 paradigm and the subsequent secretion of different Ig isotypes does not necessarily hold 
true for pigs as it is for mice. For example, IL-10 has been described in mice as a pivotal cytokine 
in the downregulation of murine Th2 responses. It inhibits Th1 cytokines, down-regulates MHC 
class II antigen expressing and inhibits the production of oxygen intermediates. This is not the 
case in cattle (Brown et al., 1994) indicating that findings in mice can not be blindly copied to 
other species.  
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8.3. The effect of 1α,25(OH)2D3 and CpG-ODN on protection at the intestinal mucosa 
after an IM immunisation  
 
To test the effect of 1α,25(OH)2D3 and CpG-ODN on protection against mucosal infection, 
F4 fimbriae of enterotoxigenic E. coli (ETEC) were used as immunizing antigens and the F4+-
ETEC as a challenge strain. F4+-ETEC are an important cause of neonatal and PWD in piglets. To 
protect against PWD, the induction of an active IgA response is required. Different factors such as 
cytokines, the route of immunisation and the antigen-dose can influence the induction of an IgA 
response. The effect of the dose of F4 on the IgA response was studied in chapter 6. Pigs were 
intramuscularly injected with 1, 0.1 or 0.01 mg of F4-fimbriae and tested for their F4-specific 
isotype-specific serum antibody response as well as for the number of antigen-specific isotype-
specific ASC in the local draining lymph node. Intramuscular immunisation with 0.1 mg resulted 
in higher IgA serum antibodies and higher number of F4-specfic IgA ASC in the local draining 
lymph node than with the 1 mg or the 0.01 mg doses. The lowest IgA response was seen in the 1 
mg group. Therefore, the effect of 1α,25(OH)2D3 and CpG-ODN on protection against and F4+-
ETEC infection was evaluated by intramuscularly immunizing F4-seronegative F4R+ suckling 
piglets twice with 0.1 mg F4-fimbriae in incomplete Freund’s adjuvant (IFA) supplemented with 
either 2 µg of 1α,25(OH)2D3 or 500 µg CpG-ODN or without supplement (Chapter 7). Following 
ETEC challenge all F4-vaccinated animals showed a reduced F4+ ETEC excretion in comparison 
with animals injected with PBS in IFA. The best protection was seen using 1α,25(OH)2D3. 
Interestingly, IM injection of F4 in IFA also reduced the faecal ETEC excretion and induced even 
the highest F4-specific IgA serum antibody response. In chapter 6, it was already demonstrated 
that this dose was optimal for inducing IgA. 1α,25-Dihydroxyvitamin D3 could not increase this 
IgA response. This in contrast with the HSA-studies in which the IgA response could be increased 
(Chapter 2 and 3) and shows that the nature of the antigen also influences the effect of 
1α,25(OH)2D3 on the immune responses (Hughes et al., 1998). The F4-antigen, that has a 
polymeric nature, induces already potent immune antibody responses when given with IFA which 
are difficult to ameliorate. 
In all IM immunisations in this thesis, IFA was used as adjuvant. IFA has been shown to 
stimulate the humoral immunity as well as the cellular immunity and has been used in 
experimentally veterinary vaccines such as equine influenza virus (Street 1967), hog cholera (Ott 
et al., 1962), Newcastle disease (Eidson 1982) and infectious canine hepatitis (Fastier et al., 
1964). Remarkably, the combination of F4-fimbriae in IFA even reduced the faecal F4+-E. coli 
excretion, although not significantly. The reason for this reduction could be due to the high serum 
IgA titers. 
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Of all F4-vaccinated groups, only the 1α,25(OH)2D3 injected animals displayed a secondary 
IgA serum response upon ETEC challenge (Chapter 7). This indicates that the vaccine, 
supplemented with 1α,25(OH)2D3, is able to prime the intestinal mucosal immune system. This is 
consistent with results in chapter 3, which demonstrated an increased number of antigen-specific 
IgA ASC in the PP as well as in the LP after an IM injection of HSA supplemented with 
1,25(OH)2D3. However, in that study the number of antigen-specific ASC was not very high. 
There must have been enough IgA+-memory B cells in the mucosa after the IM immunisation to 
give a booster response upon challenge that lead to a significant reduction in the faecal F4+-E. coli 
excretion. Probably not enough F4-specific IgA ASC appeared to give complete protection. In 
mice studies, 1α,25(OH)2D3 changes the maturation and migratory properties of DC subsequent to 
antigen stimulation (Enioutina et al., 2000). The DC preferentially home towards the Peyer’s 
patches and may be responsible for the good mucosal immune response and the appearance of 
IgA+-B cells and IgA+ memory cells. The mechanism of the mucosal priming of pigs 
intramuscularly immunized with antigen and 1α,25(OH)2D3 still has to be elucidated. 
The protective effect of CpG-ODN could not be explained by enhanced antibody responses 
but rather by an enhanced cellular response as assessed by the proliferation assay. In vivo CpG-
ODN enhance the mitogen-induced as well as the antigen-specific proliferation. Further studies 
are required to fully characterize the role of CpG-ODN in the protection against an F4+-ETEC 
infections. 
 
8.4. Main conclusions and future perspectives 
 
In this thesis, the adjuvant-properties of 1α,25(OH)2D3 and CpG-ODN and more specifically 
their capacity to modulate towards an IgA response were analysed. The present work 
demonstrated, that IM immunisation of pigs with an antigen in IFA and supplemented with 
1α,25(OH)2D3 or CpG-ODN enhanced the IgA serum antibody response as well as the IgA titers 
in different mucosal secretions. Especially, the steroid hormone seems to modulate towards the 
IgA isotype. The increased IgA response due to the steroid hormone seems to be transient and 
antigen-dependent. Whether or not a Th2-like response is involved in this modulation could not 
clearly be demonstrated. Most likely the classification of T-helper cells in Th1/Th2/Th3-cells is 
not that clear in pigs as it is in mice. CpG-ODN induced a more general activation of the immune 
system. It was demonstrated that CpG-ODN activate B cells directly whereas T cells are probably 
activated indirectly. An experiment in which newly-weaned piglets were challenged with F4+-
ETEC after they were IM immunized with F4-fimbriae during the suckling period showed that 
protection can be enhanced by addition of 1α,25(OH)2D3 and CpG-ODN to the fimbriae. Since 
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F4+-ETEC but also other mucosal infections are an important cause of disease in young piglets 
with weight-loss, sometimes mortality but always important economical losses as a consequence, 
modulation of a systemic towards a mucosal immune response could be a major breakthrough in 
the prophylaxis against these diseases. Further studies are needed to examine whether in the 
presence of maternal antibodies a systemic (IM, ID, SC) or even an oral administration of 
vaccines supplemented with 1α,25(OH)2D3 still results in a priming of the intestinal mucosal 
immune system. CpG-ODN on the other hand may be used in vaccines by linking these CpG-
ODN directly to antigens or by adding the motifs to the backbone of DNA-vaccines so enhancing 
the uptake and the immunogenicity of these vaccines. 
   
 
Summary  153 
 
SUMMARY 
Intestinal infections are an important cause of disease, weight-loss and mortality in young 
animals. Whether newborns and suckling animals can be protected by milk antibodies, this 
passive protection disappears after weaning. Weaned animals need an active intestinal immunity 
for protection against enteropathogens. This means that these young animals need to be 
immunized during the suckling period in the presence of lactogenic, often antigen-specific, 
antibodies. The presence of these antibodies mortgages the oral vaccination route. Parenteral 
vaccination in the presence of declining maternal serum antibodies is another option. However, 
parenteral vaccines in general stimulate the systemic rather than the mucosal immune system. 
Therefore the use of immunomodulating adjuvants, which could modulate from a systemic 
towards a mucosal immune response, in parenteral vaccines is an interesting approach to face this 
problem.  
In the present thesis the immunomodulating capacity of 1α,25-Dihydroxyvitamin D3 
(1α,25(OH)2D3) and synthetic cytidine-phosphate-guanosine-oligodeoxynuclotides (CpG-ODN) 
was studied on an intramuscular (IM)-induced immune response. 1α,25-Dihydroxyvitamin D3, the 
active form of vitamin D, exerts its effects as a steroid hormone by activation of the nuclear 
vitamin D receptor and appears to modulate a systemic immune response towards a protective 
mucosal (IgA) immune response in mice. This IgA response was accompanied with the presence 
of a Th2-cytokine profile in the local draining lymph node after vaccination. CpG-ODN, which 
are DNA-sequences characteristic for many bacteria, have potent immunoenhancing properties 
and are classified as Th1-modulating adjuvants. Co-administration of CpG-ODN and an antigen 
showed induced antigen-specific humoral, cellular immune responses, and protection upon 
challenge. 
 
Chapter 1 reviews the immunomodulating properties of 1α,25(OH)2D3 as well as CpG-
ODN. Short definitions of these agents, their effects on the different immune cells, their toxicity 
as well as their applications are described. Most of these effects are determined for rodents and 
man but not for companion and farm animals. The Th1/Th2 paradigm and the role of the 
cytokines in modulating the immune responses are emphasized. In the final part of the review, the 
use of 1α,25(OH)2D3 and CpG-ODN as potent immunomodulating adjuvants in veterinary 
medicine are discussed. 
 
Chapters 2 to 7 present the experimental work of the thesis. The objective was to examine 
the following questions:  
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Can 1α,25(OH)2D3 enhance the antigen-specific IgA  response after IM immunisation? 
Is the enhanced IgA response correlated with a Th2-like cytokine response ?  
Can co-administration of an antigen with 1α,25(OH)2D3 prime for an antigen-specific 
mucosal intestinal immune response? Is there homing of antigen-specific antibody secreting cells 
(ASC) towards the gut associated lymphoid tissue (GALT)?  
Can CpG-ODN be used as an immunomodulating/immunoenhancing adjuvant  for IM 
immunisation? Which cell types are activated by CpG-ODN and which CpG-ODN sequences are 
immunostimulating? 
Does intramuscular immunisation of F4-fimbriae supplemented with 1α,25(OH)2D3 or CpG-
ODN result in protection against challenge with F4+-ETEC ?  
 
In chapter 2, the effect of 1α,25(OH)2D3 on the isotype-specific antibody response in serum 
as well as the IgA titer in mucosal secretions was determined after IM injection of human serum 
albumin (has) in incomplete Freund’s adjuvant (IFA) with or without 1α,25(OH)2D3. The steroid 
hormone significantly enhanced transiently the antigen-specific IgA and IgM serum antibody 
responses and increased the IgA titers in saliva, feces and nasal secretions. 1α,25-
Dihdyroxyvitamin D3  also enhanced the antigen-specific IgA and IgG ASC in the local draining 
lymph nodes.  
In chapter 3, ELIspot assays of systemic lymphoid tissues (local draining lymph node, 
spleen and bone marrow) as well as gut associated lymphoid tissue (GALT) showed slightly 
higher numbers of HSA-specific IgA ASC in the systemic lymphoid organs as well as in the 
Peyer’s patches (PP) of the 1α,25(OH)2D3 injected pigs. This might suggest that IM administered 
antigen co-administered with 1α,25(OH)2D3 can prime the intestinal mucosal immune system. 
1α,25-Dihydroxyvitamin D3 increased the % of CD25+ cells, an activation marker, in the local 
draining lymph node but did not affect the relative distribution of CD4+, CD8+, MHC II+ and IgM+ 
cells indicating more activated T- and B cells using the steroid hormone. Mixed cytokine profiles 
(Th1/Th2/Th3) of the monomorphonuclear cells of the local draining lymph node were detected 
by real time PCR. In pigs 1α,25(OH)2D3 did not induce a clear Th2 response as observed in mice. 
Although some trends in these profiles were observed: after the first immunisation a higher IL-10 
(Th2) and a significantly lower IL-2 (Th1-like) mRNA expression were seen while after the 
booster immunisation even a significantly higher IL-2 (Th1-like) accompanied with lower IFN-γ 
(Th1-like) and TGF-β mRNA (Th3-like) expressions were observed. 
In chapter 4, it was shown that CpG-ODN (5’GCT-AGA-CGT-TAG-CGT-3’) can be used 
as adjuvant in pigs for intramuscular immunisations. Indeed, injection of 500 µg of these CpG-
ODN together with ovalbumin (OVA) enhanced the serum IgM, IgA, IgG1, IgG2 as well as the 
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IgG antibody responses and induced showed significantly higher OVA-specific IgA antibodies in 
saliva and nasal secretions. This enhanced antibody response appeared CpG-dinucleotide 
independent as similar effects were seen after IM injection of antigen supplemented with 500 µg 
GpC-ODN (same sequence but CpG-dinucleotide is reversed in GpC). The OVA-specific 
antibody titers obtained after a single injection of antigen combined with either of both ODNs 
were as high as the titers in control OVA injected animals after two injections. CpG-ODN as well 
as GpC-ODN also stimulated the cellular immune responses since enhanced OVA and ConA-
specific proliferation were obtained with MC of different lymphoid tissues. Furthermore, there 
was a tendency for a higher IFN-γ (Th1-like) mRNA-expression in the MC of the local draining 
lymph node while the IL-6 mRNA expression was significantly lower. No significant difference 
in TGF-β (Th3-like) and IL-10 (Th2-like) were observed. Since single immunisations containing 
ODN equals double immunisations without ODN, this adjuvant could make a second 
immunisation redundant. 
 
In vitro proliferation assays of PBMC using two different CpG-ODN sequences (Chapter 5) 
showed that the swine-specific ODN sequence [Bs] = 5’-ggTGCATCGATGCAGggggg-3’ is 
optimal for proliferation of porcine PBMC while the CpG-ODN used in chapter 4 did not induce 
any proliferation. Moreover, it was shown that addition of a phosphorothioate G-stretch at both 
ends ameliorates that proliferation. Results demonstrated that a 4-days culture with this motif 
increased B cell blasting as well as the B-cell percentage with 12%. On the other hand a similar 
decrease of CD3+T cells was observed. Also MHC class II+-cells were enhanced with 3% was as 
well as an enhanced expression of MHC II-molecules on these cells. On the other hand no 
difference in the percentage of macrophages was observed. Therefore, it is believed that B-cells 
are the primary target cells for this CpG-ODN. Whereas methylation of CpG-dinucleotide should 
reduce or eliminate immunostimulation of the CpG-ODN, this effect differed depending on the 
manufacturer of the oligodeoxynucleotides. 
 
Chapter 6 demonstrated that also the dose of an antigen can modulate an IM induced 
immune response as shown for F4-fimbriae. Indeed, 1mg purified F4-fimbriae significantly 
decreased the primary F4-specific IgG and IgM responses in comparison with the lower doses of 
0.1 and 0.01 mg F4. However, the high dose primed for an unusually high secondary IgM 
response. The polymeric nature of the fimbriae could make it act as a T-cell independent antigen. 
The dose of 0.1 mg induced the highest numbers of IgA ASC in the local draining lymph as well 
as the highest F4-specific IgA serum response, which was significantly higher than after injection 
with 0.01 and 1mg F4. The dose of 0.1 mg purified F4 seems to be optimal for inducing F4-
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specific IgA responses after IM immunisation. It is conceivable that IM injection of different 
doses F4 induces distinct patterns of cytokines resulting in different ratios of F4-specific isotypes. 
 
Chapter 7 analysed whether IM immunisation of suckling piglets with 0.1 mg F4-fimbriae 
could protect against oral challenge with F4+-ETEC and whether addition of 1α,25(OH)2D3 or 
CpG-ODN could improve this protection. It was clearly shown that IM injection reduced the F4+-
ETEC faecal excretion upon challenge. The highest reduction and the only statistically significant 
reduction in comparison with the control group (no F4-immunisation) was observed in the 
1α,25(OH)2D3 treated animals. Only the steroid-treated animals showed a secondary IgA response 
upon ETEC challenge indicating that F4-primed memory B cells might be present in the GALT at 
that moment. CpG-ODN did not enhance the secondary antibody response but significantly 
increased the F4-specific as well as mitogen-induced proliferation of pheripheral blood 
monomorphonuclear cells indicating a direct or indirect overall effect on T-lymphocytes. 
Nevertheless the CpG-ODN also seemed to reduce faecal excretion of F4+-E. coli. Results of this 
chapter revealed the potential of 1α,25(OH)2D3 to be used in veterinary vaccines against 
enteropathogens. 
The final chapter presents the general discussion and conclusions with respect to the 
obtained results. In this thesis it was demonstrated that 1α,25(OH)2D3 as well as CpG-ODN can be 
used as potential immunostimulating/-modulating adjuvants after IM immunisation in pigs. Both 
agents were able to enhance antigen-specific antibody responses and IgA antibody titers in 
mucosal secretions at some time points after IM injection. Moreover, results indicate that 
supplementation with 1α,25(OH)2D3 or CpG-ODN into the vaccine can prime mucosal surfaces in 
the gut. This priming resulted in a partial protection upon oral challenge with live bacteria. 
Despite strong adjuvanticity we have no evidence to consider CpG-ODN or 1α,25(OH)2D3 as 
typical Th1 or Th2-modulating adjuvants respectively. Moreover, there is no evidence at all that 
in pigs the Th1 or Th2-cytokine profiles are correlated with the subsequent secretion of specific Ig 
isotypes by differentiated B cells as clearly demonstrated in mice.  
Nevertheless, the knowledge of the immunomodulating and -regulating mechanisms of 
CpG-ODN and 1α,25(OH)2D3 is of great importance to design new or improve current veterinary 
vaccines. The different techniques used in this thesis (in vitro proliferation, real time PCR for 
quantificantion of cytokines, ELIspot assays, etc) allow screening for other potential 
immunomodulators in different domestic animal species. 
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SAMENVATTING  
 
Intestinale infecties met o.a. enterotoxigene Escherichia coli (ETEC) vormen een 
belangrijke oorzaak van diarree met gewichtsverlies en mogelijks zelfs sterfte bij neonatale en 
pasgespeende biggen. Neonatale en zuigende biggen zijn beschermd tegen deze infecties door de 
aanwezigheid van een lactogene immuniteit. Deze passieve immuniteit kan geïnduceerd worden 
door vaccinatie van zeugen tijdens de dracht. Na het spenen verdwijnt deze lactogene immuniteit 
en worden de dieren opnieuw gevoelig voor intestinale infecties. Op dat ogenblik is een actieve 
intestinale mucosale immuniteit vereist voor protectie. Deze kan enkel bekomen worden indien de 
biggen gevaccineerd worden tijdens de zoogperiode, dus in de aanwezigheid van lactogene 
immuniteit. Melkcomponenten en antistoffen in de melk kunnen interfereren met een immunisatie 
via de orale weg. Parenterale immunisatie van zogende dieren is een ander alternatief. Parenterale 
vaccinatie stimuleert in de regel echter eerder het systemisch dan wel het mucosaal 
immuunsysteem. Om die reden moet er gebruik gemaakt worden van adjuvantia die in staat zijn 
een systemische immuunrespons te moduleren naar een mucosale respons. 
Het in dit proefschrift beschreven onderzoek evalueert bij het varken de 
immunostimulerende en immunomodulerende eigenschappen van twee adjuvantia, namelijk 
1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) en synthetische cytidine-fosfaat-guanosine 
oligodeoxynuclotide sequenties (CpG-motieven), op een intramusculaire immunisatie. 
1α,25-Dihydroxyvitamin D3, de actieve vorm van vitamine D3, oefent zijn immunomodulerende 
werking uit door activatie van de nucleaire vitamine D receptor. Deze receptor vormt samen met 
de retinoïd X receptor een heterodimeer die de transcriptie regelt van bepaalde doelwitgenen. 
Deze doelwitgenen zijn onder andere genen voor cytokines zoals IL-2, IFN-γ, enz. Bij muizen 
werd aangetoond dat 1α,25(OH)2D3 in staat is een systemische immuunrespons te moduleren naar 
een mucosale IgA respons. Hierbij werden verhoogde IgA serumantistoffen alsook een stijging 
van het aantal IgA antistoffen-producerende cellen ter hoogte van het darm-geassocieerde lymfoïd 
weefsel (GALT) gevonden. Dit ging tevens gepaard met een stijging van Th2-cytokines ter hoogte 
van de lokaal drainerende lymfeklier. Daarom wordt 1α,25(OH)2D3 geklasseerd als een Th2-
modulerend adjuvans.  
CpG-ODN-motieven komen frequent voor in bacterieel DNA. Deze CpG-motieven behoren 
tot de klasse van ‘bacteriële’ adjuvantia. De immunostimulerende werking van bacterieel DNA en 
synthetische CpG-motieven is volledig te wijten aan de aanwezigheid van een CpG-dinucleotide 
in een welbepaalde context zijnde een “3’-purine-purine-CpG-pyrimidine-pyrimidine-5’ 
configuratie. Onderzoek bij muizen toonde aan dat CpG-motieven goede adjuvantia zijn wat zich 
vertaalt in een verhoging van de antigeen-specifieke humorale en cellulaire immuunrespons met  
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een verbeterde bescherming na een experimentele infectie. Bovendien moduleren de CpG-
motieven de immunologische respons door activatie van B-cellen en antigeen-presenterende 
cellen en door Th1-cytokines, cytokines die een celgemedieerde respons in de hand werken.  
De immunostimulerende eigenschappen van 1α,25(OH)2D3 en CpG-motieven alsook hun 
mogelijke toepassingen in de diergeneeskunde worden beschreven in deel 1 van deze thesis 
(hoofdstuk 1, overzicht van de literatuur). Verder wordt de recente kennis bij mens en muis over 
Th1-,Th2- en Th3-cytokines beschreven alsook hun rol in het moduleren van de 
antistoffenrespons naar bepaalde isotypes. Ook wat hierover gekend is bij het varken wordt 
bediscussieerd. 
Deel III (hoofstukken 2-7) bevat het eigen onderzoek. Hierbij werden de volgende vragen 
onderzocht (Deel II, Aims of the study). 
• Kan 1α,25(OH)2D3 de antigeen-specifieke IgA respons verhogen na intramusculaire 
(IM) immunisatie? 
• Indien ja, is de verhoogde IgA respons gecorreleerd met een Th2-cytokinerespons? 
• Is er een priming van de intestinale mucosale immuniteit na IM vaccinatie met 
antigeen plus 1α,25(OH)2D3 , m.a.w. vindt men antigeen-specifieke antistoffen-
producerende cellen t.h.v. het GALT na deze vaccinatie? 
• Kunnen CpG-motieven gebruikt worden als immunostimulerende en/of 
modulerende adjuvantia na IM immunisatie? Indien ja, welke sequentie en welke 
cellen worden door deze CpG-motieven geactiveerd? 
• Leidt IM immunisatie van zuigende biggen met F4-fimbriae samen met 
1α,25(OH)2D3 en/of CpG-motieven tot bescherming tegenover een infectie met F4+-
ETEC?  
In hoofdstuk 2 werd aangetoond dat varkens na IM injectie met humaan serumalbumine 
(HSA) gesupplementeerd met 2 µg 1α,25(OH)2D3 tijdelijk een significant hogere serum IgA en 
IgM respons vertoonden dan varkens die geen 1α,25(OH)2D3 kregen toegediend. Verder werden 
bij deze varkens op sommige tijdstippen hogere HSA-specifieke IgA antistoffen gedetecteerd in 
de faeces, het speeksel en het neussekreet. Bovendien was de lokaal drainerende lymfeklier sterk 
vergroot en werden in de drainerende lymfeklieren ook een hoger aantal HSA-specifieke IgA en 
IgG antistoffen-producerende cellen gevonden. Deze resultaten tonen aan dat 1α,25(OH)2D3 in 
staat is de systemische maar ook de mucosale antigeen-specifieke IgA antistoffenrespons te 
verhogen.  
Deze resultaten werden bevestigd in een tweede experiment (hoofdstuk 3) waarin werd 
aangetoond dat 1α,25(OH)2D3 moduleert naar een IgA respons. Immers in de groep geïnjecteerd  
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met HSA en 1α,25(OH)2D3 was enkel de HSA-specifieke serum IgA respons en niet de IgM of 
IgG respons verhoogd. Ook in de lokaal drainerende lymfeklier was er een niet significante  
toename van het aantal HSA-specifieke IgA antistoffen-producerende cellen, terwijl in de jejunale 
en ileale Peyerse platen (GALT) meer HSA-specifieke antistoffen-producerende cellen werden 
gedetecteerd bij dieren geïnjecteerd met 1α,25(OH)2D3. Op verschillende tijdstippen na IM 
injectie werd enerzijds de relatieve distributie van CD2+-, CD4+-,CD8+-,CD25+- en IgM+ -cellen 
bepaald en anderzijds werd ook de cytokine mRNA expressie voor IL-2, IL-4, IL-6,IL-10, IFN-γ 
en TGF-β gekwantificeerd. Een significante stijging van CD25+-cellen na de tweede IM injectie 
met antigeen plus 1α,25(OH)2D3 toont aan dat er een algemene activatie is van T-en/of B-cellen 
o.i.v. 1α,25(OH)2D3. Ondanks een duidelijk verhoogde IL-10 (Th2-like) en een verlaagde IL-2 
mRNA (Th1-like) expressie na de eerste IM immunisatie, kon er geen duidelijke Th2-
cytokinerepons worden aangetoond. Deze resultaten tonen aan dat intramusculaire toediening van 
een antigeen samen met 1α,25(OH)2D3 het mucosaal immuunsysteem bij biggen kan ‘primen’ met 
verhoogde aantallen IgA antistoffen-producerende cellen ter hoogte van de Peyerse platen. 
In hoofdstuk 4 werd aangetoond dat muizen-specifieke CpG-motieven (5’GCT-AGA-CGT-
TAG-CGT-3’) alsook de omgekeerde “GpC-motieven” (=5’GCT-AGA-GCT-TAG-GCT-3’), 
kunnen gebruikt worden als immunostimulerend adjuvans bij varkens. Injectie van biggen met 1 
mg ovalbumine (OVA) in incompleet Freund’s adjuvant (IFA), gesupplementeerd met 500 µg van 
deze CpG-motieven of de GpC-motieven, verhoogden de OVA-specifieke antistoffenrespons. De 
antistoffenrespons, na 1 IM injectie van biggen met CpG-motieven, was even hoog als deze na 2 
IM injecties in afwezigheid van deze motieven. Door CpG-en/of GpC-motieven te gebruiken, 
verhoogde tevens de OVA-specifieke IgA respons in speeksel en neussekreet. Beide motieven 
verhoogden tevens de OVA-specifieke evenals de ConA-geïnduceerde proliferatie van 
monomorfonucleaire cellen geïsoleerd uit het bloed, de milt en de lokaal drainerende lymfeklier. 
Dit ging gepaard met een significant lagere expressie van IL-6 mRNA. CpG-motieven 
induceerden tevens een lichte stijging van IFN-γ mRNA. Er kon echter geen duidelijke Th1-
cytokine respons worden aangetoond in tegenstelling met wat volgens de literatuur zou kunnen 
verwacht worden. 
Hoofdstuk 5 beschrijft de resultaten van de in vitro proliferatie van monomorfonucleaire 
cellen uit perifeer bloed na incubatie met 2 verschillende CpG-motieven motieven namelijk 5’-
GCTAGACGTTAGCGT-3’, dat gebruikt werd in de in vivo studie (hoofdstuk 4), en 5’-
TGCATCGATGCAG-3’, een varkensspecifiek CpG-motief. Er werden tevens wijzigingen in 
beide motieven aangebracht zoals onder andere methylatie van het C-nucleotide, toevoegen van 
poly-G staarten en fosfor-thioaatbindingen. Resultaten van deze studie toonden aan dat incubatie 
met het CpG-motief 5’-ggTGCATCGATGCAGggggg-3’ (voorzien van een poly G  
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staart uit fosfor-thioaatbindingen) resulteerde in een toename van B- en MHC II+-cellen met 
respektievelijk 12 en 3 % alsook in een kleine toename van ‘B-cell blasting’. Ook de MHC II-
expressie nam toe. Hieruit werd besloten dat dit dit CpG-motief de perifere bloed B-cellen van het 
varken stimuleert. Of deze stimulatie rechtstreeks of onrechtstreeks gebeurt kan hieruit niet 
geconcludeerd worden.  
Het uiteindelijke doel van deze thesis was na te gaan of 1α,25(OH)2D3 en/of CpG-ODN na 
IM injectie ook protectie kon geven ter hoogte van de darm. Dit werd nagegaan in het F4-model 
waarbij dieren intramusculair worden geïnjecteerd met F4 antigeen en vervolgens aan een 
challenge met F4+-enterotoxigene E. coli worden onderworpen. Hiertoe was het nodig de optimale 
dosis te bepalen voor een intramusculaire immunisatie. In hoofdstuk 6 werd de antigeen-
specifieke isotype-specifieke antistoffenrespons nagegaan van IM injecties met verschillende 
dosissen F4-antigeen. Intramusculaire injectie met een hoge dosis (1 mg)  F4 fimbriae 
onderdrukte significant de primaire F4-specifieke IgM en IgG respons in vergelijking met de 
lagere dosissen (0,1 en 0,01 mg F4 fimbriae) maar leidde tot een significant hogere secundaire 
IgM respons. De dosissen van 0,1 en 0,01 mg F4 fimbriae induceerden een hoger aantal F4-
specifieke IgA en IgG antistoffen-producerende cellen in de lokaal drainerende lymfeklier. 
Daarenboven bleek uit deze studie dat voornamelijk de 0,1 mg dosis optimaal is voor de inductie 
van een F4-specifieke IgA respons. Dus niet alleen het adjuvans maar ook de dosis van het 
antigeen kan belangrijk zijn voor het moduleren van een immuunrespons. 
In het finaal experiment (hoofdstuk 7) werd nagegaan of F4-receptor positieve biggen 
beschermd konden worden tegen een orale infectie met een virulente F4+-ETEC stam door een IM 
immunisatie met 0,1 mg F4 fimbriae, al dan niet gesupplementeerd met 1α,25(OH)2D3 of CpG-
motieven. Hiervoor werd het aantal F4+-ETEC/gram faeces/dier bepaald na experimentele 
infectie. De resultaten tonen aan dat de IM immunisatie met 0,1 mg F4 fimbriae in IFA een daling 
van F4+-ETEC in de faeces tot gevolg had in vergelijking met de controlegroep. Deze daling was 
meer uitgesproken en zelfs significant wanneer gelijktijdig respectievelijk CpG-motieven en 
1α,25(OH)2D3 werden toegediend. Biggen, geïnjecteerd met 1α,25(OH)2D3, vertoonden een 
secundaire serum IgA respons na de experimentele infectie met ETEC. Dit in tegenstelling met de 
andere groepen. Daarom werd gesuggereerd dat IM injectie van antigeen samen met 
1α,25(OH)2D3 resulteerde in een priming ter hoogte van de intestinale mucosa. De aanwezigheid 
van memory IgA B-cellen kan inderdaad een verklaring zijn voor de partiële bescherming bij de 
1α,25(OH)2D3-behandelde biggen op het moment van de infectie. Tevens werd opnieuw 
aangetoond dat CpG-motieven de proliferatie van perifere bloed monomorfonucleaire cellen 
significant verhoogt. De rol van de cellulaire immuniteit en van de CpG-motieven in de 
bescherming tegenover intestinale infecties is onduidelijk. 
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Deel IV (hoofdstuk 8) bevat de algemene discussie en de belangrijkste conclusies. Dit werk 
heeft aangetoond dat systemische vaccinatie (IM immunisatie) kan leiden tot een partieel 
protectieve en tijdelijk verhoogde IgA respons mits toevoegen van 1α,25(OH)2D3 en/of CpG-
motieven.  
Vooral toevoegen van 1α,25(OH)2D3 verhoogt de antigeen-specifieke IgA respons in het 
serum en in de mucosale secreties. Er werd eveneens aangetoond dat CpG-motieven kunnen 
gebruikt worden als immunostimulerende en/of immunomodulerende adjuvantia. Of Th2- en/of 
Th1-cytokines betrokken zijn in deze modulatie kon niet duidelijk worden opgehelderd. De 
bekomen resultaten suggereren dat Th1 en Th2 niet zo uitgesproken zijn bij het varken dan bij 
mens en muizen. Het experiment waarbij biggen werden geïnfecteerd met een virulente F4+-
ETEC stam wees uit dat 1α,25(OH)2D3 kan gebruikt worden als potentiële adjuvantia in vaccins 
voor intestinale infecties na systemische (IM) vaccinatie. In de toekomst dient verder onderzocht 
te worden of beide adjuvantia en/of andere vaccinatieroutes de mucosale respons nog kunnen 
verbeteren.
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